NUCLEIC ACIDS AND PROTEINS RELATED TO ALZHEIMER'S DISEASE, AND USES THEREFOR

Abstract: The present invention describes the identification, isolation, sequencing and characterization of several human genes which interact with the presenilins, mutations in which may lead to Familial Alzheimer's Disease. These presenilin-interacting protein genes may be involved in the pathways which, when affected by mutant presenilins, lead to the development of Alzheimer's Disease. In addition, mutations in the presenilin-interacting protein genes, even in the absence of defects in the presenilins, may be causative of Alzheimer's Disease. Nucleic acids and proteins comprising or derived from the presenilin-interacting proteins are useful in screening and diagnosing Alzheimer's Disease, in identifying and developing therapeutics for treatment of Alzheimer's Disease, and in producing cell lines and transgenic animals useful as models of Alzheimer's Disease.

Description: NUCLEIC ACIDS AND PROTEINS RELATED TO ALZHEIMER'S DISEASE, AND USES THEREFOR Field of the Invention The present invention relates generally to the field of neurological and physiological dysfunctions associated with Alzheimer's Disease. More particularly, the invention is concerned with the identification, isolation and cloning of genes which are associated with Alzheimer's Disease, as well as their corresponding transcripts and protein products. The present invention also relates to methods for detecting and diagnosing carriers of normal and mutant alleles of these genes, to methods for detecting and diagnosing Alzheimer's Disease, to methods of identifying other genes and proteins related to, or interacting with, the genes and proteins ofthe invention, to methods of screening for potential therapeutics for Alzheimer's Disease, to methods of treatment for Alzheimer's Disease, and to cell lines and animal models useful in screening for and evaluating potentially useful therapies for Alzheimer's Disease. Background ofthe Invention Alzheimer's Disease (AD) is a degenerative disorder ofthe human central nervous system characterized by progressive memory impairment and cognitive and intellectual decline during mid to late adult life (Katzman, 1986). The disease is accompanied by a constellation of neuro-pathologic features principal amongst which are the presence of extracellular amyloid or senile plaques, and neurofibrillary tangles in neurons. The etiology of this disease is complex, although in some families it appears to be inherited as an autosomal dominant trait. Linkage studies have identified three genes associated with the development of AD: β-amyloid precursor protein (APP) (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991 ; Karlinsky et al., 1992; Mullan et al., 1992), presenilin- 1 (PS-1) (Sherrington, 1995), and presenilin-2 (PS-2) (Rogaev, 1995, and Levy-Lahad, 1995). The presenilins are multi-spanning membrane proteins which were described in substantial detail in PCT Publication WO96/34099, the entire disclosure of which is incorporated herein by reference. Although the functions ofthe presenilins are unknown, a number of autosomal dominant presenilin mutations have been identified which are strongly associated with the development of early-onset, aggressive, Familial Alzheimer's Disease (FAD). The present disclosure describes the identification, isolation, sequencing and characterization of several human genes which interact with the presenilins, mutations in which may lead to FAD. These presenilin-interacting protein genes may be involved in the pathways which, when affected by mutant presenilins, lead to the development of Alzheimer's Disease. In addition, mutations in the presenilin- interacting protein genes, even in the absence of defects in the presenilins, may be causative of Alzheimer's Disease. Summary of the Invention The present invention is based, in part, upon the identification, isolation, sequencing and characterization of several human genes, referred to herein as "presenilin-interacting protein genes" or "PS-interacting protein genes." The products of these genes are believed to interact in vivo with the human presenilin- 1 proteins and, therefore, are implicated in the biochemical pathways which are affected in Alzheimer's Disease. Each of these genes, therefore, presents a new therapeutic target for the treatment of Alzheimer's Disease. In addition, PS -interacting protein nucleic acids, PS -interacting proteins and peptides, antibodies to the PS-interacting proteins, cells transformed with PS-interacting protein nucleic acids, and transgenic animals altered with PS-interacting protein nucleic acids, all possess various utilities, as described herein, for the diagnosis, therapy and continued investigation of Alzheimer's Disease and related disorders. Thus, it is one object ofthe invention to provide isolated nucleic acids encoding at least a PS -interacting domain of a PS-interacting protein. These PS- interacting proteins include mammalian S5a subunits ofthe 26S proteasome, the GT24 protein, the p0071 protein, the Rabl 1 protein, the retinoid X receptor-β, the cytoplasmic chaperonin, and several sequences identified herein as clones Y2H35, Y2H171, and Y2H41. Preferred nucleotide and amino acid sequences are provided herein. It is another object ofthe invention to provide probes and primers for these PS-interacting protein genes, and to provide nucleic acids which encode small antigenic determinants of these genes. Therefore, preferred embodiments include sequences of at least 10, 15 or 20 consecutive nucleotides selected from the disclosed sequences. Using the nucleic acid sequences and antibodies disclosed and enabled herein, methods for identifying allelic variants or heterospecific homologues of a human PS-interacting protein and gene are provided. The methods may be practiced using nucleic acid hybridization or amplification techniques, immunochemical techniques, or any other technique known in the art. The allelic variants may include other normal human alleles as well as mutant alleles ofthe PS-interacting protein genes which may be causative of Alzheimer's Disease. The heterospecific homologues may be from other mammalian species, such as mice, rats, dogs, cats or non-human primates, or may be from invertebrate species, such as Drosophila or C. elegans. Thus, it is another object ofthe invention to provide nucleic acids which encode allelic or heterospecific variants ofthe disclosed sequences, as well as the allelic or heterospecific proteins encoded by them. The it another object ofthe invention to provide vectors, and particularly expression vectors, which include any ofthe above-described nucleic acids. It is a further object ofthe invention to provide vectors in which PS-interacting protein nucleic acid sequences are operably joined to exogenous regulatory regions to produce altered patterns of expression, or to exogenous coding regions to produce fusion proteins. Conversely, it is another object to provide nucleic acids in which PS- interacting protein regulatory regions are operably joined to exogenous coding regions, including standard marker genes, to produce constructs in which the regulation of PS-interacting protein genes may be studied and used in assays for therapeutics. It is another object ofthe invention to provide host cells and transgenic animals which have been transformed with any ofthe above-described nucleic acids of the invention. The host cells may be prokaryotic or eukaryotic cells and, in particular, may be gametes, zygotes, fetal cells, or stem cells useful in producing transgenic animal models. In particularly preferred embodiments, the present invention provides a non-human animal model for Alzheimer's Disease, in which the genome ofthe animal, or an ancestor thereof, has been modified by at least one recombinant construct which has introduced one ofthe following modifications: (1) insertion of nucleotide sequences encoding at least a functional domain of a heterospecific normal PS-interacting protein, (2) insertion of nucleotide sequences encoding at least a functional domain of a heterospecific mutant PS-interacting protein, (3) insertion of nucleotide sequences encoding at least a functional domain of a conspecific homologue of a heterospecific mutant PS-interacting protein, and (4) inactivation of an endogenous PS-interacting protein gene. Preferred transgenic animal models are rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non- human primates, but invertebrates are also contemplated for certain utilities. It is another object ofthe invention to provide methods for producing at least a functional domain of a PS-interacting protein using the nucleic acids ofthe invention. In addition, the present invention also provides substantially pure preparations of such proteins, including short peptide sequences for used as irnrnunogens. Thus, the invention provides peptides comprising at least 10 or 15 consecutive amino acid residues from the disclosed and otherwise enabled sequences. The invention further provides substantially pure preparations of peptides which comprise at least a PS-interacting domain of a PS -interacting protein, as well as substantially pure preparations ofthe entire proteins. Using the substantially pure peptides and proteins enabled herein, the invention also provides methods for producing antibodies which selectively bind to a PS-interacting protein, as well as cell lines which produce these antibodies. Another object ofthe present invention is to provide methods of identifying compounds which may have utility in the treatment of Alzheimer's Disease and related disorders. These methods include methods for identifying compounds which can modulate the expression of a PS-interacting protein gene, methods for identifying compounds which can selectively bind to a PS-interacting protein, and methods of identifying compounds which can modulate activity of a PS- interacting protein. These methods may be conducted in vitro or in vivo, and may employ the transformed cell lines and transgenic animal models ofthe invention. The methods also may be part of a clinical trial in which compounds identified by the methods of the invention are further tested in human subjects. It is another object ofthe invention to provide methods of diagnosing or screening for inherited forms of Alzheimer's Disease by determining if a subject bears a mutant PS-interacting protein gene. Mutant PS-interacting genes may be detected by assays including direct nucleotide sequencing, probe specific hybridization, restriction enzyme digest and mapping, PCR mapping, ligase-mediated PCR detection, RNase protection, electrophoretic mobility shift detection, or chemical mismatch cleavage. Alternatively, mutant forms of a PS-interacting protein may be detected by assays including immunoassays, protease assays, or electrophoretic mobility assays. It is also an object ofthe invention to provide pharmaceutical preparations which may be used in the treatment of Alzheimer's Disease and related disorders which result from aberration in biochemical pathways involving the PS-interacting proteins disclosed and enabled herein. Thus, the present invention also provides pharmaceutical preparations comprising a substantially pure PS-interacting protein, an expression vector operably encoding a PS -interacting protein, an expression vector operably encoding a PS-interacting protein antisense sequence, an antibody which selectively binds to a mutant PS-interacting protein, or an antigenic determinant of a mutant PS -interacting protein. These pharmaceutical preparations may be used to treat a patient bearing a mutant PS -interacting protein gene which is causative of Alzheimer's Disease or related disorders. These an other objects ofthe present invention are described more fully in the following specification and appended claims. Detailed Description ofthe Invention I. Definitions In order to facilitate review ofthe various embodiments ofthe invention, and an understanding ofthe various elements and constituents used in making and using the invention, the following definitions are provided for particular terms used in the description and appended claims: Presenilin. As used without further modification herein, the terms "presenilin" or "presenilins" mean the presenilin- 1 (PS1) and/or the presenilin-2 (PS2) genes/proteins. In particular, the unmodified terms "presenilin" or "presenilins" refer to the mammalian PS1 and/or PS2 genes/proteins and, preferably, the human PS1 and/or PS2 genes/proteins as described and disclosed in PCT Publication WO96/34099. Normal. As used herein with respect to genes, the term "normal" refers to a gene which encodes a normal protein. As used herein with respect to proteins, the term "normal" means a protein which performs its usual or normal physiological role and which is not associated with, or causative of, a pathogenic condition or state. Therefore, as used herein, the term "normal" is essentially synonymous with the usual meaning ofthe phrase "wild type." For any given gene, or corresponding protein, a multiplicity of normal allelic variants may exist, none of which is associated with the development of a pathogenic condition or state. Such normal allelic variants include, but are not limited to, variants in which one or more nucleotide substitutions do not result in a change in the encoded amino acid sequence. Mutant. As used herein with respect to genes, the term "mutant" refers to a gene which encodes a mutant protein. As used herein with respect to proteins, the term "mutant" means a protein which does not perform its usual or normal physiological role and which is associated with, or causative of, a pathogenic condition or state. Therefore, as used herein, the term "mutant" is essentially synonymous with the terms "dysfunctional," "pathogenic," "disease-causing," and "deleterious." With respect to the presenilin and presenilin-interacting protein genes and proteins ofthe present invention, the term "mutant" refers to genes/proteins bearing one or more nucleotide/amino acid substitutions, insertions and/or deletions which typically lead to the development ofthe symptoms of Alzheimer's Disease and/or other relevant inheritable phenotypes (e.g. cerebral hemorrhage, mental retardation, schizophrenia, psychosis, and depression) when expressed in humans. This definition is understood to include the various mutations that naturally exist, including but not limited to those disclosed herein, as well as synthetic or recombinant mutations produced by human intervention. The term "mutant," as applied to these genes, is not intended to embrace sequence variants which, due to the degeneracy of the genetic code, encode proteins identical to the normal sequences disclosed or otherwise enabled herein; nor is it intended to embrace sequence variants which, although they encode different proteins, encode proteins which are functionally equivalent to normal proteins. Substantially pure. As used herein with respect to proteins (including antibodies) or other preparations, the term "substantially pure" means that the preparation is essentially free of other substances to an extent practical and appropriate for its intended use. In particular, a protein preparation is substantially pure if it is sufficiently free from other biological constituents so as to be useful in, for example, generating antibodies, sequencing, or producing pharmaceutical preparations. By techniques well known in the art, substantially pure proteins or peptides may be produced in light ofthe nucleic acid and amino acid sequences disclosed herein. In particular, in light ofthe nucleic acid and amino acid sequences disclosed herein, one of ordinary skill in the art may, by application or serial application of well-known methods including HPLC or immuno-affinity chromatography or electrophoretic separation, obtain proteins or peptides of any generally feasible purity. Preferably, but not necessarily, "substantially pure" preparations include at least 60% by weight (dry weight) the compound of interest. More preferably the preparation is at least 75% or 90%, and most preferably at least 99%, by weight the compound of interest. Purity can be measured by any appropriate method, e.g., column chromatography, gel electrophoresis, or HPLC analysis. With respect to proteins, including antibodies, if a preparation includes two or more different compounds of interest (e.g., two or more different antibodies, immunogens, functional domains, or other polypeptides ofthe invention), a "substantially pure" preparation is preferably one in which the total weight (dry weight) of all the compounds of interest is at least 60% ofthe total dry weight. Similarly, for such preparations containing two or more compounds of interest, it is preferred that the total weight ofthe compounds of interest be at least 75%, more preferably at least 90%, and most preferably at least 99%, ofthe total dry weight ofthe preparation. Finally, in the event that the protein of interest is mixed with one or more other proteins (e.g., serum albumin) or compounds (e.g., diluents, excipients, salts, polysaccharides, sugars, lipids) for purposes of administration, stability, storage, and the like, such other proteins or compounds may be ignored in calculation ofthe purity ofthe preparation. Isolated nucleic acid. As used herein, an "isolated nucleic acid" is a ribonucleic acid, deoxyribonucleic acid, or nucleic acid analog comprising a polynucleotide sequence that is isolated or separate from sequences that are immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome ofthe organism from which it is derived. The term therefore includes, for example, a recombinant nucleic acid which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequences and/or including exogenous regulatory elements. Substantiallv identical sequence. As used herein, a "substantially identical" amino acid sequence is an amino acid sequence which differs only by conservative amino acid substitutions, for example, substitution of one amino acid for another ofthe same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non-conservative substitutions, deletions, or insertions located at positions of the amino acid sequence which do not destroy the function ofthe protein (assayed, e.g., as described herein). Preferably, such a sequence is at least 85%, more preferably 90%, and most preferably 95% identical at the amino acid level to the sequence ofthe protein or peptide to which it is being compared. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides. A "substantially identical" nucleic acid sequence codes for a substantially identical amino acid sequence as defined above. Transformed cell. As used herein, a "transformed cell" is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule of interest. The nucleic acid of interest will typically encode a peptide or protein. The transformed cell may express the sequence of interest or may be used only to propagate the sequence. The term "transformed" may be used herein to embrace any method of introducing exogenous nucleic acids including, but not limited to, transformation, transfection, electroporation, microinjection, viral-mediated transfection, and the like. Operably joined. As used herein, a coding sequence and a regulatory region are said to be "operably joined" when they are covalently linked in such a way as to place the expression or transcription ofthe coding sequence under the influence or control ofthe regulatory region. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of promoter function results in the transcription ofthe coding sequence and if the nature ofthe linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability ofthe regulatory region to direct the transcription ofthe coding sequences, or (3) interfere with the ability ofthe corresponding RNA transcript to be translated into a protein. Thus, a regulatory region would be operably joined to a coding sequence if the regulatory region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide. Stringent hybridization conditions. Stringent hybridization conditions is a term of art understood by those of ordinary skill in the art. For any given nucleic acid sequence, stringent hybridization conditions are those conditions of temperature, chaotrophic acids, buffer, and ionic strength which will permit hybridization of that nucleic acid sequence to its complementary sequence and not to substantially different sequences. The exact conditions which constitute "stringent" conditions, depend upon the nature ofthe nucleic acid sequence, the length ofthe sequence, and the frequency of occurrence of subsets of that sequence within other non-identical sequences. By varying hybridization conditions from a level of stringency at which non-specific hybridization occurs to a level at which only specific hybridization is observed, one of ordinary skill in the art can, without undue experimentation, determine conditions which will allow a given sequence to hybridize only with complementary sequences. Suitable ranges of such stringency conditions are described in Krause and Aaronson (1991). Hybridization conditions, depending upon the length and commonality of a sequence, may include temperatures of 20°C-65°C and ionic strengths from 5x to 0.1 x SSC. Highly stringent hybridization conditions may include temperatures as low as 40-42°C (when denaturants such as formamide are included) or up to 60-65 °C in ionic strengths as low as 0.1 x SSC. These ranges, however, are only illustrative and, depending upon the nature ofthe target sequence, and possible future technological developments, may be more stringent than necessary. Less than stringent conditions are employed to isolate nucleic acid sequences which are substantially similar, allelic or homologous to any given sequence. Selectively binds. As used herein with respect to antibodies, an antibody is said to "selectively bind" to a target if the antibody recognizes and binds the target of interest but does not substantially recognize and bind other molecules in a sample, e.g., a biological sample, which includes the target of interest. That is, the antibody must bind to its target with sufficient specificity so as to distinguish the target from essentially all of molecules which would reasonably be present in a biological sample including the target. II. The Presenilins and Presenilin-interacting Proteins The present invention is based, in part, upon the discovery of a family of mammalian genes which, when mutated, are associated with the development of Alzheimer's Disease. The discovery of these genes, designated presenilin- 1 (PS1) and presenilin-2 (PS2), as well as the characterization of these genes, their protein products, mutants, invertebrate homologues, and possible functional roles, are described in PCT Publication WO96/34099. The present invention is further based, in part, upon the discovery of a group of proteins which interact with the presenilins under physiological conditions and which, therefore, are believed to be involved in the biochemical pathways which are altered in Alzheimer's Disease. These proteins are referred to herein as presenilin-interacting (PS-interacting) proteins. Because mutations in the presenilins are known to be causative of Alzheimer's Disease, each of the PS-interacting genes and proteins disclosed and described herein presents a novel target for therapeutic intervention in Alzheimer's Disease. That is, modulation ofthe interactions of these proteins with the presenilins, or modulation ofthe interactions of at least the PS-interacting domains of these PS-interacting proteins with at least the interacting domains ofthe presenilins, provides a means of modulating the activity and or availability ofthe presenilins, or of modulating the activity and/or availability ofthe PS -interacting proteins. Furthermore, as aberrations in the interactions of mutant presenilins with one or more of these PS-interacting proteins is causative of Alzheimer's Disease, mutations in one or more of these PS-interacting proteins are also likely to be causative of Alzheimer's Disease. Therefore, each ofthe PS- interacting genes and proteins disclosed and described herein presents a novel target for diagnosis of forms of familial and/or sporadic Alzheimer's Disease with an etiology independent of mutations in the presenilins. Finally, as described more fully below, the PS-interacting genes and proteins described and disclosed herein provide for new assays for compounds which affect the interactions ofthe presenilins and PS- interacting proteins, assays for other members of the biochemical pathways involved in the etiology of Alzheimer's Disease, and new cell lines and transgenic animal models for use in such assays. 1. Presenilin Processing Employing the antibodies and protein-binding assays described and/or enabled in PCT Publication WO96/34099, the processing and protein-protein interactions of both normal and mutant presenilins were investigated. It was found that mutations in the presenilins appear to lead to changes in both their intracellular processing (e.g., endoproteolytic cleavage, ubiquitination, and clearance) and their intracellular interactions with other proteins expressed in human brain. As described below, knowledge of presenilin processing and interactions, and particularly changes in mutant presenilin processing and interactions, provides for new diagnostic and therapeutic targets for Alzheimer's Disease and related disorders. Western blot analysis suggests that the normal presenilins undergo proteolytic cleavage to yield characteristic N- and C-terminal fragments. As noted above, the normal presenilin proteins have an expected molecular mass of 47-51 kDa depending, in part, upon mRNA splice variations, electrophoretic conditions, etc. Analysis of Western blots suggests, however, that the normal presenilin proteins undergo proteolytic cleavage to yield an approximately 35 kDa N-terminal fragment and an approximately 18 kDa C-terminal fragment. In particular, Western blots bearing lysates from wild-type native human fibroblasts, human neocortical brain tissue from control subjects, and neocortical brain tissue from non-transgenic and PS1 transgenic mice using antibodies ("14.2") recognizing PS 1 -specific residues 1-25 at the N-terminus reveal the presence of a strong immunoreactive band of approximately 35 kDa and, after longer exposures, a weaker band of approximately 45 kDa which presumably represents the full-length PS1 protein. Antibodies ("520") directed at residues 304-318 at the apex ofthe TM6→7 loop of PS1, and antibodies ("4627") directed at residues 457-467 in the C-terminus of PS1, both recognize the same strong band of approximately 18 kDa. Antibodies 520 also recognize a weak band of 45 kDa coincident with the PS1 band detected by 14.2. Sequencing ofthe major C-terminal fragment from PSl-transfected human embryonic kidney cells (HEK 293) showed that the principal endoproteolytic cleavage occurs near M298 in the proximal portion ofthe TM6— >7 loop, possibly by enzymes other than the proteasome. These observations suggest that an endoproteolytic cleavage event occurs near the junction of exons 9 and 10 of PS 1. Full length PS1 in these cells is quickly turned over (t ]/2 < 60 min.) by the proteasome. To determine whether mutations in the presenilin proteins result in alterations of their proteolytic cleavage, Western blots containing lysates of fibroblast and neocortical brain homogenates from normal subjects and subjects carrying PS I mutations were investigated with the PS1 specific antibody Ab 14.2. In fibroblasts, there were no obvious differences in the relative intensities ofthe protein bands when lysates from heterozygous carriers ofthe PS1 mutations were compared with normal homozygotes. In contrast, there appeared to be a difference between PS1 mutation carriers and normals in homogenates of temporal neocortex from AD affected heterozygous carriers of either the PS1 A246E or C410Y mutations (which are located in TM6 and TM7 respectively). In heterozygotes, a strongly immunoreactive band of approximately 45 kDa was detected which initially appeared to correspond to the full- length PS 1 protein. Further analysis, however, revealed that this band represents an alternatively processed presenilin product. A similar band corresponding to this mutant processed PS 1 was observed in neocortical homogenates from some sporadic late-onset AD patients. These data suggest that (1) some pathogenic PS1 mutations associated with early-onset AD alter the way in which the presenilins are processed through endoproteolytic and proteasome pathways and (2) the presenilin proteins, and changes in the processing ofthe presenilins in the brain, are also implicated in late- onset and sporadic AD. 2. Presenilin-interacting Proteins In order to identify proteins which may bind to or otherwise interact with the presenilins in vivo, a yeast two-hybrid system was used as described below (Example 1). In particular, because mutations in the TM6— >7 loop domains are known to be causative of AD, a yeast two-hybrid system was used to identify cellular proteins which may interact with normal and mutant presenilin TM6→7 loop domains. Yeast two-hybrid studies were also done with cDNAs corresponding to the C-terminal 18 kDa endoproteolytic cleavage fragment, and with cDNAs corresponding to the TM1→2 intraluminal loop domain, which is also the site ofthe FAD associated Yl 15H missense mutation. In brief, cDNA sequences encoding the TM6—»7 loop (i.e., residues 266 to 409 of PS1) were ligated in- frame to the GAL4 DNA-binding domain in the pAS2-l yeast expression plasmid vector (Clontech). This plasmid was then co-transformed into S. cerevisiae strain Y 190 together with a library of human brain cDNAs ligated into the ρACT2 yeast expression vector bearing the GAL4 activation domain (Clontech). After appropriate selection and re-screening, a number of clones were recovered and sequenced bearing human brain cDNAs encoding peptides which interacted with the normal presenilin TM6→7 domain. To determine whether these presenilin interactions would be modified by AD related mutations within the TM6→7 loop, the yeast two-hybrid system was again used with TM6- 7 loop peptides containing the L286V, the L392V, and the exon 10 splicing mutants. When these mutant constructs were used as "bait" to re-screen the brain cDNA:GAL4 activation domain library, some but not all ofthe brain cDNA sequences which interacted with the normal presenilin were recovered. In addition, several new clones were identified which interacted with the mutant but not the normal presenilins. The clones corresponding to the PS-interacting proteins with the highest presenilin affinity are described in Example 1 and below. PS-interacting proteins, particularly those which interact selectively with either the normal or mutant presenilins, provide new targets for the identification of useful pharmaceuticals, new targets for diagnostic tools in the identification of individuals at risk, new sequences for the production of transformed cell lines and transgenic animal models, and new bases for therapeutic intervention in Alzheimer's Disease. In particular, the onset of AD may be associated with aberrant interactions between mutant presenilin proteins and normal forms of PS-interacting proteins such as those identified using the methods described herein. These changes may increase or decrease interactions present with normal PS 1 or may cause interaction with a novel mutation-specific PS-interacting protein. In addition, however, aberrant interactions may result from normal presenilins binding to mutant forms ofthe PS- interacting proteins and, therefore, mutations in the PS-interacting proteins may also be causative of AD. A. The S5a Subunit ofthe 26S Proteasome Two overlapping clones have been identified as representing a portion of the human protein alternatively known as Antisecretory Factor ("ASF") or the Multiubiquitin chain-binding S5a subunit ofthe 26S proteasome ("S5a"). These clones, which together include residues 70-377 of S5a, were shown to interact with the normal presenilin TM6→7 loop domain but only weakly with two TM6— 7 loop domain mutants tested (L286V, L392V). The PS1 :S5a interaction was confirmed by co-immunoprecipitation studies, and immunocytochemical studies showed S5a and PS1 are expressed in contiguous intracellular compartments in brain cells typically affected by AD. The interaction between PS1 and the proteasome could be relevant to the pathogenesis of Alzheimer's Disease (AD) through several possible mechanisms. First, most mammalian cells seem to maintain very low levels ofthe PS1 holoprotein. A notable exception to this are cells expressing the PS 1 Δ290-319 splicing mutation, which results in a mutant PS 1 holoprotein which is not endoproteolytically cleaved and which is, therefore, readily detectable. In the case ofthe Δ290-319 splicing mutation at least, the presence ofthe mutant PS1 holoprotein, or the absence or reduction in the 35 kDa N-terminal and 18 kDa C-terminal fragments, appears sufficient to cause AD. It is possible, therefore, that even very subtle changes in the turnover ofthe mutant PS1 holoprotein might have significant pathophysiological effects. Thus, mutations in either the presenilins or S5a which perturb the PS1 :S5a interaction in the mammalian CNS may cause the presenilin holoprotein to be aberrantly processed and cause AD. Therefore, modulation of presenilin proteolytic pathways might be applied therapeutically to enhance removal of mutant holoprotein. To assess a potential in vivo relationship between PSl and the S5a subunit ofthe 26S proteasome, the effects of proteasome inhibitors on PSl metabolism were investigated. Short term organotypic cultures of neonatal rat hippocampus and carcinoma of colon (CaCo2) cells (which express high levels of both PSl and PS2) were administered either the specific, reversible proteasome inhibitor N-acetyl- leucinyl-leucinyl-norleucinyl-H (LLnL) (Rock et al., 1994), or the specific irreversible proteasome inhibitor lactacystin (Fenteany et al., 1995). Both agents caused an increase in the steady state levels of PSl holoprotein. Both agents also prolonged the half-life ofthe PSl holoprotein in pulse chase experiments in hippocampal slices from ~15 minutes to ~35 minutes. As noted above, the PSl holoprotein appears to be rapidly turned over in normal cells. However, even after four hours of metabolic labelling, neither ofthe proteasome inhibitors affected the level of the 35 kDa N- terminal PSl fragment, or resulted in the appearance of novel species. These studies imply that the majority ofthe PSl holoprotein is catabolized directly via a rapid, proteasome dependent pathway in a manner similar to several other integral membrane proteins (e.g. Sec61 and CFTR). On the other hand, because the -35 kDa and ~ 18 kDa terminal fragments are still produced in the presence of proteasome inhibitors, this endoproteolytic cleavage of PSl is probably not mediated by the proteasome pathway. Therefore, it appears that at least two proteolytic pathways act upon the PSl holoprotein. An alternate possibility is that mutant PSl :S5a interactions may modify the function or the cellular regulation of S5a. To address this possibility, S5a levels were examined by Western blotting of lysates from postmortem temporal neocortex from non-AD neurologic controls (n = 8), sporadic AD (n = 8) and PSl -linked FAD (n = 4). In the majority of non-AD brains, polyclonal anti-S5a antibodies specifically detected an S5a species with Mr of- 50 kDa, which could be abolished by preabsorption ofthe antibody with recombinant His 6 -S5a or with extracts ofmvc-S5a transfected cells. In a subset of these control cases an additional S5a reactive band was observed at -34 kDa. In contrast, in tissue from all subjects with sporadic late onset AD, the predominant S5a reactive species was observed at ~ 40 kDa which was not seen in control tissue. The origin, and the functional significance of this altered electrophoretic mobility is unclear but indicates that S5a processing is altered in AD brains, irrespective of whether the AD is presenilin-linked or sporadic. Thus, the presenilin-proteasome interaction appears significant in several respects. First, the facts that the normal presenilin TM6→7 loop domain interacts with the S5a protein, that the mutant presenilin TM6→7 loop domains fail to interact (or interact very weakly) with the S5a protein, that presenilins bearing mutations in the TM6→7 loop domain appear to be differently cleaved and multiubiquitinated, that proteasomes are known to be involved in the cleavage and clearance of a variety of proteins (particularly multiubiquitinated proteins), that inhibition of proteasome activity inhibits cleavage ofthe presenilin holoproteins, and that S5a processing is altered in AD brains, all suggest (1) that the S5a subunit and the 26S proteasome are involved in the normal processing ofthe presenilins and that mutations which disrupt this normal interaction may be responsible for the abnormal processing observed in TM6→7 loop domain mutants; or (2) that the presenilin-proteasome interaction may modulate the activity of PSl, S5a, or both, with or without involving proteasome- mediated presenilin processing; or (3) that modulation ofthe normal quality control function of proteasome-mediated degradation of misfolded or mutant membrane proteins trafficking through the ER and Golgi (such as APP, Notch, or Prion proteins), and of misfolded, mutant, or ubiquitinated cytoplasmic proteins (including structural proteins such as tau, and short lived, proteasome processed signaling molecules such as NFkB). Thus, defective proteasome function might selectively cause these proteins (especially βAPP, tau, Prion) to be aberrantly metabolized. The latter would lead to the accumulation of neurotoxic, amyloidogenic protease-resistant derivatives such as Aβ and PrPsc, the accumulation of neurofibrillary tangles, and defective intracellular signaling functions. In support of these hypotheses, it should be noted that failure to clear hyperubiquitinated phosphorylated tau and other microtubule associated proteins is a prominent feature of Alzheimer's Disease (Kosik and Greenberg, 1994), suggesting a possible link between TM6→7 loop domain mutants, presenilin- proteasome interactions, tau-proteasome interactions, and the neurofibrillary tangles of tau protein in AD brains. Finally, proteasomes are known to be capable of degrading APP and of binding the Aβ peptides which are associated with Alzheimer's Disease, suggesting a possible link between TM6→7 loop domain mutants, presenilin-proteasome interactions, APP -proteasome interactions, and the amyloid plaques characteristic of AD brains. Furthermore, administration of proteasome inhibitors such as LLnL and Lactacystin cause severe disturbances in βAPP metabolism with increases in intracellular immature N-glycosylated βAPP, and the secretion of much larger amounts of Aβ 42 isoforms into the media (Klafki, et al., 1996). Therefore, presenilin processing and the presenilin-proteasome interaction are clear targets for the diagnosis as well as therapeutic intervention in AD. Thus, as described below, assays may now be provided for drugs which affect the proteasome- mediated cleavage ofthe presenilins, which affect the alternative endoproteolytic cleavage and ubiquitination ofthe mutant presenilins, or which otherwise affect the processing and trafficking of the presenilins or the S5a subunit of the proteasome. In addition, as mutations in the 26S proteasome which disrupt the normal processing of the presenilins are likely to be causative of Alzheimer's Disease, additional diagnostic assays are provided for detecting mutations in the S5a or other subunits of the proteasome. Finally, additional transformed cell lines and transgenic models may now be provided which have been altered by the introduction of a normal or mutant sequence encoding at least a functional domain ofthe proteasome. The appearance of abnormal electrophoretic forms of S5a (and/or other proteasome subunits) in biologic tissues and fluids can be used as a clinical test for diagnosis and monitoring of disease activity in subjects with sporadic forms of AD. B. GT24: A Protein with "Armadillo" Repeats Another PS-interacting protein, designated GT24, was identified from several over-lapping clones obtained using a PS 1 266J , 09 domain as bait in the yeast two- hybrid system and a human adult brain cDNA library. Six longer GT24 clones of -3.8 kb in size were subsequently obtained by screening of conventional cDNA libraries. The open reading frame within the longest GT24 clone obtained to date (Accession number U81004) suggests that GT24 is a protein of at least 1040 amino acids with a unique N-terminus, and considerable homology to several armadillo (arm) repeat proteins at its C-terminus. Thus, for example, residues 440-862 of GT24 (numbering from Accession number U81004) have 32-56% identity (p=1.2e 133 ) to residues 440-854 of murine pi 20 protein (Accession number Z 17804), and residues 367-815 of GT24 have 26-42% identity (p=0.0017) to residues 245-465 ofthe D, melanogaster armadillo segment polarity protein (Accession number PI 8824). The GT24 gene maps to chromosome 5pl5 near the anonymous microsatellite marker D5S748 and the Cri-du-Chat syndrome locus. Hybridization of unique 5' sequences of GT24 to Northern blots reveals that the GT24 gene is expressed as a range of transcripts varying in size between -3.9 and 5.0 kb in several regions of human brain, and in several non-neurologic tissues such as heart. In addition, in situ hybridization studies using a 289 bp single copy fragment from the 5' end of GT24 in four month old murine brain reveal GT24 transcription closely parallels that of PSl, with robust expression in dentate and hippocampal neurons, in scattered neocortical neurons, and in cerebellar Purkinje cells. In day El 3 murine embryos, GT24 is widely expressed at low levels, but is expressed at somewhat higher levels in somites and in the neural tube. A physiological in vivo interaction between GT24 and PS 1 is supported by co- immunoprecipitation studies in HEK293 cells transiently transfected with a wild type human PSl cDNA, a c-myc-tagged cDNA encoding residues 484-1040 of GT24 (including the C-terminal arm repeats), or both cDNAs. Cell lysates were immunoprecipitated with anti-PS 1 antibodies and then investigated for the presence of the mvc-GT24 protein by immuno-blotting. In PSl/mvc-GT24 double transfected cells, the immunoprecipitates contained a robust anti-mvc reactive band of Mr -60 kDa, which co-migrated with a mvc-GT24 control. In cells transfected with myc- GT24 only, a very weak band was detected after long exposures, presumably reflecting interaction ofthe mvc-GT24 with low levels of endogenous PS 1. No myc- reactive bands were detected in cells transfected with PSl alone, or in any ofthe transfected cells immunoprecipitated with pre-immune serum. Taken together, these observations strongly suggest that the observed PSl :GT24 interaction is physiologically relevant. To explore whether mutations in the TM6-TM7 loop of PSl might influence the PSl :GT24 interaction, we employed quantitative liquid β-galactosidase assays to directly compare the yeast-two-hybrid interaction ofthe C-terminal residues 499-1040 of GT24 with wildtype and mutant PSl 26(μ409 . These studies revealed that the interaction of GT24 499 . 104<) with a L286V mutant PSl domain was not significantly different from the interaction with the corresponding wild type PS 1 domain. In contrast, there was a significant reduction in the GT24 499 . 1040 interaction with the L392V mutant PSl construct. The absence of an effect ofthe L286V mutation, and the presence of an effect with the L392V mutation, may suggest that some mutations may effect PSl :GT24 binding, while others may modulate the PSl response to GT24 binding. The PS 1 :GT24 interaction could support several functions. The arm repeat motif of GT24 has been detected in several proteins with diverse functions including β-catenin and its invertebrate homologue armadillo, plakoglobin, pi 20, the adenomatous polyposis coli (APC) gene, suppressor of RNA polymerase 1 in yeast (SRP1), and smGDS. For example, β-catenin, pi 20 and plakoglobin play an essential role in intercellular adhesion, β-catenin/armadillo is involved in transduction of winglessAVnt signals during cell fate specification, and β-catenin and pi 20 may play a role in other receptor mediated signal transduction events including responses to trophic factors such as PDGF, EGF, CSF-1 and NGF. If the PS1:GT24 interaction is part of intercellular signaling pathways for trophic factors, or is involved in cell-cell adherence, disruption ofthe interaction may be involved in the neurodegenerative processes in PS-linked FAD brains, and in the increased sensitivity of PSl or PS2 transfected cells to apoptosis (Wolozin et al., 1996). It is of note that at least one arm protein, smGDS, stimulates GDP/GTP exchange on intracellular G-proteins (Kikuchi et al. 1992; Borguski et al., 1993), and that mutant forms of both βAPP and PS2 are thought to activate programmed cell death pathways through mechanisms involving heterotrimeric GTP/GDP proteins (Wolozin et al, 1996; Okamoto, et al., 1995; Yamatsuji, et al, 1996). The interaction between PS 1 and GT24 may also be involved in some of the developmental phenotypes associated with homozygous PS 1 knockouts in mice such as failed somitogenesis ofthe caudal embryo, short tail, and fatal cerebral hemorrhage at around day E13.5 (Wong et al., 1996). The resemblance of these skeletal phenotypes to those associated with null mutations in PA 1 and Notch, and the apparent suppressor effect of mutations in sell 2 on Notch/linl2 mediated signaling in C. elegans suggest that the PS proteins function in the Notch signaling pathway. In addition, mice homozygous for a knockout ofthe Wnt-3a gene (Takada et al., 1994), and murine homozygotes for a spontaneous mutation, "vestigial tail" or vt, in the Wnt-3a gene (Greco et al., 1996), have skeletal phenotypes of defective caudal somite and tail bud formation. The Wnt-3 knockouts are embryonic lethal by day 12.5. These phenotypes are similar to those of homozygous knockouts ofthe murine PSl gene (Wong et al., 1996). The observation that GT24 binds to PSl, is expressed in embryonic somites, and contains the armadillo repeat motif of other proteins used in the downstream signaling in the Wingless/Wnt pathway suggests that PSl is a downstream element in the GT24- WinglessAVnt pathway. This can be exploited to create a bioassay for drugs affecting the GT24-PS 1 interaction directly, or affecting upstream or downstream components of that interaction pathway, and can therefore be used to monitor the effects of presenilin mutations. For example, cells transfected with normal or mutant presenilins may be exposed to soluble Wnt-3a protein (or other Wnt proteins such as Wnt- 1 ) and assayed for changes which are specific to the Wingless/Wnt signaling pathway, or for any ofthe other changes described herein for cell assays (e.g., intracellular ion levels, Aβ processing, apoptosis, etc.). Thus, the GT24 protein also presents new targets for diagnosis as well as therapeutic intervention in AD. For example, as mutations in the GT24 protein may also be causative of Alzheimer's Disease, additional diagnostic assays are provided for detecting mutations in these sequences. Similarly, additional transformed cell lines and transgenic models may now be provided which have been altered by introduction of a normal or mutant nucleic acid encoding at least a functional domain of the GT24 protein, and particularly the functional domains (e.g., residues 70-377) which interact with the presenilins. Such transformed cells and transgenics will have utility in assays for compounds which modulate the presenilin-GT24 interactions. C. pQ071 : A Protein with "Armadillo" Repeats Another independent clone isolated in the initial screening with the wild type PS 1 26M09 "bait" also encodes a peptide with C-terminal arm repeats (clone Y2H25, Accession number U81005). A longer cDNA sequence corresponding to the Y2H25 clone has been deposited with GenBank as human protein p0071 (Accession number X81889) and is reproduced herein as SEQ ID NO: 5. Clone Y2H25 corresponds essentially to nucleotide positions 1682-1994 of SEQ LD NO: 5. Comparison ofthe predicted sequence ofthe Y2H25/p0071 ORF with that of GT24 confirms that they are related proteins with 47% overall amino acid sequence identity, and with 70% identity between residues 346-862 of GT24 and residues 509-1022 of p0071. This suggests that PSl interacts with a novel class of arm repeat containing proteins. The broad -4.5 kb hybridization signal obtained on Northern blots with the unique 5' end of GT24 could reflect either alternative splicing/polyadenylation of GT24 or, less likely, the existence of additional members of this family with higher degrees of N-terminal homology to GT24 than p0071. Cells transformed with these sequences, or transgenic animals including these sequences, will have additional utility as animal models of AD and for use in screening for compounds which modulate the action of normal and mutant presenilins. D. Rab l l One clone (Y2H9), disclosed herein as SEQ ID NO: 5, was identified as interacting with the normal PS 1 TM6— >7 loop domain and appears to correspond to a known gene, Rabl 1, available through Accession numbers X56740 and X53143. Rabl 1 is believed to be involved in protein/vesicle trafficking in the ER/Golgi. Note the possible relationship to processing of membrane proteins such as βAPP and Notch with resultant overproduction of toxic Aβ peptides (especially neurotoxic AJ3,. 42(43) isoforms) (Scheuner, et al, 1995). E. Retinoid X Receptor-β One clone (Y2H23b), disclosed herein as SEQ ID NO: 6, was identified as interacting with the normal PS 1 TM6— »7 loop domain and appears to correspond to a known gene, known variously as the retinoid X receptor-β, nuclear receptor co- regulator, or MHC Class I regulatory element, and is available through Accession numbers M84820, X63522 and M81766. This gene is believed to be involved in intercellular signaling, suggesting a possible relationship to the intercellular signaling function mediated by C. elegans sell2 and Notch/lin-12 (transcription activator). F. Cytoplasmic Chaperonin One clone (Y2H27), disclosed herein as SEQ ID NO: 8, was identified as interacting with the normal PSl TM6- 7 loop domain and appears to correspond to a known gene, a cytoplasmic chaperonin containing TCP-1, available through Accession numbers Ul 7104 and X74801. G. Clone Y2H35 One clone (Y2H35), disclosed herein as SEQ LD NO: 7, was identified as interacting with the normal PSl TM6→7 loop domain and appears to correspond to a sequence that codes for a protein of unknown function, available through Accession number R 12984, but which displays evolutionary conservation in yeast sequences. H. Clone Y2H171 One clone (Y2H171), disclosed herein as SEQ ID NO: 9, was identified as interacting with the normal PSl TM6→7 loop domain and appears to correspond to a known expressed repeat sequence available through Accession number D55326. I. Clone Y2H41 One clone (Y2H41) was identified which reacts strongly with the TM6- 7 loop domains of both PSl and PS2 as well as the mutant loop domains of PSl . The sequence, disclosed as SEQ ID NO: 10, shows strong homology to an EST of unknown function (Accession number T64843). III. Preferred Embodiments Based, in part, upon the discoveries disclosed and described herein, the following preferred embodiments ofthe present invention are provided. 1. Isolated Nucleic Acids In one series of embodiments, the present invention provides isolated nucleic acids corresponding to, or relating to, the nucleic acid sequences disclosed herein, which encode at least the PS-interacting domain of a PS-interacting protein. As described more fully below, the disclosed and enabled sequences include normal sequences from humans and other mammalian species, mutant sequences from humans and other mammalian species, homologous sequences from non-mammalian species such as Drosophila and C. elegans. subsets of these sequences useful as probes and PCR primers, subsets of these sequences encoding fragments ofthe PS-interacting proteins or corresponding to particular structural domains or polymorphic regions, complementary or antisense sequences corresponding to fragments ofthe PS- interacting protein genes, sequences in which the PS-interacting protein coding regions have been operably joined to exogenous regulatory regions, and sequences encoding fusion proteins in which portions ofthe PS-interacting proteins are fused to other proteins useful as markers of expression, as "tags" for purification, or in screens and assays for other proteins which interact with the PS-interacting proteins. Thus, in a first series of embodiments, isolated nucleic acid sequences are provided which encode at least a PS-interacting domain of a normal or mutant version of a PS-interacting protein. Examples of such nucleic acid sequences are disclosed herein as SEQ LD NOs: 1, 3, and 5-10. In addition, given the sequences ofthe PS- interacting domains ofthe PS-interacting proteins disclosed herein, one of ordinary skill in the art is clearly enabled to obtain the entire genomic or cDNA sequence encoding the entire PS-interacting proteins. Thus, for example, based upon the initial clone ofthe GT24 protein obtained using the yeast two-hybrid system (Example 1), the larger GT24 clone disclosed as SEQ ID NO: 3 was obtained by standard methods known in the art. Complete cDNA or genomic clones of each ofthe genes encoding the disclosed sequences may be similarly obtained by one of ordinary skill in the art. Therefore, the present invention provides complete genomic sequences as well as cDNA sequences corresponding to the PS-interacting protein genes ofthe invention. Alternatively, the nucleic acids ofthe invention may comprise recombinant genes or "minigenes" in which all or some introns ofthe PS-interacting protein genes have been removed, or in which various combinations of introns and exons and local cis- acting regulatory elements have been engineered in propagation or expression constructs or vectors. For purposes of reducing the size of a recombinant PS- interacting protein gene, a cDNA gene may be employed, or various combinations of introns and untranslated exons may be removed from a DNA construct. These and many variations on these embodiments are now enabled by the identification and description ofthe PS-interacting proteins provided herein. In addition to the disclosed PS-interacting protein and gene sequences, one of ordinary skill in the art is now enabled to identify and isolate nucleic acids representing PS-interacting genes or cDNAs which are allelic to the disclosed sequences or which are heterospecific homologues. Thus, the present invention provides isolated nucleic acids corresponding to these alleles and homologues, as well as the various above-described recombinant constructs derived from these sequences, by means which are well known in the art. Briefly, one of ordinary skill in the art may now screen preparations of genomic or cDNA, including samples prepared from individual organisms (e.g., human AD patients or their family members) as well as bacterial, viral, yeast or other libraries of genomic or cDNA, using probes or PCR primers to identify allelic or homologous sequences. Because it is desirable to identify mutations in the PS-interacting proteins which may contribute to the development of AD or other disorders, because it is desirable to identify polymorphisms in the PS -interacting proteins which are not pathogenic, and because it is also desirable to create a variety of animal models which may be used to study AD and screen for potential therapeutics, it is particularly contemplated that additional PS-mteracting protein sequences will be isolated from other preparations or libraries of human nucleic acids and from preparations or libraries from animals including rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates. Furthermore, PS-interacting protein homologues from yeast or invertebrate species, including C. elegans and other nematodes, as well as Drosophila and other insects, may have particular utility for drug screening. Standard hybridization screening or PCR techniques may be employed (as used, for example, in the identification ofthe mPSl gene disclosed in PCT Publication WO96/34099) to identify and/or isolate such allelic and homologous sequences using relatively short PS-interacting protein gene sequences. The sequences may include 8 or fewer nucleotides depending upon the nature ofthe target sequences, the method employed, and the specificity required. Future technological developments may allow the advantageous use of even shorter sequences. With current technology, sequences of 9-50 nucleotides, and preferably about 18-24 are preferred. These sequences may be chosen from those disclosed herein, or may be derived from other allelic or heterospecific homologues enabled herein. When probing mRNA or screening cDNA libraries, probes and primers from coding sequences (rather than introns) are preferably employed, and sequences which are omitted in alternative splice variants typically are avoided unless it is specifically desired to identify those variants. Allelic variants ofthe PS -interacting protein genes may be expected to hybridize to the disclosed sequences under stringent hybridization conditions, as defined herein, whereas lower stringency may be employed to identify heterospecific homologues. In another series of embodiments, the present invention provides for isolated nucleic acids which include subsets ofthe PS-interacting protein sequences or their complements. As noted above, such sequences will have utility as probes and PCR primers in the identification and isolation of allelic and homologous variants of the PS -interacting protein genes. Subsequences corresponding to polymorphic regions ofthe PS-interacting proteins, will also have particular utility in screening and/or genotyping individuals for diagnostic purposes, as described below. In addition, and also as described below, such subsets will have utility for encoding (1) fragments ofthe PS-interacting proteins for inclusion in fusion proteins, (2) fragments which comprise functional domains ofthe PS-interacting proteins for use in binding studies, (3) fragments ofthe PS-interacting proteins which may be used as immunogens to raise antibodies against the PS-interacting proteins, and (4) fragments ofthe PS-interacting proteins which may act as competitive inhibitors or as mimetics ofthe PS-interacting proteins to inhibit or mimic their physiological functions. Finally, such subsets may encode or represent complementary or antisense sequences which can hybridize to the PS -interacting protein genes or PS-interacting protein mRNA transcripts under physiological conditions to inhibit the transcription or translation of those sequences. Therefore, depending upon the intended use, the present invention provides nucleic acid subsequences ofthe PS -interacting protein genes which may have lengths varying from 8-10 nucleotides (e.g., for use as PCR primers) to nearly the full size ofthe PS-interacting protein genomic or cDNAs. Thus, the present invention provides isolated nucleic acids comprising sequences corresponding to at least 8-10, preferably 15, and more preferably at least 20 consecutive nucleotides ofthe PS-interacting protein genes, as disclosed or otherwise enabled herein, or to their complements. As noted above, however, shorter sequences may be useful with different technologies. In another series of embodiments, the present invention provides nucleic acids in which the coding sequences for the PS -interacting proteins, with or without introns or recombinantly engineered as described above, are operably joined to endogenous or exogenous 5' and/or 3' regulatory regions. Using the present disclosure and standard genetic techniques (e.g., PCR extensions, targeting gene walking), one of ordinary skill in the art is now enabled to clone the 5' and/or 3' endogenous regulatory regions of any ofthe disclosed PS-interacting protein genes. Similarly, allelic variants of these endogenous regulatory regions, as well as endogenous regulatory regions from other mammalian homologues, are similarly enabled without undue experimentation. Alternatively, exogenous regulatory regions (i.e., regulatory regions from a different conspecific gene or a heterospecific regulatory region) may be operably joined to the PS-interacting protein coding sequences in order to drive expression. Appropriate 5' regulatory regions will include promoter elements and may also include additional elements such as operator or enhancer sequences, ribosome binding sequences, RNA capping sequences, and the like. The regulatory region may be selected from sequences that control the expression of genes of prokaryotic or eukaryotic cells, their viruses, and combinations thereof. Such regulatory regions include, but are not limited to, the lac system, the trp system, the tac system, and the trc system; major operator and promoter regions of phage λ; the control region ofthe fd coat protein; early and late promoters of SV40; promoters derived from polyoma, adeno virus, retrovirus, baculovirus, and simian virus; 3- phosphogly cerate kinase promoter; yeast acid phosphatase promoters; yeast alpha- mating factors; promoter elements of other eukaryotic genes expressed in neurons or other cell types; and combinations thereof. In particular, regulatory elements may be chosen which are inducible or repressible (e.g., the β-galactosidase promoter) to allow for controlled and/or manipulable expression ofthe PS-interacting protein genes in cells transformed with these nucleic acids. Alternatively, the PS-interacting protein coding regions may be operably joined with regulatory elements which provide for tissue specific expression in multicellular organisms. Such constructs are particularly useful for the production of transgenic organisms to cause expression ofthe PS- interacting protein genes only in appropriate tissues. The choice of appropriate regulatory regions is within the ability and discretion of one of ordinary skill in the art and the recombinant use of many such regulatory regions is now established in the art. In another series of embodiments, the present invention provides for isolated nucleic acids encoding all or a portion ofthe PS-interacting proteins in the form of a fusion protein. In these embodiments, a nucleic acid regulatory region (endogenous or exogenous) is operably joined to a first coding region which is co valently joined in- frame to a second coding region. The second coding region optionally may be covalently joined to one or more additional coding regions and the last coding region is joined to a termination codon and, optionally, appropriate 3' regulatory regions (e.g., polyadenylation signals). The PS-interacting protein sequences ofthe fusion protein may represent the first, second, or any additional coding regions. The PS-interacting protein sequences may be conserved or non- conserved domains and can be placed in any coding region ofthe fusion. The non- PS-interacting protein sequences ofthe fusion may be chosen according to the needs and discretion ofthe practitioner and are not limited by the present invention. Useful non-PS-interacting protein sequences include, for example, short sequence "tags" such as antigenic determinants or poly-His tags which may be used to aid in the identification or purification ofthe resultant fusion protein. Alternatively, the non- PS-interacting protein coding region may encode a large protein or protein fragment, such as an enzyme or binding protein which also may assist in the identification and purification ofthe protein, or which may be useful in an assay such as those described below. Particularly contemplated fusion proteins include poly-His and GST (glutathione S-transferase) fusions which are useful in isolating and purifying the presenilins-interacting proteins, and the yeast two hybrid fusions, described below, which are useful in assays to identify other proteins which bind to or interact with the PS-interacting proteins. In another series of embodiments, the present invention provides isolated nucleic acids in the form of recombinant DNA constructs in which a marker or reporter gene (e.g., β-galactosidase, luciferase) is operably joined to the 5' regulatory region of a PS-interacting protein gene such that expression ofthe marker gene is under the control of those regulatory sequences. Using the PS-interacting protein regulatory regions enabled herein, including regulatory regions from human and other mammalian species, one of ordinary skill in the art is now enabled to produce such constructs. As discussed more fully below, such isolated nucleic acids may be used to produce cells, cell lines or transgenic animals which are useful in the identification of compounds which can, directly or indirectly, differentially affect the expression ofthe PS -interacting proteins. Finally, the isolated nucleic acids ofthe present invention include any of the above described sequences when included in vectors. Appropriate vectors include cloning vectors and expression vectors of all types, including plasmids, phagemids, cosmids, episomes, and the like, as well as integration vectors. The vectors may also include various marker genes (e.g., antibiotic resistance or susceptibility genes) which are useful in identifying cells successfully transformed therewith. In addition, the vectors may include regulatory sequences to which the nucleic acids ofthe invention are operably joined, and/or may also include coding regions such that the nucleic acids ofthe invention, when appropriately ligated into the vector, are expressed as fusion proteins. Such vectors may also include vectors for use in yeast "two hybrid," baculovirus, and phage-display systems. The vectors may be chosen to be useful for prokaryotic, eukaryotic or viral expression, as needed or desired for the particular application. For example, vaccinia virus vectors or simian virus vectors with the SV40 promoter (e.g., pSV2), or Herpes simplex virus or adeno-associated virus may be useful for transfection of mammalian cells including neurons in culture or in vivo, and the baculovirus vectors may be used in transfecting insect cells (e.g., butterfly cells). A great variety of different vectors are now commercially available and otherwise known in the art, and the choice of an appropriate vector is within the ability and discretion of one of ordinary skill in the art. 2. Substantially Pure Proteins The present invention provides for substantially pure preparations ofthe PS-interacting proteins, fragments ofthe PS -interacting proteins, and fusion proteins including the PS-interacting proteins or fragments thereof. The proteins, fragments and fusions have utility, as described herein, in the generation of antibodies to normal and mutant PS-interacting proteins, in the identification of proteins (aside from the presenilins) which bind to the PS -interacting proteins, and in diagnostic and therapeutic methods. Therefore, depending upon the intended use, the present invention provides substantially pure proteins or peptides comprising amino acid sequences which are subsequences of the complete PS-interacting proteins and which may have lengths varying from 4-10 amino acids (e.g., for use as immunogens), or 10- 100 amino acids (e.g., for use in binding assays), to the complete PS-interacting proteins. Thus, the present invention provides substantially pure proteins or peptides comprising sequences corresponding to at least 4-5, preferably 6-10, and more preferably at least 50 or 100 consecutive amino acids ofthe PS-interacting proteins, as disclosed or otherwise enabled herein. The proteins or peptides ofthe invention may be isolated and purified by any of a variety of methods selected on the basis ofthe properties revealed by their protein sequences. For example, the PS-interacting proteins may be isolated from cells in which the PS-interacting protein is normally highly expressed. Alternatively the PS -interacting protein, fusion protein, or fragment thereof, may be purified from cells transformed or transfected with expression vectors (e.g., baculovirus systems such as the pPbac and pMbac vectors (Stratagene, La Jolla, CA); yeast expression systems such as the pYESHIS Xpress vectors (Invitrogen, San Diego, CA); eukaryotic expression systems such as pcDNA3 (Invitrogen, San Diego, CA) which has constant constitutive expression, or LacSwitch (Stratagene, La Jolla, CA) which is inducible; or prokaryotic expression vectors such as pKK233-3 (Clontech, Palo Alto, CA). In the event that the protein or fragment integrates into the endoplasmic reticulum or plasma membrane ofthe recombinant cells (e.g., eukaryotic cells), the protein may be purified from the membrane fraction. Altematively, if the protein aggregates in inclusion bodies within the recombinant cells (e.g., prokaryotic cells), the protein may be purified from whole lysed cells or from solubilized inclusion bodies. Purification can be achieved using standard protein purification procedures including, but not limited to, gel-filtration chromatography, ion-exchange chromatography, high-performance liquid chromatography (RP-HPLC, ion-exchange HPLC, size-exclusion HPLC, high-performance chromatofocusing chromatography, hydrophobic interaction chromatography, immunoprecipitation, or immunoaffinity purification. Gel electrophoresis (e.g., PAGE, SDS-PAGE) can also be used to isolate a protein or peptide based on its molecular weight, charge properties and hydrophobicity. A PS-interacting protein, or a fragment thereof, may also be conveniently purified by creating a fusion protein including the desired PS-interacting protein sequence fused to another peptide such as an antigenic determinant or poly-His tag (e.g., QIAexpress vectors, QIAGEN Corp., Chatsworth, CA), or a larger protein (e.g., GST using the pGEX-27 vector (Amrad, USA) or green fluorescent protein using the Green Lantern vector (GIBCO/BRL. Gaithersburg, MD). The fusion protein may be expressed and recovered from prokaryotic or eukaryotic cells and purified by any standard method based upon the fusion vector sequence. For example, the fusion protein may be purified by immunoaffinity or immunoprecipitation with an antibody to the non-PS-interacting protein portion ofthe fusion or, in the case of a poly-His tag, by affinity binding to a nickel column. The desired PS-interacting protein or fragment may then be further purified from the fusion protein by enzymatic cleavage ofthe fusion protein. Methods for preparing and using such fusion constructs for the purification of proteins are well known in the art and several kits are commercially available for this purpose. In light ofthe present disclosure, one is now enabled to employ such fusion constructs with the PS-interacting proteins. 3. Antibodies to the PS-interacting Proteins The present invention also provides antibodies, and methods of making antibodies, which selectively bind to the PS-interacting proteins or fragments thereof. Of particular importance, by identifying the PS-interacting domains ofthe PS- interacting proteins, and methods of identifying mutant forms ofthe PS-interacting proteins associated with Alzheimer's Disease, the present invention provides antibodies, and methods of making antibodies, which will selectively bind to and, thereby, identify and/or distinguish normal and mutant (i.e., pathogenic) forms ofthe PS-interacting proteins. The antibodies ofthe invention have utility as laboratory reagents for, inter alia, immunoaffinity purification ofthe PS-interacting proteins, Western blotting to identify cells or tissues expressing the PS-interacting proteins, and immunocytochemistry or immunofluorescence techniques to establish the subcellular location ofthe proteins. In addition, as described below, the antibodies ofthe invention may be used as diagnostics tools to identify carriers of AD-related PS- interacting protein alleles, or as therapeutic tools to selectively bind and inhibit pathogenic forms ofthe PS-interacting proteins in vivo. The antibodies ofthe invention may be generated using the entire PS- interacting proteins ofthe invention, or using any PS-interacting protein epitope which is characteristic of that protein and which substantially distinguishes it from other host proteins. Any method of choosing antigenic determinants known in the art may, of course, be employed. Such epitopes may be identified by comparing sequences of, for example, 4-10 amino acid residues from a PS-interacting protein sequence to computer databases of protein sequences from the relevant host. In addition, larger fragments (e.g., 8-20 or, preferably, 9-15 residues) including one or more potential epitopes may also be employed. Antibodies to the PS-interacting domains (identified by the yeast two-hybrid assays described below) are expected to have the greatest utility both diagnostically and therapeutically. On the other hand, antibodies against highly conserved domains are expected to have the greatest utility for purification or identification of PS -interacting proteins. PS-interacting protein immunogen preparations may be produced from crude extracts (e.g., lysates or membrane fractions of cells highly expressing the proteins), from proteins or peptides substantially purified from cells which naturally or recombinantly express them or, for short immunogens, by chemical peptide synthesis. The immunogens may also be in the form of a fusion protein in which the non-PS-interacting protein region is chosen for its adjuvant properties. As used herein, a PS-interacting protein immunogen shall be defined as a preparation including a peptide comprising at least 4-8, and preferably at least 9-15 consecutive amino acid residues of a PS -interacting proteins, as disclosed or otherwise enabled herein. Sequences of fewer residues may, of course, also have utility depending upon the intended use and future technological developments. Therefore, any PS- interacting protein derived sequences which are employed to generate antibodies to the PS-interacting proteins should be regarded as PS-interacting protein immunogens. The antibodies of the invention may be polyclonal or monoclonal, or may be antibody fragments, including Fab fragments, F(ab') 2 , and single chain antibody fragments. In addition, after identifying useful antibodies by the method ofthe invention, recombinant antibodies may be generated, including any ofthe antibody fragments listed above, as well as humanized antibodies based upon non-human antibodies to the PS -interacting proteins. In light ofthe present disclosure, as well as the characterization of other PS-interacting proteins enabled herein, one of ordinary skill in the art may produce the above-described antibodies by any of a variety of standard means well known in the art. For an overview of antibody techniques, see Antibody Engineering: A Practical Guide. Borrebaek, ed., W.H. Freeman & Company, NY (1992), or Antibody Engineering. 2nd Ed., Borrebaek, ed., Oxford University Press, Oxford (1995). As a general matter, polyclonal antibodies may be generated by first immunizing a mouse, rabbit, goat or other suitable animal with the PS-interacting protein immunogen in a suitable carrier. To increase the immunogenicity ofthe preparation, the immunogen may be coupled to a carrier protein or mixed with an adjuvant (e.g., Freund's adjuvant). Booster injections, although not necessary are recommended. After an appropriate period to allow for the development of a humoral response, preferably several weeks, the animals may be bled and the sera may be purified to isolate the immunoglobulin component. Similarly, as a general matter, monoclonal anti-PS-interacting protein antibodies may be produced by first injecting a mouse, rabbit, goat or other suitable animal with a PS-interacting protein immunogen in a suitable carrier. As above, carrier proteins or adjuvants may be utilized and booster injections (e.g., bi- or tri¬ weekly over 8-10 weeks) are recommended. After allowing for development of a humoral response, the animals are sacrificed and their spleens are removed and resuspended in, for example, phosphate buffered saline (PBS). The spleen cells serve as a source of lymphocytes, some of which are producing antibody ofthe appropriate specificity. These cells are then fused with an immortalized cell line (e.g., myeloma), and the products ofthe fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT. The wells are serially screened and replated, each time selecting cells making useful antibody. Typically, several screening and replating procedures are carried out until over 90% ofthe wells contain single clones which are positive for antibody production. Monoclonal antibodies produced by such clones may be purified by standard methods such as affinity chromatography using Protein A Sepharose, by ion-exchange chromatography, or by variations and combinations of these techniques. The antibodies ofthe invention may be labelled or conjugated with other compounds or materials for diagnostic and/or therapeutic uses. For example, they may be coupled to radionuclides, fluorescent compounds, or enzymes for imaging or therapy, or to liposomes for the targeting of compounds contained in the liposomes to a specific tissue location. 4. Transformed Cell Lines The present invention also provides for cells or cell lines, both prokaryotic and eukaryotic, which have been transformed or transfected with the nucleic acids of the present invention so as to cause clonal propagation of those nucleic acids and/or expression ofthe proteins or peptides encoded thereby. Such cells or cell lines will have utility both in the propagation and production ofthe nucleic acids and proteins of the present invention but also, as further described herein, as model systems for diagnostic and therapeutic assays. In particular, it is expected that cells co- transformed with PS-interacting protein sequences as well as presenilin sequences wwiill have improved utility as models ofthe biochemical pathways which may be affected in AD. For example, cells co-transformed with the interacting domains of PS- interacting sequences and presenilins in yeast two-hybrid fusion constructs, will have utility in screening for compounds which either enhance or inhibit interactions between these domains. Similarly, for cells transformed with a heterospecific presenilin, co-transformation with a similarly heterospecific PS -interacting protein, or co-transformation and homologous recombination to introduce a similarly heterospecific PS-interacting domain of a PS-interacting protein (e.g., "humanizing" a non-human endogenous PS-interacting protein), will result in a better model system for studying the interactions ofthe presenilins and the PS-interacting proteins. Cells transformed with only PS-interacting sequences will, of course, have utility of their own for studying the role of these proteins in the etiology of AD, and also as precursors for presenilin co-transformed cells. As used herein, the term "transformed cell" is intended to embrace any cell, or the descendant of any cell, into which has been introduced any ofthe nucleic acids ofthe invention, whether by transformation, transfection, infection, or other means. Methods of producing appropriate vectors, transforming cells with those vectors, and identifying transformants are well known in the art and are only briefly reviewed here (see, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). Prokaryotic cells useful for producing the transformed cells ofthe invention include members of the bacterial genera Escherichia (e.g., E. coli " ). Pseudomonas (e.g., P. aeruginosa). and Bacillus (e.g., B. subtillus. R stearothermophilus). as well as many others well known and frequently used in the art. Prokaryotic cells are particularly useful for the production of large quantities of the proteins or peptides ofthe invention (e.g., normal or mutant PS-interacting proteins, fragments ofthe PS-interacting proteins, fusion proteins ofthe PS- interacting proteins). Bacterial cells (e.g., E. coli) may be used with a variety of expression vector systems including, for example, plasmids with the T7 RNA polymerase/promoter system, bacteriophage λ regulatory sequences, or Ml 3 Phage mGPI-2. Bacterial hosts may also be transformed with fusion protein vectors which create, for example, lacZ, trpE, maltose-binding protein, poly-His tags, or glutathione- S-transferase fusion proteins. All of these, as well as many other prokaryotic expression systems, are well known in the art and widely available commercially (e.g., pGEX-27 (Amrad, USA) for GST fusions). Eukaryotic cells and cell lines useful for producing the transformed cells of the invention include mammalian cells and cell lines (e.g., PC 12, COS, CHO, fibroblasts, myelomas, neuroblastomas, hybridomas, human embryonic kidney 293, oocytes, embryonic stem cells), insect cells lines (e.g., using baculovirus vectors such as pPbac or pMbac (Stratagene, La Jolla, CA)), yeast (e.g., using yeast expression vectors such as pYESHIS (Invitrogen, CA)), and fungi. Eukaryotic cells are particularly useful for embodiments in which it is necessary that the PS-interacting proteins, or functional fragments thereof, perform the functions and/or undergo the intracellular interactions associated with either the normal or mutant proteins. Thus, for example, transformed eukaryotic cells are preferred for use as models of PS- interacting protein function or interaction, and assays for screening candidate therapeutics preferably employ transformed eukaryotic cells. To accomplish expression in eukaryotic cells, a wide variety of vectors have been developed and are commercially available which allow inducible (e.g., LacSwitch expression vectors, Stratagene, La Jolla, CA) or cognate (e.g., pcDNA3 vectors, Invitrogen, Chatsworth, CA) expression of PS-interacting protein nucleotide sequences under the regulation of an artificial promoter element. Such promoter elements are often derived from CMV or SV40 viral genes, although other strong promoter elements which are active in eukaryotic cells can also be employed to induce transcription of PS-interacting protein nucleotide sequences. Typically, these vectors also contain an artificial polyadenylation sequence and 3' UTR which can also be derived from exogenous viral gene sequences or from other eukaryotic genes. Furthermore, in some constructs, artificial, non-coding, spliceable introns and exons are included in the vector to enhance expression ofthe nucleotide sequence of interest. These expression systems are commonly available from commercial sources and are typified by vectors such as ρcDNA3 and pZeoSV (Invitrogen, San Diego, CA). Innumerable commercially-available as well as custom-designed expression vectors are available from commercial sources to allow expression of any desired PS- interacting protein transcript in more or less any desired cell type, either constitutively or after exposure to a certain exogenous stimulus (e.g., withdrawal of tetracycline or exposure to IPTG). Vectors may be introduced into the recipient or "host" cells by various methods well known in the art including, but not limited to, calcium phosphate transfection, strontium phosphate transfection, DEAE dextran transfection, electroporation, lipofection (e.g., Dosper Liposomal transfection reagent, Boehringer Mannheim, Germany), microinjection, ballistic insertion on micro-beads, protoplast fusion or, for viral or phage vectors, by infection with the recombinant virus or phage. 5. Transgenic Animal Models The present invention also provides for the production of transgenic non- human animal models in which mutant or wild type PS-interacting protein sequences are expressed, or in which the PS-interacting protein genes have been inactivated (e.g., "knock-out" deletions), for the study of Alzheimer's Disease, for the screening of candidate pharmaceutical compounds, for the creation of explanted mammalian CNS cell cultures (e.g., neuronal, glial, organotypic or mixed cell cultures), and for the evaluation of potential therapeutic interventions. Prior to the present invention, a partial animal model for Alzheimer's Disease existed via the insertion and over- expression of a mutant form ofthe human amyloid precursor protein gene as a minigene under the regulation ofthe platelet-derived growth factor β receptor promoter element (Games et al., 1995). This mutant (βAPP 717 Val→Ile) causes the appearance of synaptic pathology and amyloid β peptide deposition in the brain of transgenic animals bearing this transgene in high copy number. These changes in the brain ofthe transgenic animal are very similar to that seen in human AD (Games et al., 1995). It is, however, as yet unclear whether these animals become demented, but there is general consensus that it is now possible to recreate at least some aspects of AD in mice. In addition, transgenic animal models in which the presenilin genes are genetically engineered are disclosed in PCT Publication WO96/34099. These transgenic animal models have been shown to have altered Aβ production and altered hippocampus-dependent memory function. Animal species suitable for use in the animal models ofthe present invention include, but are not limited to, rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates (e.g., Rhesus monkeys, chimpanzees). For initial studies, transgenic rodents (e.g., mice) may be preferred due to their relative ease of maintenance and shorter life spans. However, transgenic yeast or invertebrates (e.g., nematodes, insects) may be preferred for some studies because they will allow for even more rapid and inexpensive screening. For example, invertebrates bearing mutant PS-interacting protein homologues (or mammalian PS- interacting protein transgenes) which cause a rapidly occurring and easily scored phenotype (e.g., abnormal vulva or eye development after several days) can be used as screens for drugs which block the effect ofthe mutant gene. Such invertebrates may prove far more rapid and efficient for mass screenings than larger vertebrate animals. Once lead compounds are found through such screens, they may be tested in higher animals such a rodents. Ultimately, transgenic non-human primates may be preferred for longer term studies due to their greater similarity to humans and their higher cognitive abilities. Using the nucleic acids disclosed and otherwise enabled herein, there are now several available approaches for the creation of a transgenic animal model for Alzheimer's Disease. Thus, the enabled animal models include: (1) Animals in which sequences encoding at least a functional domain of a normal human PS-interacting protein gene have been recombinantly introduced into the genome ofthe animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; in which sequences encoding at least a functional domain of a normal human PS-interacting protein gene have been recombinantly substituted for one or both copies ofthe animal's homologous PS-interacting protein gene by homologous recombination or gene targeting; and/or in which one or both copies of one ofthe animal's homologous PS-interacting protein genes have been recombinantly "humanized" by the partial substitution of sequences encoding the human homologue by homologous recombination or gene targeting. These animals are useful for evaluating the effects ofthe transgenic procedures, and the effects ofthe introduction or substitution of a human or humanized PS-interacting protein gene. (2) Animals in which sequences encoding at least a functional domain of a mutant (i.e., pathogenic) human PS- interacting protein gene have been recombinantly introduced into the genome ofthe animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; in which sequences encoding at least a functional domain of a mutant human PS- interacting protein gene have been recombinantly substituted for one or both copies of the animal's homologous PS -interacting protein gene by homologous recombination or gene targeting; and or in which one or both copies of one ofthe animal's homologous PS -interacting protein genes have been recombinantly "humanized" by the partial substitution of sequences encoding a mutant human homologue by homologous recombination or gene targeting. These animals are useful as models which will display some or all ofthe characteristics, whether at the biochemical, physiological and/or behavioral level, of humans carrying one or more alleles which are pathogenic of Alzheimer's Disease or other diseases associated with mutations in the PS-interacting protein genes. (3) Animals in which sequences encoding at least a functional domain of a mutant version of one of that animal's PS -interacting protein genes (bearing, for example, a specific mutation corresponding to, or similar to, one ofthe pathogenic mutations ofthe human PS-interacting proteins) have been recombinantly introduced into the genome ofthe animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; and/or in which sequences encoding at least a functional domain of a mutant version of one of that animal's PS-interacting protein genes (bearing, for example, a specific mutation corresponding to, or similar to, one ofthe pathogenic mutations ofthe human PS-interacting proteins) have been recombinantly substituted for one or both copies ofthe animal's homologous PS- interacting protein gene by homologous recombination or gene targeting. These animals are also useful as models which will display some or all ofthe characteristics, whether at the biochemical, physiological and/or behavioral level, of humans carrying one or more alleles which are pathogenic of Alzheimer's Disease. (4) "Knock-out" animals in which one or both copies of one ofthe animal's PS-interacting protein genes have been partially or completely deleted by homologous recombination or gene targeting, or have been inactivated by the insertion or substitution by homologous recombination or gene targeting of exogenous sequences (e.g., stop codons, lox p sites). Such animals are useful models to study the effects which loss of PS-interacting protein gene expression may have, to evaluate whether loss of function is preferable to continued expression of mutant forms, and to examine whether other genes can be recruited to replace a mutant PS-interacting protein or to intervene with the effects of other genes (e.g., PSl, PS2, APP or ApoE) causing AD as a treatment for AD or other disorders. For example, a normal PS-interacting protein gene may be necessary for the action of mutant presenilin or APP genes to actually be expressed as AD and, therefore, transgenic PS-interacting protein animal models may be of use in elucidating such multigenic interactions. In addition to transgenic animal models in which the expression of one or more ofthe PS-interacting proteins is altered, the present invention also provides for the production of transgenic animal models in which the expression of one or more of the presenilins, APP, or ApoE is altered. The nucleic acids encoding the presenilins, APP, and ApoE are known in the art, a methods for producing transgenic animals with these sequences are also known (see, e.g., PCT Publication WO96/34099; Games et al., 1995). Indeed, because non-human animals may differ from humans not only in their PS-interacting protein sequences, but also in the sequences of their presenilin, APP and/or ApoE homologues, it is particularly contemplated that transgenics may be produced which bear recombinant normal or mutant human sequences for at least one presenilin, APP and/or ApoE gene in addition to recombinant sequences for one or more PS-interacting proteins. Such co-transformed animal models would possess more elements ofthe human molecular biology and, therefore, are expected to be better models of human disorders. Thus, in accordance with the present invention, transgenic animal models may be produced bearing normal or mutant sequences for one or more PS-interacting proteins, or interacting domains of these proteins. These animals will have utility in that they can be crossed with animals bearing a variety of normal or mutant presenilin, APP or ApoE sequences to produce co-transformed animal models. Furthermore, as detailed below, it is expected that mutations in the PS-interacting genes, like mutations in the presenilins themselves, may be causative of Alzheimer's Disease and/or other disorders as well (e.g., other cognitive, intellectual, neurological or psychological disorders such as cerebral hemorrhage, schizophrenia, depression, mental retardation and epilepsy). Therefore, transgenic animal models bearing normal or mutant sequences corresponding to the PS- interacting proteins, absent transformation with any presenilin, APP or ApoE sequences, will have utility of their own in the study of such disorders. As detailed below, preferred choices for transgenic animal models transformed with PS-interacting proteins, or domains of PS-interacting proteins, include those transformed with normal or mutant sequences corresponding to the clones identified and described in Example 1 and disclosed in SEQ ID NOs: 1-12. These clones, which interact with normal or mutant PSl TM6→7 loop domains, were identified according to the methods described in Example 1 , below, and PCT Publication WO96/34099. These clones, longer nucleic acid sequences comprising these clones, and other clones identified according to this and other methods ofthe invention (e.g., allelic and splice variants or heterospecific homologues of these clones) may all be employed in accordance with the present invention to produce animal models which, with or without co-transformation with presenilin, APP and/or ApoE sequences, will have utility in the study of Alzheimer's Disease and/or other cognitive, intellectual, neurological or psychological disorders. Thus, using the nucleic acids disclosed and otherwise enabled herein, one of ordinary skill in the art may now produce any of the following types of transgenic animal models with altered PS-interacting protein expression: (1) Animals in which sequences encoding at least a functional domain of a normal human PS-interacting protein gene have been recombinantly introduced into the genome ofthe animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; in which sequences encoding at least a functional domain of a normal human PS-interacting protein gene have been recombinantly substituted for one or both copies ofthe animal's homologous PS-interacting protein gene by homologous recombination or gene targeting; and/or in which one or both copies of one ofthe animal's homologous PS -interacting protein genes have been recombinantly "humanized" by the partial substitution of sequences encoding the human homologue by homologous recombination or gene targeting. These animals are particularly useful for providing transgenic models which express human PS-interacting proteins as well as human presenilin proteins. They are also useful in evaluating the effects ofthe transgenic procedures, and the effects ofthe introduction or substitution of a human or humanized PS-interacting protein gene. (2) Animals in which sequences encoding at least a functional domain of a mutant (i.e., pathogenic) human PS-interacting protein gene have been recombinantly introduced into the genome ofthe animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; in which sequences encoding at least a functional domain of a mutant human PS-interacting protein gene have been recombinantly substituted for one or both copies ofthe animal's homologous PS-interacting protein gene by homologous recombination or gene targeting; and/or in which one or both copies of one ofthe animal's homologous PS-interacting protein genes have been recombinantly "humanized" by the partial substitution of sequences encoding a mutant human homologue by homologous recombination or gene targeting. These animals are useful as models which will display some or all ofthe characteristics, whether at the biochemical, physiological and/or behavioral level, of humans carrying one or more alleles which are pathogenic of Alzheimer's Disease or other diseases associated with mutations in these PS- interacting genes. (3) Animals in which sequences encoding at least a functional domain of a mutant version of one of that animal's PS-interacting protein genes (bearing, for example, a specific mutation corresponding to, or similar to, one ofthe pathogenic mutations ofthe human PS-interacting proteins) have been recombinantly introduced into the genome ofthe animal as an additional gene, under the regulation of either an exogenous or an endogenous promoter element, and as either a minigene or a large genomic fragment; and/or in which sequences encoding at least a functional domain of a mutant version of one of that animal's PS-interacting protein genes (bearing, for example, a specific mutation corresponding to, or similar to, one ofthe pathogenic mutations ofthe humans PS-interacting proteins) have been recombinantly substituted for one or both copies ofthe animal's homologous PS-interacting protein gene by homologous recombination or gene targeting. These animals are also useful as models which will display some or all ofthe characteristics, whether at the biochemical, physiological and/or behavioral level, of humans carrying one or more alleles which are pathogenic of Alzheimer's Disease. (4) "Knock-out" animals in which one or both copies of one ofthe animal's PS-interacting protein genes have been partially or completely deleted by homologous recombination or gene targeting, or have been inactivated by the insertion or substitution by homologous recombination or gene targeting of exogenous sequences (e.g., stop codons, lox p sites). Such animals are useful models to study the effects which loss of PS- interacting protein gene expression may have, to evaluate whether loss of function is preferable to continued expression, and to examine whether other genes can be recruited to replace a mutant PS-interacting protein or to intervene with the effects of other genes (e.g., APP or ApoE) causing AD as a treatment for AD or other disorders. For example, a normal PS-interacting protein may be necessary for the action of mutant PSl, PS2 or APP genes to actually be expressed as AD and, therefore, transgenic PS-interacting protein animal models may be of use in elucidating such multigenic interactions. In some preferred embodiments, transgenic animal models are produced in which just the PS-interacting domains ofthe PS-interacting proteins are introduced into the genome ofthe animal by homologous recombination. Thus, for example, preferred embodiments include transgenic animals in which the PS-interacting domains of PS-interacting proteins are "humanized" by homologous recombination with sequences from human PS-interacting proteins. These animals may then be bred with transgenics in which normal or mutant presenilin sequences have been introduced. The progeny of these animals, having both human presenilin and human PS-interacting protein sequences, will provide improved animal models for Alzheimer's Disease. To create an animal model (e.g., a transgenic mouse), a normal or mutant PS-interacting gene (e.g., normal or mutant S5a, GT24, p0071, Rabl 1, etc.), or a normal or mutant version of a recombinant nucleic acid encoding at least a functional domain of a PS-interacting gene (e.g., the PS-interacting domains obtained in the yeast two-hybrid system), can be inserted into a germ line or stem cell using standard techniques of oocyte microinjection, or transfection or microinjection into embryonic stem cells. Animals produced by these or similar processes are referred to as transgenic. Similarly, if it is desired to inactivate or replace an endogenous presenilin or PS-interacting protein gene, homologous recombination using embryonic stem cells may be employed. Animals produced by these or similar processes are referred to as "knock-out" (inactivation) or "knock-in" (replacement) models. For oocyte injection, one or more copies ofthe recombinant DNA constructs ofthe present invention may be inserted into the pronucleus of a just- fertilized oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The livebom animals are screened for integrants using analysis of DNA (e.g., from the tail veins of offspring mice) for the presence ofthe inserted recombinant transgene sequences. The transgene may be either a complete genomic sequence injected as a YAC, BAC, PAC or other chromosome DNA fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing all of the coding region and other elements found to be necessary for optimum expression. Retroviral infection of early embryos can also be done to insert the recombinant DNA constructs ofthe invention. In this method, the transgene (e.g., a normal or mutant S5a, GT24, p0071, Rab 11, etc., sequence) is inserted into a retroviral vector which is used to infect embryos (e.g., mouse or non-human primate embryos) directly during the early stages of development to generate chimeras, some of which will lead to germline transmission. Homologous recombination using stem cells allows for the screening of gene transfer cells to identify the rare homologous recombination events. Once identified, these can be used to generate chimeras by injection of blastocysts, and a proportion ofthe resulting animals will show germline transmission from the recombinant line. This methodology is especially useful if inactivation of a gene is desired. For example, inactivation ofthe S5a gene in mice may be accomplished by designing a DNA fragment which contains sequences from an S5a coding region flanking a selectable marker. Homologous recombination leads to the insertion ofthe marker sequences in the middle ofthe coding region, causing inactivation ofthe S5a gene and/or deletion of internal sequences. DNA analysis of individual clones can then be used to recognize the homologous recombination events. The techniques of generating transgenic animals, as well as the techniques for homologous recombination or gene targeting, are now widely accepted and practiced. A laboratory manual on the manipulation ofthe mouse embryo, for example, is available detailing standard laboratory techniques for the production of transgenic mice (Hogan et al., 1986). To create a transgene, the target sequence of interest (e.g., normal or mutant presenilin sequences, normal or mutant PS-interacting protein sequences) are typically ligated into a cloning site located downstream of some promoter element which will regulate the expression of RNA from the sequence. Downstream ofthe coding sequence, there is typically an artificial polyadenylation sequence. In the transgenic models that have been used to successfully create animals which mimic aspects of inherited human neurodegenerative diseases, the most successful promoter elements have been the platelet-derived growth factor receptor β gene subunit promoter and the hamster prion protein gene promoter, although other promoter elements which direct expression in central nervous system cells would also be useful. An alternate approach to creating a transgene is to use an endogenous presenilin or PS-interacting protein gene promoter and regulatory sequences to drive expression ofthe transgene. Finally, it is possible to create transgenes using large genomic DNA fragments such as YACs which contain the entire desired gene as well as its appropriate regulatory sequences. Such constructs have been successfully used to drive human APP expression in transgenic mice (Lamb et al., 1993). Animal models can also be created by targeting the endogenous presenilin or PS-interacting protein gene in order to alter the endogenous sequence by homologous recombination. These targeting events can have the effect of removing endogenous sequence (knock-out) or altering the endogenous sequence to create an amino acid change associated with human disease or an otherwise abnormal sequence (e.g., a sequence which is more like the human sequence than the original animal sequence) (knock-in animal models). A large number of vectors are available to accomplish this and appropriate sources of genomic DNA for mouse and other animal genomes to be targeted are commercially available from companies such as GenomeSystems Inc. (St. Louis, Missouri, USA). The typical feature of these targeting vector constructs is that 2 to 4 kb of genomic DNA is ligated 5' to a selectable marker (e.g., a bacterial neomycin resistance gene under its own promoter element termed a "neomycin cassette"). A second DNA fragment from the gene of interest is then ligated downstream ofthe neomycin cassette but upstream of a second selectable marker (e.g., thymidine kinase). The DNA fragments are chosen such that mutant sequences can be introduced into the germ line ofthe targeted animal by homologous replacement ofthe endogenous sequences by either one ofthe sequences included in the vector. Alternatively, the sequences can be chosen to cause deletion of sequences that would normally reside between the left and right arms ofthe vector surrounding the neomycin cassette. The former is known as a knock-in, the latter is known as a knock-out. Again, innumerable model systems have been created, particularly for targeted knock-outs of genes including those relevant to neurodegenerative diseases (e.g., targeted deletions ofthe murine APP gene by Zheng et al., 1995; targeted deletion ofthe murine prion gene associated with adult onset human CNS degeneration by Bueler et al., 1996). Finally, equivalents of transgenic animals, including animals with mutated or inactivated presenilin genes, or mutated or inactivated PS-interacting protein genes, may be produced using chemical or X-ray mutagenesis of gametes, followed by fertilization. Using the isolated nucleic acids disclosed or otherwise enabled herein, one of ordinary skill may more rapidly screen the resulting offspring by, for example, direct sequencing RFLP, PCR, or hybridization analysis to detect mutants, or Southern blotting to demonstrate loss of one allele by dosage. 6. Assays for Drugs Which Affect PS -Interacting Protein Expression In another series of embodiments, the present invention provides assays for identifying small molecules or other compounds which are capable of inducing or inhibiting the expression ofthe PS-interacting genes and proteins (e.g., S5a or GT24). The assays may be performed in vitro using non-transformed cells, immortalized cell lines, or recombinant cell lines, or in vivo using the transgenic animal models enabled herein. In particular, the assays may detect the presence of increased or decreased expression of S5a, GT24, p0071, Rab 11, or other PS-interacting genes or proteins on the basis of increased or decreased mRNA expression (using, e.g., the nucleic acid probes disclosed and enabled herein), increased or decreased levels of PS -interacting proteins (using, e.g., the anti-PS-interacting protein antibodies disclosed and enabled herein), or increased or decreased levels of expression of a marker gene (e.g., β- galactosidase or luciferase) operably joined to a PS-interacting protein 5' regulatory region in a recombinant construct. Thus, for example, one may culture cells known to express a particular PS- interacting protein and add to the culture medium one or more test compounds. After allowing a sufficient period of time (e.g., 0-72 hours) for the compound to induce or inhibit the expression ofthe PS-interacting protein, any change in levels of expression from an established baseline may be detected using any ofthe techniques described above and well known in the art. In particularly preferred embodiments, the cells are from an immortalized cell line such as a human neuroblastoma, glioblastoma or a hybridoma cell line. Using the nucleic acid probes and /or antibodies disclosed and enabled herein, detection of changes in the expression of a PS-interacting protein, and thus identification ofthe compound as an inducer or repressor of PS-interacting protein expression, requires only routine experimentation. In particularly preferred embodiments, a recombinant assay is employed in which a reporter gene such a β-galactosidase, green fluorescent protein , alkaline phosphatase, or luciferase is operably joined to the 5' regulatory regions of a PS- interacting protein gene. Preferred vectors include the Green Lantern 1 vector (GIBCO/BRL, Gaithersburg, MD) and the Great EScAPe pSEAP vector (Clontech, Palo Alto). The PS-interacting protein regulatory regions may be easily isolated and cloned by one of ordinary skill in the art in light ofthe present disclosure of coding regions from these genes. The reporter gene and regulatory regions are joined in- frame (or in each ofthe three possible reading frames) so that transcription and translation ofthe reporter gene may proceed under the control ofthe PS-interacting protein regulatory elements. The recombinant construct may then be introduced into any appropriate cell type, although mammalian cells are preferred, and human cells are most preferred. The transformed cells may be grown in culture and, after establishing the baseline level of expression ofthe reporter gene, test compounds may be added to the medium. The ease of detection ofthe expression ofthe reporter gene provides for a rapid, high through-put assay for the identification of inducers and repressors ofthe PS-interacting protein gene. Compounds identified by this method will have potential utility in modifying the expression ofthe PS-interacting protein genes in vivo. These compounds may be further tested in the animal models disclosed and enabled herein to identify those compounds having the most potent in vivo effects. In addition, as described herein with respect to small molecules having binding activity for PS- interacting proteins, these molecules may serve as "lead compounds" for the further development of pharmaceuticals by, for example, subjecting the compounds to sequential modifications, molecular modeling, and other routine procedures employed in rational drug design. 7. Identification of Compounds with PS-Interacting Protein Binding Capacity In light ofthe present disclosure, one of ordinary skill in the art is enabled to practice new screening methodologies which will be useful in the identification of proteins and other compounds which bind to, or otherwise directly interact with, the PS-interacting proteins. The proteins and compounds will include endogenous cellular components, aside from the presenilins, which interact with the PS-interacting proteins in vivo and which, therefore, provide new targets for pharmaceutical and therapeutic interventions, as well as recombinant, synthetic and otherwise exogenous compounds which may have PS-interacting protein binding capacity and, therefore, may be candidates for pharmaceutical agents. Thus, in one series of embodiments, cell lysates or tissue homogenates (e.g., human brain homogenates, lymphocyte lysates) may be screened for proteins or other compounds which bind to one ofthe normal or mutant PS-interacting proteins. Alternatively, any of a variety of exogenous compounds, both naturally occurring and/or synthetic (e.g., libraries of small molecules or peptides), may be screened for PS-interacting protein binding capacity. Small molecules are particular preferred in this context because they are more readily absorbed after oral administration, have fewer potential antigenic determinants, and/or are more likely to cross the blood brain barrier than larger molecules such as nucleic acids or proteins. The methods ofthe present invention are particularly useful in that they may be used to identify molecules which selectively or preferentially bind to a mutant form of a PS-interacting protein (rather than a normal form) and, therefore, may have particular utility in treating cases of AD which arise from mutations in the PS-interacting proteins. Once identified by the methods described above, the candidate compounds may then be produced in quantities sufficient for pharmaceutical administration or testing (e.g., μg or mg or greater quantities), and formulated in a pharmaceutically acceptable carrier (see, e.g., Remington's Pharmaceutical Sciences. Gennaro, A., ed., Mack Pub., 1990). These candidate compounds may then be administered to the transformed cells ofthe invention, to the transgenic animal models ofthe invention, to cell lines derived from the animal models or from human patients, or to Alzheimer's patients. The animal models described and enabled herein are of particular utility in further testing candidate compounds which bind to normal or mutant PS-interacting proteins for their therapeutic efficacy. In addition, once identified by the methods described above, the candidate compounds may also serve as "lead compounds" in the design and development of new pharmaceuticals. For example, as in well known in the art, sequential modification of small molecules (e.g., amino acid residue replacement with peptides; functional group replacement with peptide or non-peptide compounds) is a standard approach in the pharmaceutical industry for the development of new pharmaceuticals. Such development generally proceeds from a "lead compound" which is shown to have at least some ofthe activity (e.g., PS-interacting protein binding or blocking ability) ofthe desired pharmaceutical. In particular, when one or more compounds having at least some activity of interest (e.g., modulation of PS-interacting protein activity) are identified, structural comparison ofthe molecules can greatly inform the skilled practitioner by suggesting portions ofthe lead compounds which should be conserved and portions which may be varied in the design of new candidate compounds. Thus, the present invention also provides a means of identifying lead compounds which may be sequentially modified to produce new candidate compounds for use in the treatment of Alzheimer's Disease. These new compounds then may be tested both for binding to PS -interacting proteins and/or blocking PS- interacting protein activity, and for therapeutic efficacy (e.g., in the animal models described herein). This procedure may be iterated until compounds having the desired therapeutic activity and/or efficacy are identified. In each ofthe present series of embodiments, an assay is conducted to detect binding between a "PS-interacting protein component" and some other moiety. Of particular utility will be sequential assays in which compounds are tested for the ability to bind to only normal or only mutant forms ofthe PS-interacting domains of PS-interacting proteins in the binding assays. Such compounds are expected to have the greatest therapeutic utilities, as described more fully below. The "PS-interacting protein component" in these assays may be a complete normal or mutant form of a PS-interacting protein (e.g., S5a, GT24, p0071, Rab 11, etc.) but need not be. Rather, particular functional domains of the PS-interacting proteins, particularly the PS- interacting domains as described above, may be employed either as separate molecules or as part of a fusion protein. For example, to isolate proteins or compounds that interact with these functional domains, screening may be carried out using fusion constructs and/or synthetic peptides corresponding to these regions. Thus, for S5a, GST-fusion peptides may be made including sequences corresponding approximately to amino acids 70-377 of SEQ ID NO: 2 (included in clones Y2H29 and Y2H31, see Example 1), approximately to amino acids 206-377 of SEQ ID NO: 2 (which includes protein-protein interaction motifs, see Ferrell et al., 1996), or to any other S5a domain of interest. Similarly, for GT24, GST- or other fusion peptides may be produced including sequences corresponding approximately to amino acids 440- 815 of SEQ ID NO: 4 (including part ofthe armadillo repeat segment). Obviously, various combinations of fusion proteins and PS -interacting protein functional domains are possible and these are merely examples. In addition, the functional domains may be altered so as to aid in the assay by, for example, introducing into the functional domain a reactive group or amino acid residue (e.g., cysteine) which will facilitate immobilization ofthe domain on a substrate (e.g., using sulfhydryl reactions). Thus, for example, the PS-interacting domain of S5a may be synthesized containing an additional C-terminal cysteine residue to facilitate immobilization of the domain. Such peptides may be used to create an affinity substrate for affinity chromatography (Sulfo-link; Pierce) to isolate binding proteins for microsequencing. Similarly, other functional domain or antigenic fragments may be created with modified residues (see, e.g., Example 4). The proteins or other compounds identified by these methods may be purified and characterized by any ofthe standard methods known in the art. Proteins may, for example, be purified and separated using electrophoretic (e.g., SDS-PAGE, 2D PAGE) or chromatographic (e.g., HPLC) techniques and may then be microsequenced. For proteins with a blocked N-terminus, cleavage (e.g., by CNBr and or trypsin) ofthe particular binding protein is used to release peptide fragments. Further purification/characterization by HPLC and microsequencing and/or mass spectrometry by conventional methods provides internal sequence data on such blocked proteins. For non-protein compounds, standard organic chemical analysis techniques (e.g., IR, NMR and mass spectrometry; functional group analysis; X-ray crystallography) may be employed to determine their structure and identity. Methods for screening cellular lysates, tissue homogenates, or small molecule libraries for candidate PS-interaction protein-binding molecules are well known in the art and, in light ofthe present disclosure, may now be employed to identify compounds which bind to normal or mutant PS-interacting protein components or which modulate PS -interacting protein activity as defined by non¬ specific measures (e.g., changes in intracellular Ca 2+ , GTP/GDP ratio) or by specific measures (e.g., changes in Aβ peptide production or changes in the expression of other downstream genes which can be monitored by differential display, 2D gel electrophoresis, differential hybridization, or SAGE methods). The preferred methods involve variations on the following techniques: (1) direct extraction by affinity chromatography; (2) co-isolation of PS-interacting protein components and bound proteins or other compounds by immunoprecipitation; (3) the Biomolecular Interaction Assay (BIAcore); and (4) the yeast two-hybrid systems. These and others are discussed separately below. A. Affinity Chromatography In light ofthe present disclosure, a variety of affinity binding techniques well known in the art may be employed to isolate proteins or other compounds which bind to the PS-interacting protein disclosed or otherwise enabled herein. In general, a PS-interacting protein component may be immobilized on a substrate (e.g., a column or filter) and a solution including the test compound(s) is contacted with the PS- interacting protein, fusion or fragment under conditions which are permissive for binding. The substrate is then washed with a solution to remove unbound or weakly bound molecules. A second wash may then elute those compounds which strongly bound to the immobilized normal or mutant PS-interacting protein component. Altematively, the test compounds may be immobilized and a solution containing one or more PS-interacting protein components may be contacted with the column, filter or other substrate. The ability ofthe PS-interacting protein component to bind to the test compounds may be determined as above or a labeled form ofthe PS-interacting protein component (e.g., a radio-labeled or chemi luminescent functional domain) may be used to more rapidly assess binding to the substrate-immobilized compound(s). B. Co-Immunoprecipitation Another well characterized technique for the isolation of PS-interacting protein components and their associated proteins or other compounds is direct immunoprecipitation with antibodies. This procedure has been successfully used, for example, to isolate many ofthe synaptic vesicle associated proteins (Phizicky and Fields, 1994). Thus, either normal or mutant, free or membrane-bound PS-interacting protein components may be mixed in a solution with the candidate compound(s) under conditions which are permissive for binding, and the PS-interacting protein component may be immunoprecipitated. Proteins or other compounds which co- immunoprecipitate with the PS-interacting protein component may then be identified by standard techniques as described above. General techniques for immunoprecipitation may be found in, for example, Harlow and Lane, (1988) Antibodies: A Laboratory Manual. Cold Spring Harbor Press, Cold Spring Harbor, NY. The antibodies employed in this assay, as described and enabled herein, may be polyclonal or monoclonal, and include the various antibody fragments (e.g., Fab, F(ab') 2 ,) as well as single chain antibodies, and the like. C. The Biomolecular Interaction Assay Another useful method for the detection and isolation of binding proteins is the Biomolecular Interaction Assay or "BIAcore" system developed by Pharmacia Biosensor and described in the manufacturer's protocol (LKB Pharmacia, Sweden). In light of the present disclosure, one of ordinary skill in the art is now enabled to employ this system, or a substantial equivalent, to identify proteins or other compounds having PS-interacting protein binding capacity. The BIAcore system uses an affinity purified anti-GST antibody to immobilize GST-fusion proteins onto a sensor chip. Obviously, other fusion proteins and corresponding antibodies may be substituted. The sensor utilizes surface plasmon resonance which is an optical phenomenon that detects changes in refractive indices. A homogenate of a tissue of interest is passed over the immobilized fusion protein and protein-protein interactions are registered as changes in the refractive index. This system can be used to determine the kinetics of binding and to assess whether any observed binding is of physiological relevance. D. The Yeast Two-Hybrid System The yeast "two-hybrid" system takes advantage of transcriptional factors that are composed of two physically separable, functional domains (Phizicky and Fields, 1994). The most commonly used is the yeast GAL4 transcriptional activator consisting of a DNA binding domain and a transcriptional activation domain. Two different cloning vectors are used to generate separate fusions ofthe GAL4 domains to genes encoding potential binding proteins. The fusion proteins are co-expressed, targeted to the nucleus and, if interactions occur, activation of a reporter gene (e.g., lacZ) produces a detectable phenotype. For example, the Clontech Matchmaker System-2 may be used with the Clontech brain cDNA GAL4 activation domain fusion library with PS-interacting protein-GAL4 binding domain fusion clones (Clontech, Palo Alto, CA). In light ofthe disclosures herein, one of ordinary skill in the art is now enabled to produce a variety of PS-interacting protein fusions, including fusions including either normal or mutant functional domains ofthe PS-interacting proteins, and to screen such fusion libraries in order to identify PS-interacting protein binding proteins. E. Other Methods The nucleotide sequences and protein products, including both mutant and normal forms of these nucleic acids and their corresponding proteins, can be used with the above techniques to isolate other interacting proteins, and to identify other genes whose expression is altered by the over-expression of normal PS-interacting protein sequences, by the under-expression of normal PS-interacting protein sequences, or by the expression of mutant PS-interacting protein sequences. Identification of these other interacting proteins, as well as the identification of other genes whose expression levels are altered in AD will identify other gene targets which have direct relevance to the pathogenesis of this disease in its clinical or pathological forms. Specifically, other genes will be identified which may themselves be the site of other mutations causing Alzheimer's Disease, or which can themselves be targeted therapeutically (e.g., to reduce their expression levels to normal, or to pharmacologically block the effects of their over-expression) as a potential treatment for this disease. Specifically, these techniques rely on PCR-based and/or hybridization-based methods to identify genes which are differentially expressed between two conditions (a cell line expressing normal PS-interacting proteins compared to the same cell type expressing a mutant PS-interacting protein). These techniques include differential display, serial analysis of gene expression (SAGE), and mass-spectrometry of protein 2D-gels and subtractive hybridization (reviewed in Nowak, 1995 and Kahn, 1995). As will be obvious to one of ordinary skill in the art, there are numerous other methods of screening individual proteins or other compounds, as well as large libraries of proteins or other compounds (e.g., phage display libraries and cloning systems from Stratagene, La Jolla, CA) to identify molecules which bind to normal or mutant PS-interacting protein components. All of these methods comprise the step of mixing a normal or mutant PS-interacting protein, fusion, or fragment with test compounds, allowing for binding (if any), and assaying for bound complexes. All such methods are now enabled by the present disclosure of substantially pure PS- interacting proteins, substantially pure PS-interacting functional domain fragments, PS-interacting protein fusion proteins, PS-interacting protein antibodies, and methods of making and using the same. 8. Disrupting PS-Interacting Protein Interactions The ability to disrupt specific interactions ofthe PS-interacting proteins with the presenilins, or with other proteins, is potentially of great therapeutic value, and will be important in understanding the etiology of AD and in identifying additional targets for therapy. The methods used to identify compounds which disrupt PS-interacting protein interactions may be applied equally well to interactions involving either normal or mutant PS-interacting proteins. Assays for compounds which can disrupt PS-interacting protein interactions may be performed by any of a variety of methods well known in the art. In essence, such assays will parallel those assays for identifying proteins and compounds with binding activity toward the PS-interacting proteins. Thus, once a compound with binding activity for a PS-interacting protein is identified by any method, that method or an equivalent method may be performed in the presence of candidate compounds to identify compounds which disrupt the interaction. Thus, for example, the assay may employ methods including (1) affinity chromatography; (2) immunoprecipitation; (3) the Biomolecular Interaction Assay (BIAcore); or (4) the yeast two-hybrid systems. Such assays can be developed using either normal or mutant purified PS-interacting proteins, and/or either normal or mutant purified binding proteins (e.g., normal or mutant presenilins). For affinity methods, either the PS-interacting protein or its binding partner may be affixed to a matrix, for example in a column, and the counterpart protein (e.g., the PS-interacting protein if presenilin or another binding partner is affixed to the matrix; or a presenilin or other binding partner if the PS-interacting protein is affixed to the matrix) is then exposed to the affixed protein compound either before or after adding the candidate compound(s). In the absence of a disruptive effect by the candidate compound(s), the interaction between the PS-interacting protein and its binding partner will cause the counterpart protein to bind to the affixed protein. Any compound which disrupts the interaction will cause release ofthe counterpart protein from the matrix. Release ofthe counterpart protein from the matrix can be measured using methods known in the art. For PS-interacting protein interactions which are detectable by yeast two- hybrid systems, these assays may also be employed to identify compounds which disrupt the interaction. Briefly, a PS-interacting protein and its binding partner (or appropriate structural domains of each) are employed in the fusion proteins ofthe system, and the cells are exposed to candidate compounds to determine their effect upon the expression ofthe reporter gene. By appropriate choice of a reporter gene, such a system can be readily adapted for high through-put screening of large libraries of compounds by, for example, using a reporter gene which confers resistance to an antibiotic which is present in the medium, or which rescues an auxotrophic strain grown in minimal medium. These assays may be used to screen many different types of compounds for their disruptive effect on the interactions ofthe PS-interacting proteins. For example, the compounds may belong to a library of synthetic molecules, or be specifically designed to disrupt the interaction. The compounds may also be peptides corresponding to the interacting domain of either protein. This type of assay can be used to identify compounds that disrupt a specific interaction between a given PS- interacting protein variant and a given binding partner. In addition, compounds that disrupt all interactions with PS-interacting proteins may be identified. For example, a compound that specifically disrupts the folding of PS-interacting proteins would be expected to disrupt all interactions between PS-interacting proteins and other proteins. Alternatively, this type of disruption assay can be used to identify compounds which disrupt only a range of different PS-interacting protein interactions, or only a single PS-interacting protein interaction. 9. Methods of Identifying Compounds Modulating PS-Interacting Protein Activity In another series of embodiments, the present invention provides for methods of identifying compounds with the ability to modulate the activity of normal and mutant PS-interacting proteins. As used with respect to this series of embodiments, the term "activity" broadly includes gene and protein expression, PS- interacting protein post-translation processing, trafficking and localization, and any functional activity (e.g., enzymatic, receptor-effector, binding, channel), as well as downstream affects of any of these. It is known that Alzheimer's Disease is associated with increased production ofthe long form of Aβ peptides, the appearance of amyloid plaques and neurofibrillary tangles, decreases in cognitive function, and apoptotic cell death. Therefore, using the transformed cells and transgenic animal models ofthe present invention, cells obtained from subjects bearing normal or mutant PS- interacting protein genes, or animals or human subjects bearing naturally occurring normal or mutant PS-interacting proteins, it is now possible to screen candidate pharmaceuticals and treatments for their therapeutic effects by detecting changes in one or more of these functional characteristics or phenotypic manifestations of normal or mutant PS-interacting protein expression. Thus, the present invention provides methods for screening or assaying for proteins, small molecules or other compounds which modulate PS-interacting protein activity by contacting a cell in vivo or in vitro with a candidate compound and assaying for a change in a marker associated with normal or mutant PS-interacting protein activity. The marker associated with PS-interacting protein activity may be any measurable biochemical, physiological, histological and/or behavioral characteristic associated with PS-interacting protein expression. In particular, useful markers will include any measurable biochemical, physiological, histological and/or behavioral characteristic which distinguishes cells, tissues, animals or individuals bearing at least one mutant presenilin or PS-interacting protein gene from their normal counterparts. In addition, the marker may be any specific or non-specific measure of presenilin or PS-interacting protein activity. PS-interacting protein specific measures include measures of PS-interacting protein expression (e.g., PS-interacting protein rnRNA or protein levels) which may employ the nucleic acid probes or antibodies of the present invention. Non-specific measures include changes in cell physiology such as pH, intracellular calcium, cyclic AMP levels, GTP/GDP ratios, phosphatidylinositol activity, protein phosphorylation, etc., which can be monitored on devices such as the cytosensor microphysiometer (Molecular Devices Inc., United States). The activation or inhibition of PS-interacting protein activity in its mutant or normal form can also be monitored by examining changes in the expression of other genes (e.g., the presenilins) which are specific to the PS-interacting protein pathway leading to Alzheimer's Disease. These can be assayed by such techniques as differential display, differential hybridization, and SAGE (sequential analysis of gene expression), as well as by two dimensional gel electrophoresis of cellular lysates. In each case, the differentially-expressed genes can be ascertained by inspection of identical studies before and after application ofthe candidate compound. Furthermore, as noted elsewhere, the particular genes whose expression is modulated by the administration ofthe candidate compound can be ascertained by cloning, nucleotide sequencing, amino acid sequencing, or mass spectrometry (reviewed m Nowak, 1995). In general, a cell may be contacted with a candidate compound and, after an appropriate period (e.g., 0-72 hours for most biochemical measures of cultured cells), the marker of presenilin or PS-interacting protein activity may be assayed and compared to a baseline measurement. The baseline measurement may be made prior to contacting the cell with the candidate compound or may be an external baseline established by other experiments or known m the art. The cell may be a transformed cell ofthe present invention or an explant from an animal or individual. In particular, the cell may be an explant from a earner of a presenilin or PS-interacting protein mutation (e.g., a human subject with Alzheimer's Disease) or an animal model ofthe invention (e.g., a transgenic nematode or mouse bearing a mutant presenilin or PS- interacting protein gene). To augment the effect of presenilin or PS-interacting protein mutations on the Aβ pathway, transgenic cells or animals may be employed which have increased Aβ production. Preferred cells include those from neurological tissues such as neuronal, glial or mixed cell cultures; and cultured fibroblasts, liver, kidney, spleen, or bone marrow. The cells may be contacted with the candidate compounds in a culture in vitro or may be administered in vivo to a live animal or human subject. For live animals or human subjects, the test compound may be administered orally or by any parenteral route suitable to the compound. For clinical trials of human subjects, measurements may be conducted periodically (e.g., daily, weekly or monthly) for several months or years. Because most individuals bearing a mutation in a particular gene are heterozygous at that locus (i.e., bearing one normal and one mutant allele), compounds may be tested for their ability to modulate normal as well as mutant presenilin or PS-interacting protein activity. Thus, for example, compounds which enhance the function of normal presenilins or PS-interacting proteins may have utility in treating Alzheimer's Disease or related disorders. Alternatively, because suppression ofthe activity of both normal and mutant copies of a gene in a heterozygous individual may have less severe clinical consequences than progression of the associated disease, it may be desired to identify compound which inactivate or suppress all forms ofthe presenilins, the PS-interacting proteins, or their interactions. Preferably, however, compounds are identified which selectively or specifically inactivate or suppress the activity of mutant presenilin or PS-interacting proteins without disrupting the function of their normal counterparts. In light ofthe identification, characterization, and disclosure herein of a novel group of PS-interacting genes and proteins, the PS-interacting protein nucleic acid probes and antibodies, and the PS-interacting protein transformed cells and transgenic animals ofthe invention, one of ordinary skill in the art is now enabled by perform a great variety of assays which will detect the modulation of presenilin and/or PS-interacting protein activity by candidate compounds. Particularly preferred and contemplated embodiments are discussed in some detail below. A. PS-Interacting Protein Expression In one series of embodiments, specific measures of PS-interacting protein expression are employed to screen candidate compounds for their ability to affect presenilin activity. Thus, using the PS-interacting protein nucleic acids and antibodies disclosed and otherwise enabled herein, one may use mRNA levels or protein levels as a marker for the ability of a candidate compound to modulate PS-interacting protein activity. The use of such probes and antibodies to measure gene and protein expression is well known in the art and discussed elsewhere herein. Of particular interest may be the identification of compounds which can alter the relative levels of different variants (e.g., mutant and normal) ofthe PS-interacting proteins. B. Intracellular Localization In another series of embodiments, compounds may be screened for their ability to modulate the activity ofthe PS-interacting proteins based upon their effects on the trafficking and intracellular localization ofthe PS -interacting proteins. The presenilins and some ofthe PS-interacting proteins (e.g., S5a) have been seen immunocytochemically to be localized in membrane structures associated with the endoplasmic reticulum and Golgi apparatus. Differences in localization of mutant and normal presenilins or PS-interacting proteins may, therefore, contribute to the etiology of Alzheimer's Disease and related disorders. Compounds which can affect the localization of these proteins may, therefore, be identified as potential therapeutics. Standard techniques known in the art may be employed to detect the localization of the presenilins and PS-interacting proteins. Generally, these techniques will employ the antibodies ofthe present invention, and in particular antibodies which selectively bind to one or more mutant PS-interacting proteins but not to normal proteins. As is well known in the art, such antibodies may be labeled by any of a variety of techniques (e.g., fluorescent or radioactive tags, labeled secondary antibodies, avidin- biotin, etc.) to aid in visualizing the intracellular location of these proteins. The PS- interacting proteins may be co-localized to particular structures, as in known in the art, using antibodies to markers of those structures (e.g., TGN38 for the Golgi, transferrin receptor for post-Golgi transport vesicles, LAMP2 for lysosomes). Western blots of purified fractions from cell lysates enriched for different intracellular membrane bound organelles (e.g., lysosomes, synaptosomes, Golgi) may also be employed. B. Ion Regulation/Metabolism In another series of embodiments, compounds may be screened for their ability to modulate the activity ofthe presenilins or PS-interacting proteins based upon measures in intracellular Ca 2+ , Na + or K + levels or metabolism. As noted above, the presenilins are membrane associated proteins which may serve as, or interact with, ion receptors or ion channels. Thus, compounds may be screened for their ability to modulate presenilin and PS-interacting protein-related metabolism of calcium or other ions either in vivo or in vitro by, for example, measurements of ion channel fluxes and/or transmembrane voltage and/or current fluxes, using patch clamps, voltage clamps or fluorescent dyes sensitive to intracellular ion levels or transmembrane voltage. Ion channel or receptor function can also be assayed by measurements of activation of second messengers such as cyclic AMP, cGMP tyrosine kinases, phosphates, increases in intracellular Ca 2+ levels, etc. Recombinantly made proteins may also be reconstructed in artificial membrane systems to study ion channel conductance and, therefore, the "cell" employed in such assays may comprise an artificial membrane or cell. Assays for changes in ion regulation or metabolism can be performed on cultured cells expressing endogenous normal or mutant presenilins and PS-interacting proteins. Such studies also can be performed on cells transfected with vectors capable of expressing one ofthe presenilins or PS-interacting proteins, or functional domains of one ofthe presenilins or PS-interacting proteins, in normal or mutant form. In addition, to enhance the signal measured in such assays, cells may be co- transfected with genes encoding ion channel proteins. For example, Xenopus oocytes or rat kidney (HEK293) cells may be co-transfected with sequences encoding rat brain Na + βl subunits, rabbit skeletal muscle Ca 2+ βl subunits, or rat heart K + βl subunits. Changes in presenilin or PS-interacting protein-mediated ion channel activity can be measured by, for example, two-microelectrode voltage-clamp recordings in oocytes, by whole-cell patch-clamp recordings in HEK293 cells, or by equivalent means. C. Apoptosis or Cell Death In another series of embodiments, compounds may be screened for their ability to modulate the activity ofthe presenilins or PS-interacting proteins based upon their effects on presenilin or PS -interacting protein-related apoptosis or cell death. Thus, for example, baseline rates of apoptosis or cell death may be established for cells in culture, or the baseline degree of neuronal loss at a particular age may be established post-mortem for animal models or human subjects, and the ability of a candidate compound to suppress or inhibit apoptosis or cell death may be measured. Cell death may be measured by standard microscopic techniques (e.g., light microscopy) or apoptosis may be measured more specifically by characteristic nuclear morphologies or DNA fragmentation patterns which create nucleosomal ladders (see, e.g., Gavrieli et al., 1992; Jacobson et al., 1993; Vito et al., 1996). TUNEL may also be employed to evaluate cell death in brain (see, e.g., Lassmann et al., 1995). In preferred embodiments, compounds are screened for their ability to suppress or inhibit neuronal loss in the transgenic animal models ofthe invention. Transgenic mice bearing, for example, a mutant human, mutant mouse, or humanized mutant presenilin or PS -interacting protein gene may be employed to identify or evaluate compounds which may delay or anest the neurodegeneration associated with Alzheimer's Disease. A similar transgenic mouse model, bearing a mutant APP gene, has recently been reported by Games et al. (1995). D. Aβ Peptide Production In another series of embodiments, compounds may be screened for their ability to modulate presenilin or PS-interacting protein-related changes in APP processing. The Aβ peptide is produced in several isoforms resulting from differences in APP processing. The Aβ peptide is a 39 to 43 amino acid derivative of βAPP which is progressively deposited in diffuse and senile plaques and in blood vessels of subjects with AD. In human brain, Aβ peptides are heterogeneous at both the N- and C-termini. Several observations, however, suggest that both the full length and N- terminal truncated forms ofthe long-tailed Aβ peptides ending at residue 42 or 43 (i.e., Aβl-42/43 and Aβx-42/43) have a more important role in AD than do peptides ending at residue 40. Thus, Aβ 1-42/43 and Aβx-42/43 are an early and prominent feature of both senile plaques and diffuse plaques, while peptides ending at residue 40 (i.e., Aβl-40 and Aβx-40) are predominantly associated with a subset of mature plaques and with amyloidotic blood vessels (see, e.g., Iwatsubo et al., 1995; Gravina et al., 1995; Tamaoka et al., 1995; Podlisny et al. 1995). Furthermore, the long-tailed isoforms have a greater propensity to fibril formation, and are thought to be more neurotoxic than Aβl-40 peptides (Pike et al., 1993; Hilbich et al., 1991). Finally, missense mutations at codon 717 of the βAPP gene are associated with early onset FAD, and result in overproduction of long-tailed Aβ in the brain of affected mutation carriers, in peripheral cells and plasma of both affected and presymptomatic carriers, and in cell lines transfected with βAPP 7]7 mutant cDNAs (Tamaoka et al., 1994; Suzuki et al., 1994). Thus, in one series of embodiments, the present invention provides methods for screening candidate compounds for their ability to block or inhibit the increased production of long isoforms ofthe Aβ peptides in cells or transgenic animals expressing a normal or mutant presenilin gene and/or a normal or mutant PS- interacting protein gene. In particular, the present invention provides such methods in which cultured mammalian cells, such as brain cells or fibroblasts, have been transformed according to the methods disclosed herein, or in which transgenic animals, such as rodents or non-human primates, have been produced by the methods disclosed herein, to express relatively high levels of a normal or mutant presenilin or PS -interacting protein. Optionally, such cells or transgenic animals may also be transformed so as to express a normal or mutant form ofthe βAPP protein at relatively high levels. In this series of embodiments, the candidate compound is administered to the cell line or transgenic animals (e.g., by addition to the media of cells in culture; or by oral or parenteral administration to an animal) and, after an appropriate period (e.g., 0-72 hours for cells in culture, days or months for animal models), a biological sample is collected (e.g., cell culture supernatant or cell lysate from cells in culture; tissue homogenate or plasma from an animal) and tested for the level ofthe long isoforms ofthe Aβ peptides. The levels ofthe peptides may be determined in an absolute sense (e.g., nMol/ml) or in a relative sense (e.g., ratio of long to short Aβ isoforms). The Aβ isoforms may be detected by any means known in the art (e.g., electrophoretic separation and sequencing) but, preferably, antibodies which are specific to the long isoform are employed to determine the absolute or relative levels ofthe Aβ 1-42/43 or Aβx-42/43 peptides. Candidate pharmaceuticals or therapies which reduce the absolute or relative levels of these long Aβ isoforms, particularly in the transgenic animal models ofthe invention, are likely to have therapeutic utility in the treatment of Alzheimer's Disease, or other disorders caused by mutations in the presenilins or PS-interacting proteins, or by other aberrations in APP metabolism. E. Phosphorylation of Microtubule Associated Proteins In another series of embodiments, candidate compounds may be screened for their ability to modulate presenilin or PS-interacting protein activity by assessing the effect ofthe compound on levels of phosphorylation of microtubule associated proteins (MAPs) such as tau. The abnormal phosphorylation of tau and other MAPs in the brains of victims of Alzheimer's Disease is well known in the art. Thus, compounds which prevent or inhibit the abnormal phosphorylation of MAPs may have utility in treating presenilin or PS-interacting protein-associated diseases such as AD. As above, cells from normal or mutant animals or subjects, or the transformed cell lines and animal models ofthe invention may be employed. Preferred assays will employ cell lines or animal models transformed with a mutant human or humanized mutant presenilin or PS-interacting protein gene. The baseline phosphorylation state of MAPs in these cells may be established and then candidate compounds may be tested for their ability to prevent, inhibit or counteract the hyperphosphorylation associated with mutants. The phosphorylation state ofthe MAPs may be determined by any standard method known in the art but, preferably, antibodies which bind selectively to phosphorylated or unphosphorylated epitopes are employed. Such antibodies to phosphorylation epitopes ofthe tau protein are known in the art (e.g., ALZ50). 10. Screening and Diagnostics for Alzheimer's Disease A. General Diagnostic Methods The PS-interacting genes and gene products, as well as the PS-interacting protein derived probes, primers and antibodies, disclosed or otherwise enabled herein, are useful in the screening for carriers of alleles associated with Alzheimer's Disease, for diagnosis of victims of Alzheimer's Disease, and for the screening and diagnosis of related presenile and senile dementias, psychiatric diseases such as schizophrenia and depression, and neurologic diseases such as stroke and cerebral hemonhage, all of which are seen to a greater or lesser extent in symptomatic human subjects bearing mutations in the PS 1 or PS2 genes or in the APP gene. Individuals at risk for Alzheimer's Disease, such as those with AD present in the family pedigree, or individuals not previously known to be at risk, may be routinely screened using probes to detect the presence of a mutant PS-interacting protein gene or protein by a variety of techniques. Diagnosis of inherited cases of these diseases can be accomplished by methods based upon the nucleic acids (including genomic and mRNA/cDNA sequences), proteins, and/or antibodies disclosed and enabled herein, including functional assays designed to detect failure or augmentation ofthe normal presenilin or PS-interacting protein activity and/or the presence of specific new activities confened by mutant PS -interacting proteins. Preferably, the methods and products are based upon the human nucleic acids, proteins or antibodies, as disclosed or otherwise enabled herein. As will be obvious to one of ordinary skill in the art, however, the significant evolutionary conservation of large portions of nucleotide and amino acid sequences, even in species as diverse as humans, mice, C. elegans. and Drosophila. allow the skilled artisan to make use of non-human homologues of the PS-interacting proteins to produce useful nucleic acids, proteins and antibodies, even for applications directed toward human or other animal subjects. Thus, for brevity of exposition, but without limiting the scope ofthe invention, the following description will focus upon uses ofthe human homologues of PS-interacting proteins and genes. It will be understood, however, that homologous sequences from other species will be equivalent for many purposes. As will be appreciated by one of ordinary skill in the art, the choice of diagnostic methods ofthe present invention will be influenced by the nature ofthe available biological samples to be tested and the nature ofthe information required. Alzheimer's Disease is, of course, primarily a disease ofthe brain, but brain biopsies are invasive and expensive procedures, particularly for routine screening. Other tissues which express the presenilins or PS-interacting proteins at significant levels may, therefore, be preferred as sources for samples. B. Protein Based Screens and Diagnostics When a diagnostic assay is to be based upon PS-interacting proteins, a variety of approaches are possible. For example, diagnosis can be achieved by monitoring differences in the electrophoretic mobility of normal and mutant proteins. Such an approach will be particularly useful in identifying mutants in which charge substitutions are present, or in which insertions, deletions or substitutions have resulted in a significant change in the electrophoretic migration ofthe resultant protein. Alternatively, diagnosis may be based upon differences in the proteolytic cleavage patterns of normal and mutant proteins, differences in molar ratios ofthe various amino acid residues, or by functional assays demonstrating altered function of the gene products. In prefened embodiments, protein-based diagnostics will employ differences in the ability of antibodies to bind to normal and mutant PS-interacting proteins. Such diagnostic tests may employ antibodies which bind to the normal proteins but not to mutant proteins, or vice versa. In particular, an assay in which a plurality of monoclonal antibodies, each capable of binding to a mutant epitope, may be employed. The levels of anti-mutant antibody binding in a sample obtained from a test subject (visualized by, for example, radiolabelling, ELISA or chemiluminescence) may be compared to the levels of binding to a control sample. Alternatively, antibodies which bind to normal but not mutant proteins may be employed, and decreases in the level of antibody binding may be used to distinguish homozygous normal individuals from mutant heterozygotes or homozygotes. Such antibody diagnostics may be used for in situ immunohistochemistry using biopsy samples of CNS tissues obtained antemortem or postmortem, including neuropathological structures associated with these diseases such as neurofibrillary tangles and amyloid plaques, or may be used with fluid samples such a cerebrospinal fluid or with peripheral tissues such as white blood cells. C. Nucleic Acid Based Screens and Diagnostics When the diagnostic assay is to be based upon nucleic acids from a sample, the assay may be based upon mRNA, cDNA or genomic DNA. When mRNA is used from a sample, there are considerations with respect to source tissues and the possibility of alternative splicing. That is, there may be little or no expression of transcripts unless appropriate tissue sources are chosen or available, and alternative splicing may result in the loss of some information or difficulty in interpretation. Whether mRNA, cDNA or genomic DNA is assayed, standard methods well known in the art may be used to detect the presence of a particular sequence either in situ or in vitro (see, e.g., Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring Harbor Press, Cold Spring Harbor, NY). As a general matter, however, any tissue with nucleated cells may be examined. Genomic DNA used for the diagnosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material. The DNA may be isolated and used directly for detection of a specific sequence or may be amplified by the polymerase chain reaction (PCR) prior to analysis. Similarly, RNA or cDNA may also be used, with or without PCR amplification. To detect a specific nucleic acid sequence, direct nucleotide sequencing, hybridization using specific oligonucleotides, restriction enzyme digest and mapping, PCR mapping, RNase protection, chemical mismatch cleavage, ligase-mediated detection, and various other methods may be employed. Oligonucleotides specific to particular sequences can be chemically synthesized and labeled radioactively or non- radioactively (e.g., biotin tags, ethidium bromide), and hybridized to individual samples immobilized on membranes or other solid-supports (e.g., by dot-blot or transfer from gels after electrophoresis), or in solution. The presence or absence of the target sequences may then be visualized using methods such as autoradiography, fluorometry, or colorimetry. These procedures can be automated using redundant, short oligonucleotides of known sequence fixed in high density to silicon chips. (1) Appropriate Probes and Primers Whether for hybridization, RNase protection, ligase-mediated detection, PCR amplification or any other standards methods described herein and well known in the art, a variety of subsequences ofthe PS-interacting protein sequences disclosed or otherwise enabled herein will be useful as probes and/or primers. These sequences or subsequences will include both normal sequences and deleterious mutant sequences. In general, useful sequences will include at least 8-9, more preferably 10-50, and most preferably 18-24 consecutive nucleotides from introns, exons or intron/exon boundaries. Depending upon the target sequence, the specificity required, and future technological developments, shorter sequences may also have utility. Therefore, any PS-interacting protein derived sequence which is employed to isolate, clone, amplify, identify or otherwise manipulate a PS-interacting protein sequence may be regarded as an appropriate probe or primer. Particularly contemplated as useful will be sequences including nucleotide positions from the PS-interacting protein genes in which disease- causing mutations are known to be present, or sequences which flank these positions. (2) Hybridization Screening For in situ detection of a normal or mutant PS-interacting protein-related nucleic acid sequence, a sample of tissue may be prepared by standard techniques and then contacted with one or more ofthe above-described probes, preferably one which is labeled to facilitate detection, and an assay for nucleic acid hybridization is conducted under stringent conditions which permit hybridization only between the probe and highly or perfectly complementary sequences. Because many mutations consist of a single nucleotide substitution, high stringency hybridization conditions may be required to distinguish normal sequences from most mutant sequences. When the PS -interacting protein genotypes ofthe subject's parents are known, probes may be chosen accordingly. Alternatively, probes to a variety of mutants may be employed sequentially or in combination. Because most individuals carrying mutations in the PS-interacting proteins will be heterozygous, probes to normal sequences also may be employed and homozygous normal individuals may be distinguished from mutant heterozygotes by the amount of binding (e.g., by intensity of radioactive signal). In another variation, competitive binding assays may be employed in which both normal and mutant probes are used but only one is labeled. (3) Restriction Mapping Sequence alterations may also create or destroy fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by gel-blot hybridization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or decrease of conesponding restriction fragment numbers. Such restriction fragment length polymorphism analysis (RFLP), or restriction mapping, may be employed with genomic DNA, mRNA or cDNA. The PS-interacting protein sequences may be amplified by PCR using the above-described primers prior to restriction, in which case the lengths ofthe PCR products may indicate the presence or absence of particular restriction sites, and/or may be subjected to restriction after amplification. The restriction fragments may be visualized by any convenient means (e.g., under UV light in the presence of ethidium bromide). (4) PCR Mapping In another series of embodiments, a single base substitution mutation may be detected based on differential PCR product length or production in PCR. Thus, primers which span mutant sites or which, preferably, have 3' termini at mutation sites, may be employed to amplify a sample of genomic DNA, mRNA or cDNA from a subject. A mismatch at a mutational site may be expected to alter the ability ofthe normal or mutant primers to promote the polymerase reaction and, thereby, result in product profiles which differ between normal subjects and heterozygous and/or homozygous mutants. The PCR products ofthe normal and mutant gene may be differentially separated and detected by standard techniques, such as polyacrylamide or agarose gel electrophoresis and visualization with labeled probes, ethidium bromide or the like. Because of possible non-specific priming or readthrough of mutation sites, as well as the fact that most carriers of mutant alleles will be heterozygous, the power of this technique may be low. (5) Electrophoretic Mobility Genetic testing based on DNA sequence differences also may be achieved by detection of alterations in electrophoretic mobility of DNA, mRNA or cDNA fragments in gels. Small sequence deletions and insertions, for example, can be visualized by high resolution gel electrophoresis of single or double stranded DNA, or as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis. Mutations or polymoφhisms in the PS-interacting protein genes may also be detected by methods which exploit mobility shifts due to single-stranded conformational polymoφhisms (SSCP) associated with mRNA or single-stranded DNA secondary structures. (6) Chemical Cleavage of Mismatches Mutations in the PS-interacting protein genes may also be detected by employing the chemical cleavage of mismatch (CCM) method (see, e.g., Saleeba and Cotton, 1993, and references therein). In this technique, probes (up to - 1 kb) may be mixed with a sample of genomic DNA, cDNA or mRNA obtained from a subject. The sample and probes are mixed and subjected to conditions which allow for heteroduplex formation (if any). Preferably, both the probe and sample nucleic acids are double-stranded, or the probe and sample may be PCR amplified together, to ensure creation of all possible mismatch heteroduplexes. Mismatched T residues are reactive to osmium tetroxide and mismatched C residues are reactive to hydroxylamine. Because each mismatched A will be accompanied by a mismatched T, and each mismatched G will be accompanied by a mismatched C, any nucleotide differences between the probe and sample (including small insertions or deletions) will lead to the formation of at least one reactive heteroduplex. After treatment with osmium tetroxide and/or hydroxylamine to modify any mismatch sites, the mixture is subjected to chemical cleavage at any modified mismatch sites by, for example, reaction with piperidine. The mixture may then be analyzed by standard techniques such as gel electrophoresis to detect cleavage products which would indicate mismatches between the probe and sample. (7) Other Methods Various other methods of detecting PS-interacting protein mutations, based upon the sequences disclosed and otherwise enabled herein, will be apparent to those of ordinary skill in the art. Any of these may be employed in accordance with the present invention. These include, but are not limited to, nuclease protection assays (SI or ligase-mediated), ligated PCR, denaturing gradient gel electrophoresis (DGGE; see, e.g., Fischer and Lerman, 1983), restriction endonuclease fingeφrinting combined with SSCP (REF-SSCP; see, e.g., Liu and Sommer, 1995), and the like. D. Other Screens and Diagnostics In inherited cases, as the primary event, and in non-inherited cases as a secondary event due to the disease state, abnormal processing of the presenilins, PS- interacting proteins, APP, or proteins reacting with the presenilins, PS-interacting proteins, or APP may occur. This can be detected as abnormal phosphorylation, glycosylation, glycation amidation or proteolytic cleavage products in body tissues or fluids (e.g., CSF or blood). Diagnosis also can be made by observation of alterations in transcnption, translation, and post-translational modification and processing, as well as alterations in the intracellular and extracellular trafficking of gene products in the bram and penpheral cells. Such changes will include alterations m the amount of messenger RNA and/or protein, alteration in phosphorylation state, abnormal intracellular location distribution, abnormal extracellular distribution, etc. Such assays will include: Northern Blots (e.g., with PS -interacting protem-specific and non-specific nucleotide probes), Western blots and enzyme-linked immunosorbent assays (ELISA) (e.g., with antibodies raised specifically to a PS-mteracting protein or PS-interacting functional domain, including vanous post-translational modification states including glycosylated and phosphorylated isoforms). These assays can be performed on penpheral tissues (e.g., blood cells, plasma, cultured or other fibroblast tissues, etc.) as well as on biopsies of CNS tissues obtained antemortem or postmortem, and upon cerebrospmal fluid. Such assays might also include m situ hybridization and immunohistochemistry (to localize messenger RNA and protein to specific subcellular compartments and or within neuropathological structures associated with these diseases such as neurofibrillary tangles and amyloid plaques). E. Screening and Diagnostic Kits In accordance with the present invention, diagnostic kits are also provided which will include the reagents necessary for the above-descnbed diagnostic screens. For example, kits may be provided which include antibodies or sets of antibodies which are specific to one or more mutant epitopes. These antibodies may, in particular, be labeled by any ofthe standard means which facilitate visualization of binding. Alternatively, kits may be provided in which ohgonucleotide probes or PCR pπmers, as described above, are present for the detection and/or amplification of normal or mutant presenilin and/or PS-interacting protein nucleotide sequences. Again, such probes may be labeled for easier detection of specific hybndization. As appropnate to the vanous diagnostic embodiments described above, the oligonucleotide probes or antibodies in such kits may be immobilized to substrates and appropnate controls may be provided. 11. Methods of Treatment The present invention now provides a basis for therapeutic intervention in diseases which are caused, or which may be caused, by mutations in the PS- interacting proteins. As noted above, mutations in the hPSl and hPS2 genes have been associated with the development of early onset forms of Alzheimer's Disease and, therefore, the present invention is particularly directed to the treatment of subjects diagnosed with, or at risk of developing, Alzheimer's Disease. Without being bound to any particular theory ofthe invention, the effect of the Alzheimer's Disease related mutations in the presenilins appears to be a gain of a novel function, or an acceleration of a normal function, which directly or indirectly causes abenant processing ofthe Amyloid Precursor Protein (APP) into Aβ peptide, abnormal phosphorylation homeostasis, and/or abnormal apoptosis in the brain. Such a gain of function or acceleration of function model would be consistent with the adult onset ofthe symptoms and the dominant inheritance of Alzheimer's Disease. Nonetheless, the mechanism by which mutations in the presenilins may cause these effects remains unknown. The present invention, by identifying a set of PS-interacting proteins, provides new therapeutic targets for intervening in the etiology of presenilin-related AD. In addition, as mutations in the presenilins may cause AD, it is likely that mutations in the PS-interacting proteins may also cause AD. The fact that the PS- interacting protein S5a is alternately processed in the brains of victims of sporadic AD, as well as in the brains of victims of presenilin-linked AD, suggests that, at the very least, this PS-interacting protein is involved in the etiology of AD independent of mutations in the presenilins. It is likely that the other PS-interacting proteins also may be involved in non-presenilin-linked AD. Therapies to treat PS-interacting protein-associated diseases such as AD may be based upon (1) administration of normal PS-interacting proteins, (2) gene therapy with normal PS -interacting protein genes to compensate for or replace the mutant genes, (3) gene therapy based upon antisense sequences to mutant PS- interacting protein genes or which "knock-out" the mutant genes, (4) gene therapy based upon sequences which encode a protein which blocks or corrects the deleterious effects of PS-interacting protein mutants, (5) immuno therapy based upon antibodies to normal and/or mutant PS-interacting proteins, or (6) small molecules (drugs) which alter PS -interacting protein expression, alter interactions between PS-interacting proteins and other proteins or ligands, or which otherwise block the abenant function of mutant presenilin or PS-interacting proteins by altering the structure ofthe mutant proteins, by enhancing their metabolic clearance, or by inhibiting their function. A. Protein Therapy Treatment of Alzheimer's Disease, or other disorders resulting from PS- interacting protein mutations, may be performed by replacing the mutant protein with normal protein, by modulating the function ofthe mutant protein, or by providing an excess of normal protein to reduce the effect of any aberrant function ofthe mutant proteins. To accomplish this, it is necessary to obtain, as described and enabled herein, large amounts of substantially pure PS-interacting protein from cultured cell systems which can express the protein. Delivery ofthe protein to the affected brain areas or other tissues can then be accomplished using appropriate packaging or administration systems including, for example, liposome mediated protein delivery to the target cells. B. Gene Therapy In one series of embodiments, gene therapy may be employed in which normal copies of a PS-interacting protein gene are introduced into patients to code successfully for normal protein in one or more different affected cell types. The gene must be delivered to those cells in a form in which it can be taken up and code for sufficient protein to provide effective function. Thus, it is prefened that the recombinant gene be operably joined to a strong promoter so as to provide a high level of expression which will compensate for, or out-compete, the mutant proteins. As noted above, the recombinant construct may contain endogenous or exogenous regulatory elements, inducible or repressible regulatory elements, or tissue-specific regulatory elements. In another series of embodiments, gene therapy may be employed to replace the mutant gene by homologous recombination with a recombinant construct. The recombinant construct may contain a normal copy ofthe targeted PS-interacting protein gene, in which case the defect is corrected in situ, or may contain a "knock¬ out" construct which introduces a stop codon, missense mutation, or deletion which abolished function ofthe mutant gene. It should be noted in this respect that such a construct may knock-out both the normal and mutant copies of the targeted gene in a heterozygous individual, but the total loss of gene function may be less deleterious to the individual than continued progression ofthe disease state. In another series of embodiments, antisense gene therapy may be employed. The antisense therapy is based on the fact that sequence-specific suppression of gene expression can be achieved by intracellular hybridization between mRNA or DNA and a complementary antisense species. The formation of a hybrid duplex may then interfere with the transcription ofthe gene and/or the processing, transport, translation and/or stability ofthe target mRNA. Antisense strategies may use a variety of approaches including the administration of antisense oligonucleotides or antisense oligonucleotide analogs (e.g., analogs with phosphorothioate backbones) or transfection with antisense RNA expression vectors. Again, such vectors may include exogenous or endogenous regulatory regions, inducible or repressible regulatory elements, or tissue-specific regulatory elements. In another series of embodiments, gene therapy may be used to introduce a recombinant construct encoding a protein or peptide which blocks or otherwise conects the abenant function caused by a mutant presenilin or PS-interacting protein gene. In one embodiment, the recombinant gene may encode a peptide which conesponds to a domain of a PS-interacting which has been found to abnormally interact with another cell protein or other cell ligand (e.g., a mutant presenilin). Thus, for example, if a mutant PSl TM6→7 domain is found to interact with a PS- interacting protein but the conesponding normal TM6→7 domain does not undergo this interaction, gene therapy may be employed to provide an excess ofthe mutant TM6— >7 domain which may compete with the mutant presenilin protein and inhibit or block the abenant interaction. Alternatively, the PS-interacting domain of a PS- interacting protein which interacts with a mutant, but not a normal, presenilin may be encoded and expressed by a recombinant construct in order to compete with, and thereby inhibit or block, the abenant interaction. Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression. A full length PS-interacting protein gene, subsequences encoding functional domains of these proteins, or any ofthe other therapeutic peptides described above, can be cloned into a retroviral vector and expression may be driven from its endogenous promoter, from the retroviral long terminal repeat, or from a promoter specific for the target cell type of interest (e.g., neurons). Other viral vectors which can be used include adeno- associated virus, vaccinia virus, bovine papilloma virus, or a heφes virus such as Epstein-Ban virus. C. Immunotherapy Immunotherapy is also possible for Alzheimer's Disease. Antibodies may be raised to a normal or mutant PS -interacting protein (or a portion thereof) and are administered to the patient to bind or block an aberrant interaction (e.g., with a mutant presenilin) and prevent its deleterious effects. Simultaneously, expression ofthe normal protein product could be encouraged. Altematively, antibodies may be raised to specific complexes between mutant or wild-type PS-interacting proteins and their interaction partners. A further approach is to stimulate endogenous antibody production to the desired antigen. Administration could be in the form of a one time immunogenic preparation or vaccine immunization. The PS-interacting protein or other antigen may be mixed with pharmaceutically acceptable carriers or excipients compatible with the protein. The immunogenic composition and vaccine may further contain auxiliary substances such as emulsifying agents or adjuvants to enhance effectiveness. Immunogenic compositions and vaccines may be administered parenterally by injection subcutaneously or intramuscularly. D. Small Molecule Therapeutics As described and enabled herein, the present invention provides for a number of methods of identifying small molecules or other compounds which may be useful in the treatment of Alzheimer's Disease or other disorders caused by mutations in the presenilins or PS-interacting proteins. Thus, for example, the present invention provides for methods of identifying proteins which bind to normal or mutant PS- interacting proteins (aside from the presenilins). The invention also provides for methods of identifying small molecules which can be used to disrupt abenant interactions between mutant presenilins and/or PS-interacting proteins and such other binding proteins or other cell components. Examples Example 1. Isolation of PS-interacting proteins by two-hybrid yeast system. To identify proteins interacting with the presenilin proteins, a commercially available yeast two-hybrid kit ("Matchmaker System 2" from Clontech, Palo Alto, CA) was employed to screen a brain cDNA library for clones which interact with functional domains ofthe presenilins. In view ofthe likelihood that the TM6— 7 loop domains ofthe presenilins are important functional domains, partial cDNA sequences encoding either residues 266-409 ofthe normal PSl protein or residues 272-390 ofthe normal PS2 protein were ligated in- frame into the EcoRI and BamHI sites ofthe pAS2-l fusion-protein expression vector (Clontech). The resultant fusion proteins contain the GAL4 DNA binding domain coupled in-frame either to the TM6→7 loop ofthe PSl protein or to the TM6→7 loop ofthe PS2 protein. These expression plasmids were co-transformed into S. cerevisiae strain Y190 together with a library of human brain cDNAs ligated into the pACT2 yeast fusion-protein expression vector (Clontech) bearing the GAL4 activation domain using modified lithium acetate protocols ofthe "Matchmaker System 2" yeast two-hybrid kit (Clontech, Palo Alto, CA). Yeast clones bearing human brain cDNAs which interact with the TM6→7 loop domain were selected for His- resistance by plating on SD minimal medium lacking histidine and for βgal+ activation by color selection. The His+ βgal+ clones were then purged ofthe pAS2-l "bait" construct by culture in lOμg/ml cyclohexamide and the unknown "trapped" inserts of the human brain cDNAs encoding PS-interacting proteins were isolated by PCR and sequenced. Of 6 million initial transformants, 200 positive clones were obtained after His- selection, and 42 after βgal+ color selection, carried out in accordance with the manufacturer's protocol for selection of positive colonies. Of these 42 clones there were several independent clones representing the same genes. To address the likelihood that mutations in the presenilins cause AD through the acquisition of a novel but toxic function (i.e., dominant gain of function mutation) which is mediated by a novel interaction between the mutant proteins and one or more other cellular proteins, the human brain cDNA library cloned into the pACT2 expression vector (Clontech) was re-screened using mutant TM6-»7 loop domain sequences as described above and according to manufacturer's protocols. In particular, mutant presenilin sequences conesponding to residues 260-409 of PSl TM6→7 loop domains bearing mutations L286V, L392V and Δ290-319 were ligated in- frame into the GAL4 DNA-binding domain ofthe pAS2-l vector (Clontech) and used to screen the human brain cDNA:GAL4 activation domain library of p ACT vectors (Clontech). Yeast were co-transformed, positive colonies were selected, and "trapped" sequences were recovered and sequenced as described above. In addition to some ofthe same sequences recovered with the normal TM6— 7 loop domains, several new sequences were obtained which reflect abenant interactions ofthe mutant presenilins with normal cellular proteins. The recovered and sequenced clones conesponding to these PS-interacting proteins were compared to the public sequence databases using the BL:ASTN algorithm via the NCBI e-mail server. Descriptions of several of these clones follow: Antisecretory Factor/ Proteasome S5a Subunit. Two overlapping clones (Y2H29 and Y2H31) were identified which conespond to a C-terminal fragment of a protein altematively identified as Antisecretory Factor ("ASF") or the Multiubiquitin chain binding S5a subunit ofthe 26S proteasome ("S5a") (Johansson et al. 1995; Fenell et al., 1996). The complete nucleotide and amino acid sequences ofthe S5a subunit are available through the public databases under Accession number U51007 and are reproduced here as SEQ ID NO: 1 and SEQ ID NO: 2. The nucleotide sequences ofthe Y2H29 and Y2H31 clones include nucleotides 351-1330 of SEQ ID NO: 1 and amino acid residues 70-377 of SEQ ID NO: 2. Thus, residues 70-377 of the full S5a subunit include the PS-interacting domain of this protein. Residues 206- 377 of S5a contain certain motifs that are important for protein-protein interactions (Fenell et al., 1996). The PS 1 -S5a subunit interaction was directly re-tested for both wild type and mutant PSl TM6→7 loop (residues 260-409) by transforming Y187 yeast cells with the appropriate wild type or mutant (L286V, L392V or Δ290-319) cDNA ligated in-frame to the GAL4-DNA binding domain of pACT2. The Δ290-319 mutant fusion construct displayed autonomous βgal activation in the absence of any S5a "target sequence" and, therefore, could not be further analyzed. In contrast, both the L286V and L392V mutant constructs interacted specifically with the S5a construct. Quantitative assays, however, showed that these interactions were weaker than those involving the wild type PS1 26(M09 sequence and that the degree of interaction was crudely conelated with the age of onset of FAD. The difference in βgal activation was not attributable to instability ofthe mutant PS1 26(M09 construct mRNAs or fusion proteins because Western blots of lysates of transformed yeast showed equivalent quantities of mutant or wild-type fusion proteins. Because one ofthe putative functions of S5a is to bind multi-ubiquitinated proteins, the PSl:S5a interaction observed in S. cerevisiae could arise either through yeast-dependent ubiquitination ofthe PSl^.^ construct, or by direct interaction. The former would reflect a degradative pathway, a functional and perhaps reciprocal interaction between PSl and S5a, or both. A direct interaction is favored by the fact that the PSl:S5a interaction is decreased rather than increased by the presence ofthe L286V and L392V mutations, and by the fact that neither of these mutations affect ubiquitin conjugation sites in the PS l 26θJ(09 loop (i.e., K265, K311, K314 or K395). To further examine this possibility, we investigated the direct interaction of recombinant His-tagged fusion proteins conesponding to full length S5a and the PS1 26(M09 loop. Partially purified recombinant His-tagged PS1 26(M09 loop and His- tagged S5a proteins and appropriate controls were mixed in phosphate buffered saline. The mixture was then subjected to size exclusion chromatography, and eluates were examined by SDS-PAGE and Western blotting using anti-His-tag monoclonal antibodies (Quiagen). In the crude PS1 26(M09 loop preparation alone, the PSl 26M09 loop eluted from the size exclusion column as a broad peak at 35 minutes. In the crude S5a preparation alone, S5a eluted at 25 minutes. However, when the crude PSl 26α409 loop and S5a preparations were mixed, there was a significant shift in the elution of PS 1 260 . 409 toward a higher molecular weight complex. Co-elution of S5a and PS 1 26(M09 in the same fraction was confirmed by SDS-PAGE and Western blotting of fractions using the anti-His-tag antibody. These results are consistent with a ubiquitin-independent and, therefore, possibly functional interaction. GT24 and related genes with homology to pl20/plakoglobin family. Five over-lapping clones (Y2H6, Y2H10b, Y2H17h2, Y2H24, and Y2H25) were obtained which interact with the normal PSl TM6— >7 loop domain and which appear to represent at least one novel gene. The Y2H24 clone was also found to interact with the mutant PSl TM6→7 loop domains. Note that it appears that more than one member ofthe gene family was isolated, suggesting a family of genes interacting differentially with different presenilins. The most complete available cDNA conesponding to these clones was designated GT24 and is disclosed herein as SEQ ID NO: 3 and has been deposited with GenBank as Accession number U81004. The open reading frame suggests that GT24 is a protein of at least 1040 amino acids with a unique N-terminus, and considerable homology to several armadillo (arm) repeat proteins at its C-terminus. The predicted amino acid sequence of GT24 is disclosed herein as SEQ ID NO: 4. Thus, for example, residues 440-862 of GT24 have 32-56% identity (p=1.2e '133 ) to residues 440-854 of murine pi 20 protein (Accession number Z 17804), and residues 367-815 of GT24 have 26-42% identity (p=0.0017) to residues 245-465 ofthe P. melanogaster armadillo segment polarity protein (Accession number P18824). The GT24 gene maps to chromosome 5pl5 near the anonymous microsatellite marker D5S748 and the Cri-du-Chat syndrome locus. This sequence is also nearly identical to portions of two human ESTs of unknown function (i.e., nucleotides 2701-3018 of Accession number F08730 and nucleotides 2974-3348 of Accession number T18858). These clones also show lower degrees of homology with other partial cDNA and gDNA sequences (e.g., H17245, T06654, T77214, H24294, M62015, T87427 and G04019). p0071 gene. An additional His " , βgal + clone isolated in the initial screening with wild type PSl 26< 409 "bait" had a similar nucleotide sequence to GT24 (target clone Y2H25; Accession number U81005), and would also be predicted to encode a peptide with C-terminal arm repeats. A longer cDNA sequence closely conesponding to the Y2H25 clone has been deposited in GenBank as human protein p0071 (Accession number X81889). The nucleotide and conesponding amino acid sequences of p0071 are reproduced herein as SEQ ID NOs: 5 and 6. Comparison of the predicted sequence ofthe p0071 ORF with that of GT24 confirms that they are related proteins with 47% overall amino acid sequence identity, and with 70% identity between residues 346-862 of GT24, and residues 509-1022 of p0071 (which includes residues encoded by the Y2H25 cDNA). The latter result strongly suggests that PSl interacts with a novel class of arm repeat containing proteins. The broad - 4 kb hybridization signal obtained on Northem blots with the unique 5' end of GT24 could reflect either alternate splicing/polyadenylation of GT24, or the existence of additional members of this family with higher degrees of N-terminal homology to GT24 than p0071. Rabl l gene. This clone (Y2H9), disclosed herein as SEQ ID NO: 7, was identified as interacting with the normal PSl TM6— 7 loop domain and appears to conespond to a known gene, Rabl 1, available through Accession numbers X56740 and X53143. Rabl 1 is believed to be involved in protein/vesicle trafficking in the ER/Golgi. Note the possible relationship to processing of membrane proteins such as βAPP and Notch with resultant oveφroduction of toxic Aβ peptides (especially neurotoxic Afi,^ 2(43) isoforms) (Scheuner, et al, 1995). Retinoid X receptor-β gene. This clone (Y2H23b), disclosed herein as SEQ ID NO: 8, was identified as interacting with the normal PSl TM6→7 loop domain and appears to conespond to a known gene, known variously as the retinoid X receptor-β, nuclear receptor co-regulator or MHC Class I regulatory element, and available through Accession numbers M84820, X63522 and M81766. This gene is believed to be involved in intercellular signaling, suggesting a possible relationship to the intercellular signaling function mediated by C. elegans sell 2 and Notch/lin-12 (transcription activator). Cytoplasmic chaperonin gene. This clone (Y2H27), disclosed herein as SEQ ID NO: 9, was identified as interacting with the normal PS 1 TM6- 7 loop domain and appears to conespond to a known gene, a cytoplasmic chaperonin containing TCP-1, available through Accession numbers U17104 and X74801. Unknown gene (Y2H35 . This clone (Y2H35), disclosed herein as SEQ ID NO: 10, was identified as interacting with the normal PSl TM6— 7 loop domain and appears to conespond to a known gene of unknown function, available through Accession number R12984, which shows conservation down through yeast. Unknown gene fY2H171 ). This clone (Y2H171), disclosed herein as SEQ ID NO: 11, was identified as interacting with the normal PSl TM6->7 loop domain and appears to conespond to a known expressed repeat sequence available through Accession number D55326. Unknown gene (Y2H41). This clone (Y2H41) was identified which reacts strongly with the TM6-→7 loop domains of both PSl and PS2 as well as the mutant loop domains of PSl. The sequence, disclosed as SEQ ID NO: 12, shows strong homology to an EST of unknown function (Accession number T64843). Example 2. Isolation of presenilin binding proteins by affinity chromatography. To identify the proteins which may be involved in the biochemical function ofthe presenilins, PS-interacting proteins were isolated using affinity chromatography. A GST- fusion protein containing the PSl TM6→7 loop, prepared as described in Example 3, was used to probe human brain extracts, prepared by homogenizing brain tissue by Polytron in physiological salt solution. Non-specific binding was eliminated by pre-clearing the brain homogenates of endogenous GST- binding components by incubation with glutathione-Sepharose beads. These GST- free homogenates were then incubated with the GST-PS fusion proteins to produce the desired complexes with functional binding proteins. These complexes were then recovered using the affinity glutathione-Sepharose beads. After extensive washing with phosphate buffered saline, the isolated collection of proteins was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE; Tris-tricine gradient gel 4- 20%). Two major bands were observed at -14 and 20 kD in addition to several weaker bands ranging from 50 to 60 kD. The same approach may now be used to identify proteins which have binding activity for the PS-interacting proteins and, thereby, to further elucidate the etiology of AD and to identify additional therapeutics targets for intervention in AD and related disorders. Example 3. Eukaryotic and prokaryotic expression vector systems. Constructs suitable for use in eukaryotic and prokaryotic expression systems have been generated using different classes of PSl nucleotide cDNA sequence inserts. In the first class, termed full-length constmcts, the entire PSl cDNA sequence is inserted into the expression plasmid in the conect orientation, and includes both the natural 5' UTR and 3' UTR sequences as well as the entire open reading frame. The open reading frames bear a nucleotide sequence cassette which allows either the wild type open reading frame to be included in the expression system or altematively, single or a combination of double mutations can be inserted into the open reading frame. This was accomplished by removing a restriction fragment from the wild type open reading frame using the enzymes Narl and Pflml and replacing it with a similar fragment generated by reverse transcriptase PCR and bearing the nucleotide sequence encoding either the M146L mutation or the H163R mutation. A second restriction fragment was removed from the wild type normal nucleotide sequence for the open reading frame by cleavage with the enzymes Pflml and Ncol and replaced with a restriction fragment bearing the nucleotide sequence encoding the A246E mutation, the A260V mutation, the A285V mutation, the L286V mutation, the L392V mutation or the C410Y mutation. A third variant, bearing a combination of either the M146L or H1 3R mutation in tandem with one ofthe remaining mutations, was made by linking a Narl-Pflml fragment bearing one ofthe former mutations and a Pflml-Ncol fragment bearing one ofthe latter mutations. The second class of cDNA inserts, termed truncated constmcts, was constructed by removing the 5' UTR and part ofthe 3' UTR sequences from full length wild type or mutant cDNA sequences. The 5' UTR sequence was replaced with a synthetic oligonucleotide containing a Kpnl restriction site (GGTAC/C) and a small sequence (GCCACC) to create a Kozak initiation site around the ATG at the beginning ofthe PSl ORF. The 3' UTR was replaced with an oligonucleotide with an artificial EcoRI site at the 5' end. Mutant variants of this construct were then made by inserting the mutant sequences described above at the Narl-Pflml and Pslml-Ncol sites as described above. For eukaryotic expression, these various cDNA constmcts bearing wild type and mutant sequences, as described above, were cloned into the expression vector pZeoSV in which the SV60 promoter cassette had been removed by restriction digestion and replaced with the CMV promoter element of pcDNA3 (Invitrogen). For prokaryotic expression, constmcts have been made using the glutathione S-transferase (GST) fusion vector pGEX-kg. The inserts which have been attached to the GST fusion nucleotide sequence are the same nucleotide sequences described above bearing either the normal open reading frame nucleotide sequence, or bearing a combination of single and double mutations as described above. These GST fusion constmcts allow expression ofthe partial or full-length protein in prokaryotic cell systems as mutant or wild type GST fusion proteins, thus allowing purification ofthe full-length protein followed by removal ofthe GST fusion product by thrombin digestion. A further cDNA construct was made with the GST fusion vector, to allow the production ofthe amino acid sequence conesponding to the hydrophilic acidic loop domain between TM6 and TM7 ofthe full-length protein, either as a wild type nucleotide sequence or as a mutant sequence bearing either the A285V mutation, the L286V mutation or the L392V mutation. This was accomplished by recovering wild type or mutant sequence from appropriate sources of RNA using a 5' oligonucleotide primer with a 5' BamHI restriction site (G/GATCC), and a 3' primer with a 5' EcoRI restriction site (G/AATTC). This allowed cloning of the appropriate mutant or wild type nucleotide sequence conesponding to the hydrophilic acidic loop domain at the BamHI and the EcoRI sites within the pGEX-KG vector. The PS-interacting protein genes may be similarly manipulated by recombinant means for expression in prokaryotic or eukaryotic hosts. In particular, GST or other fusion proteins may be produced which will be useful in assays (e.g., yeast two-hybrid studies) for therapeutics. Example 4. Antibody production. Peptide antigens conesponding to portions of the PS 1 protein were synthesized by solid-phase techniques and purified by reverse phase high pressure liquid chromatography. Peptides were covalently linked to keyhole limpet hemocyanin (KLH) via disulfide linkages that were made possible by the addition of a cysteine residue at the peptide C-terminus ofthe presenilin fragment. This additional residue does not appear normally in the protein sequence and was included only to facilitate linkage to the KLH molecule. A total of three New Zealand white rabbits were immunized with peptide- KLH complexes for each peptide antigen in combination with Freund's adjuvant and were subsequently given booster injections at seven day intervals. Antisera were collected for each peptide and pooled and IgG precipitated with ammonium sulfate. Antibodies were then affinity purified with Sulfo-link agarose (Pierce) coupled with the appropriate peptide. This final purification is required to remove non-specific interactions of other antibodies present in either the pre- or post-immune serum. The specificity of each antibody was confirmed by three tests. First, each detected single predominant bands ofthe approximate size predicted for presenilin- 1 on Western blots of brain homogenate. Second, each cross-reacted with recombinant fusion proteins bearing the appropriate sequence. Third each could be specifically blocked by pre-absoφtion with recombinant PS 1 or the immunizing peptide. Antibodies to peptides derived from the PS -interacting proteins may be produced by similar means. Example 5. Transgenic mice. A series of wild type and mutant PS 1 and PS2 genes were constructed for use in the preparation of transgenic mice. Mutant versions of PS 1 and PS2 were generated by site-directed mutagenesis ofthe cloned cDNAs using standard techniques. The cDNAs and their mutant versions were used to prepare two classes of mutant and wild type PSl and PS2 cDNAs, as described in Example 3. The first class, refened to as "full-length" cDNAs, were prepared by removing approximately 200 bp ofthe 3' untranslated region immediately before the polyA site by digestion with EcoRI (PSl) or PvuII (PS2). The second class, refened to as "truncated" cDNAs, were prepared by replacing the 5' untranslated region with a ribosome binding site (Kozak consensus sequence) placed immediately 5' ofthe ATG start codon. Various full length and truncated wild type and mutant PSl and PS2 cDNAs, prepared as described above, were introduced into one or more ofthe following vectors and the resulting constmcts were used as a source of gene for the production of transgenic mice. The cos.TET expression vector: This vector was derived from a cosmid clone containing the Syrian hamster PrP gene. It has been described in detail by Scott et al. (1992) and Hsiao et al. (1995). PSl and PS2 cDNAs (full length or truncated) were inserted into this vector at its Sail site. The final constmcts contain 20 kb of 5' sequence flanking the inserted cDNA. This 5' flanking sequence includes the PrP gene promoter, 50 bp of a PrP gene 5' untranslated region exon, a splice donor site, a 1 kb intron, and a splice acceptor site located immediately adjacent to the Sail site into which the PSl or PS2 cDNA was inserted. The 3' sequence flanking the inserted cDNA includes an approximately 8 kb segment of PrP 3' untranslated region including a polyadenylation signal. Digestion of this construct with NotI (PSl) or Fsel (PS2) released a fragment containing a mutant or wild type PS gene under the control ofthe PrP promoter. The released fragment was gel purified and injected into the pronuclei of fertilized mouse eggs using the method of Hsiao et al. (1995). Platelet-derived growth factor receptor β-subunit constmcts: PS cDNAs were also introduced between the Sail (full length PS 1 cDNAs) or Hindlll (truncated PS 1 cDNAs, full length PS2 cDNAs, and truncated PS2 cDNAs) at the 3' end of the human platelet derived growth factor receptor β-subunit promoter and the EcoRI site at the 5' end ofthe SV40 polyA sequence and the entire cassette was cloned into the pZeoSV vector (Invitrogen, San Diego, CA.). Fragments released by Scal/BamHI digestion were gel purified and injected into the pronuclei of fertilized mouse eggs using the method of Hsiao et al. ( 1995). Human β-actin constmcts: PSl and PS2 cDNAs were inserted into the Sail site of pBAcGH. The construct produced by this insertion includes 3.4 kb ofthe human β actin 5' flanking sequence (the human β actin promoter, a spliced 78 bp human β actin 5' untranslated exon and intron) and the PSl or PS2 insert followed by 2.2 kb of human growth hormone genomic sequence containing several introns and exons as well as a polyadenylation signal. Sfil was used to release a PS-containing fragment which was gel purified and injected into the pronuclei of fertilized mouse eggs using the method of Hsiao et al. (1995). Phosphoglvcerate kinase constmcts: PSl and PS2 cDNAs were introduced into the pkJ90 vector. The cDNAs were inserted between the Kpnl site downstream ofthe human phosphoglycerate kinase promoter and the Xbal site upstream ofthe 3' untranslated region ofthe human phosphoglycerate kinase gene. PvuII/Hindlll (PSl cDNAs) or PvuII (PS2 cDNAs) digestion was used to release a PS-containing fragment which was then gel purified and injected into the pronuclei of fertilized mouse eggs as described above. Analysis of AB in transgenic murine hippocampus: To analyze the effect of a mutant human PSl transgene in mice, a PSl mutation observed in conjunction with a particularly severe form of early-onset PSl -linked Alzheimer's disease was used, namely the M146L missense mutation (Sherrington et al., 1995). The animals, which were heterozygous for the PS 1 mutant transgene on a mixed FVB-C57BL/6 strain background, were cross-bred with similar mice bearing the human wild-type βAPP 695 cDNA under the same Syrian hamster PrP promoter similar to those animals recently described by Hsiao et al., 1995. These cross breedings were done because it is thought that human Aβ is more susceptible to the formation of aggregates than are murine Aβ peptides. The progeny of these PS1 M146L x βAPPwr cross-breedings were then genotyped to identify animals that contained both the human wild-type βAPP 695 transgene and also the mutant human PS1 M146L transgene. These mice were aged until two to three months of age and then sacrificed, with the hippocampus and neocortex being dissected rapidly from the brain and frozen. Litter mates of these mice, which contained only the wild-type human βAPP 695 transgene were also sacrificed, and their hippocampi and neocortices were dissected and rapidly frozen as well. The concentration of both total Aβ peptides (Aβ χj(0 and Aβ x-42 (43) ) as well as the subset of Aβ peptides ending on residues 42 or 43 (long-tailed Aβ 42 peptides) were then measured using a two-sandwich ELISA as described previously (Tamaoka et al., 1994; Suzuki et al., 1994). These results convincingly showed a small increase in total Aβ peptides in the double transgenic animals bearing wild-type human βAPP 695 and mutant human PS1 MI46L transgenes compared to the wild-type human βAPP 695 controls. More impressively, these measurements also showed that there was an increase in the amount of long-tailed Aβ peptides ending on residues 42 or 43 (Aβ 42 ). In contrast, litter mates bearing only the wild-type human βAPP 695 transgene had Aβ 42 long-tailed peptide values which were below the limit of quantitation ("BLQ"). These observations therefore confirm that the construction of transgenic animals can recapitulate some ofthe biochemical features of human Alzheimer's disease (namely the oveφroduction of Aβ peptide and, in particular, oveφroduction of long-tailed isoforms of Aβ peptide). These observations thus prove that the transgenic models are in fact useful in exploring therapeutic targets relevant to the treatment and prevention of Alzheimer's disease. Analvsis of hippocampus dependent memory functions in PSl transgenic mice: Fourteen transgenic C57BL/6 x FVB mice bearing the human PS1 MI46V mutant transgene under the PrP promoter (as described) above and 12 wild type litter mates aged 2.5-3 months of age (both groups were balanced for age, weight, and sex) were investigated for behavioral differences attributable to the mutant transgene. Also the qualitative observation of murine behavior in their home cages did not indicate bimodal distribution of behaviors in the sample of animals. Experiment 1. To test for subtle differences in exploratory behavior (e.g. locomotion, scanning ofthe environment through rearing, and patterns of investigation of unfamiliar environment), both PS 1 MM6V and wild type litter mates were tested in the open-field (Janus, et al. 1995). The results ofthe test revealed no significant differences between transgenics and controls in exploration of a new environment measured by mice locomotor behaviors (walking, pausing, wall leaning, rearing, grooming), (F(l,24) = .98, NS). Thus, differences any in behavior on the Morris water maze test (see below) cannot be attributed to differences in locomotor abilities, etc. Experiment 2. One week after the open-field test, the PS1 M146V mutant transgenic mice and their litter mates were trained in the Morris water maze. In this test, a mouse has to swim in a pool in order to find a submerged escape platform. The animal solves that test through learning the location ofthe platform using the available extra-maze spatial cues (Morris, 1990). This test was chosen because there is strong evidence that the hippocampal formation is involved in this form of learning. The hippocampus is also a major site of AD neuropathology in humans and defects in spatial learning (geographic disorientation, losing objects, wandering, etc.) are prominent early features of human AD. As a result the test is likely to detect early changes equivalent to those seen in human AD. The Morris test is conducted in three phases. In the first phase (the learning acquisition phase), the mouse has to learn the spatial position ofthe platform. In the second phase (the probe trial), the platform is removed from the pool and the mouse's search for the platform is recorded. In the final phase (the learning transfer phase), the platform is replaced in a new position in the pool, and the mouse has to learn that new spatial position ofthe platform. Transgenic and wild type mice did not differ in their latencies to find the platform during learning acquisition (F(l,24) = 0.81, NS), and both groups showed rapid learning across trials (F(10,15) = 11.57, p < 0.001). During the probe trial phase, mice from both groups searched the quadrant ofthe pool which originally contained the platform significantly longer than other areas ofthe pool which had not contained the platform (F(3,22) = 28.9, p < 0.001). However, the wild type controls showed a trend which was not quite statistically significant (t(24) = 1.21, p = 0.24) for an increased number of crossings of the exact previous position of the platform. In the learning transfer test, both groups showed the same latency of finding the new position ofthe platform in the initial block of trials (t(24) = 1.11, NS). Such long latency to find the new spatial position is expected because the mice spent most of their time searching for the platform in the old spatial position. However, in later trials in the learning transfer phase, the wild type mice showed shorter swim latencies to the new position ofthe platform compared to the PS1 M146V mutant transgenics (F(l,24) 2.36, p = 0.14). The results indicate that PS1 M , 46V mutant transgenic mice were less flexible in transferring learned information to a new situation and tended to persevere in their search for the platform in the old location. Thus, although no differences were found in the spontaneous exploration of a new environment and in the acquisition of new spatial information between the wild type and the PS1 M146V mutant transgenic mice, the PS1 M , 46V mutant transgenic mice were impaired in switching and/or adapting this knowledge in later situations. Electrophvsiological Recordings in the hippocampus of mutant transgenic mice: Five to six months old litter mate control and human PS1 M146V mutant transgenic mice on the same C57BL/6 x FVB strain backgrounds as above were used to study long term potentiation (LTP) as an electrophysiologic conelate of learning and memory in the hippocampus. Recordings were carried out on 400 μm thick hippocampal slices according to conventional techniques. Briefly, brains were removed and transverse sections containing hippocampi were obtained within 1 min. after mice were decapitated under halothane anesthesia. Slices were kept at room temperature in oxygenated artificial cerebrospinal fluid for one hour prior to recording. One slice at a time was transfened to the recording chamber, where they were maintained at 32 °C in an interface between oxygenated artificial cerebrospinal fluid and humidified air. Slices were then allowed to equilibrate in the recording chamber for another hour. Extracellular field recordings were carried out in the CA1 subfield of the hippocampus at the Schaeffer collateral-pyramidal cell synapse. Synaptic responses were induced by the stimulation of Schaeffer collaterals at a frequency of 0.03 Hz and an intensity of 30-50 % of maximal response. Tetani to evoke long-term potentiation consisted of 5 trains of 100 Hz stimulation lasting for 200 ms at an intertrain interval of 10 seconds. Field potentials were recorded using an Axopatch 200B amplifier (Axon Instrument). Glass pipettes were fabricated from borosilicate glass with an outer diameter of 1.5 mm, and pulled with a two step Narishige puller. Data were acquired on a 486-EBM compatible computer using PCLAMP6 software (Axon Instrument). To test for any abnormality in presynaptic function, we investigated the differences in paired-pulse facilitation, which is an example of use-dependent increase in synaptic efficacy and is considered to be presynaptic in origin. In hippocampus, when two stimuli are delivered to the Schaeffer collaterals in rapid succession, paired- pulse facilitation manifests itself as an enhanced dendritic response to the second stimulus as the interstimulus interval gets shorter. In three pairs of wild- type/transgenic mice, we did not observe any difference in the paired-pulse facilitation over an interstimulus interval range of 20 ms to 1 sec. These data suggest that in PS1 M146V mutant transgenic mice, the excitability of Schaeffer collateral fibers and neurotransmitter release are likely to be normal. Tetanic stimulation induced a long-lasting increase in the synaptic strength in both control (n = 3) and PS1 M146V mutant transgenic mice (n = 2). In slices obtained from the PS1 M146V mutant transgenic mice, long-lasting increase in the synaptic strength was 30 % more than that obtained from control mice. Although prefened embodiments ofthe invention have been described herein in detail, it will be understood by those skilled in the art that variations may be made thereto without departing from the spirit ofthe invention or the scope ofthe appended claims. References Borguski et al. (1993) Nature 366:643-654. Bueler et al. (1996) Nature 356:577-582. Chartier-Harlin et al. (1991) Nature 353:844-846. Fenell et al. (1996) FEBS Lett. 381 :143-148. Fenteany et al. (1995) Science 268:726-731. Fischer and Lerman 0983) Proc. Natl. Acad. Sci. (USA) 80:1579-1583. Games et al. (1995) Nature 373:523-527. Gavrieli et al. (1992,- J. Cell Biol. 119:493-501. Goate et al. (1991) Nature 349:704-706. Gravina et al. (1995) J. Biol. Chem. 270:7013-7016. Greco et al. (1996) Genes & Dev. 10:313-324. Hilbich et al. (1991) J. Mol. Biol. 218:149-163. Hogan et al. (1986) Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. Hsiao et al. (1995) Neuron, (in press). Iwatsubo et al. (1995) Ann. Neurol. 37:294-299. Jacobson et al. (1993) Nature 361 :365. Janus et al. (1995). Neurobiology of Learning and Memory, 64:58-67. Johansson et al. (1995) J.Biol.Chem. 270:20615-20620. Kahn (1995) Science 270:369-370. Karlinsky et al. (1992) Neurology 42:1445-1453. Katzman (1986) N. Eng. J. Med. 314:964-973. Kikuchi et al. (1992) Oncogene 7:289-293. Klafki et al. (1996) J. Biol. Chem. 271 :28655-28659. Kosik and Greenberg (1994) Alzheimer Disease. New York, Raven Press. 335-344. Krause and Aaronson (1991) Methods in Enzvmology, 200:546-556. Lamb et al. (1993) Nature Genetics 5:22-29 Lassmann et al. (1995) Acta Neuropathol. 89:35. Levy-Lehad et al. (1995) Science 269:970-973. Liu and Sommer (1995) Biotechniques 18:470-477. Morris (1990) Cold Spring Harbor Symposia on Ouantitative Biology. 55:161-173. Mullan et al. (1992) Nature Genetics 1 :345-347. Munell et al. (1991) Science 254:97-99. Nowak (1995) Science 270:368-371. Okamoto, et al. (1995) J. Biol. Chem. 270:4205-4208. Phizicky and Fields (1994) Microbiol. Reviews 59:94-123. Pike et al. (1993) J. Neurosci. 13:1676-1678. Podlisny et al. (1995) J. Biol. Chem. 270:9564-9570. Rock et al. (1994) Cell 78:761-771. Rogaev et al. (1995) Nature 376:775-778. Saleeba and Cotton (1993) Methods in Enzvmology 217:286-295. Scheuner et al. ( 1995) Soc. Neurosci. Abstr. 21 : 1500. Scott et al. (1992) Protein Sci. 1:986-997. Sherrington et al. (1995) Nature 375:754-760. Suzuki et al. (1994) Science 264:1336-1340. Takada et al. (1994) Genes & Dev. 8:174-189. Tamaoka et al. (1994) J. Biol. Chem. 269:32721-32724. Tamaoka et al. (1995) Brain Res. 679:151-156. Vito et al. (1996) Science 271:521-525. Wolozin et al. (1996) Science 274:1710-1713. Wong et al. (1996) Neuroscience 22:728. Yamatsuji et al. (1996) Science 272:1349-1352. Zheng et al. (1995) Cell 81 :525-531 SEQUENCE LISTING (1) GENERAL INFORMATION: (1) APPLICANT: ST. GEORGE-HYSLOP , PETER H. ROMMENS, JOHANNA M. FRASER, PAUL E. ( ll) TITLE OF INVENTION: NUCLEIC ACIDS AND PROTEINS RELATED TO ALZHEIMER'S DISEASE, AND USES THEREFOR (ill) NUMBER OF SEQUENCES: 12 (IV) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Sim 4 McBurney (B) STREET: 330 University Avenue, 6™ Floor (C) CITY: Toronto (D) STATE: Ontario (E) COUNTRY: Canada (F) ZIP: M5G 1R7 (V) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS /MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (VI) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: 27-JAN-1997 (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/592, 541 (B) FILING DATE: 26-JAN-1996 (Vll) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/021, 673 (B) FILING DATE: 05-JUL-1996 ( ll) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/021, 700 (B) FILING DATE: 12-JUL-1996 (Vll) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/029,895 (B) FILING DATE: 08-NOV-1996 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: DOCKET* CAN-006PR(d) (B) FILING DATE: 02-JAN-1997 (Vlii) ATTORNEY/AGENT INFORMATION: (A) NAME: RAE, Patricia A. (IX) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (416) 595-1155 (B) TELEFAX: (416) 595-1163 (2) INFORMATION FOR SEQ ID NO : 1 : (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1330 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (lx) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 145..1275 (D) OTHER INFORMATION: /product= "S5a" (XI) SEQUENCE DESCRIPTION: SEQ ID NO : 1 : AATTCCCAAA TGACCTTTTA TTTCATACAG AGATACAAAG GCAACTATGT GCAGCAACAA 60 TCTGATGGGC AGTCCAAACT CTTGGGAGGA AGTAAATTCA TGGTAAATGT CATGATGGCG 120 GTCGGGAGGG AGGAAGGTGG CAAG ATG GTG TTG GAA AGC ACT ATG GTG TGT 171 Met Val Leu Glu Ser Thr Met Val Cys 1 5 GTG GAC AAC AGT GAG TAT ATG CGG AAT GGA GAC TTC TTA CCC ACC AGG 219 Val Asp Asn Ser Glu Tyr Met Arg Asn Gly Asp P e Leu Pro Thr Arg 10 15 20 25 CTG CAG GCC CAG CAG GAT GCT GTC AAC ATA GTT TGT CAT TCA AAG ACC 267 Leu Gin Ala Gin Gin Asp Ala Val Asn He Val Cys His Ser Lys Thr 30 35 40 CGC AGC AAC CCT GAG AAC AAC GTG GGC CTT ATC ACA CTG GCT AAT GAC 315 Arg Ser Asn Pro Glu Asn Asn Val Gly Leu He Thr Leu Ala Asn Asp 45 50 55 TGT GAA GTG CTG ACC ACA CTC ACC CCA GAC ACT GGC CGT ATC CTG TCC 363 Cys Glu Val Leu Thr Thr Leu Thr Pro Asp Thr Gly Arg He Leu Ser 60 65 70 AAG CTA CAT ACT GTC CAA CCC AAG GGC AAG ATC ACC TTC TGC ACG GGC 411 Lys Leu His Thr Val Gin Pro Lys Gly Lys He Thr Phe Cys Thr Gly 75 80 85 ATC CGC GTG GCC CAT CTG GCT CTG AAG CAC CGA CAA GGC AAG AAT CAC 459 He Arg Val Ala His Leu Ala Leu Lys His Arg Gin Gly Lys Asn His 90 95 100 105 AAG ATG CGC ATC ATT GCC TTT GTG GGA AGC CCA GTG GAG GAC AAT GAG 507 Lys Met Arg He He Ala Phe Val Gly Ser Pro Val Glu Asp Asn Glu 110 115 120 AAG GAT CTG GTG AAA CTG GCT AAA CGC CTC AAG AAG GAG AAA GTA AAT 555 Lys Asp Leu Val Lys Leu Ala Lys Arg Leu Lys Lys Glu Lys Val Asn 125 130 135 GTT GAC ATT ATC AAT TTT GGG GAA GAG GAG GTG AAC ACA GAA AAG CTG 603 Val Asp He He Asn Phe Gly Glu Glu Glu Val Asn Thr Glu Lys Leu 140 145 150 ACA GCC TTT GTA AAC ACG TTG AAT GGC AAA GAT GGA ACC GGT TCT CAT 651 Thr AAllaa PPhhee VVaall AAssnn TThhrr LLeeuu Asn Gly Lys Asp Gly Thr Gly Ser His 155 160 165 CTG GTG ACA GTG CCT CCT GGG CCC AGT TTG GCT GAT GCT CTC ATC AGT 699 Leu Val Thr Val Pro Pro Gly Pro Ser Leu Ala Asp Ala Leu He Ser 170 175 180 185 TCT CCG ATT TTG GCT GGT GAA GGT GGT GCC ATG CTG GGT CTT GGT GCC 747 Ser Pro He Leu AAllaa GGllyy GGlluu GGllyy GGllyy AAllaa MMeett LLeeuu GGllyy LLeeuu GGlliy Ala 190 1 - 9-5- 2 ' 0 TiO AGT GAC TTT GAA TTT GGA GTA GAT CCC AGT GCT GAT CCT GAG CTG GCC 795 Ser Asp Phe Glu Phe Gly Val Asp Pro Ser Ala Asp Pro Glu Leu Ala 205 210 215 TTG GCC CTT CGT GTA TCT ATG GAA GAG CAG CGG CAG CGG CAG GAG GAG 843 Leu Ala Leu Arg Val Ser Met Glu Glu Gin Arg Gin Arg Gin Glu Glu 220 225 230 GAG GCC CGG CGG GCA GCT GCA GCT TCT GCT GCT GAG GCC GGG ATT GCT 891 Glu Ala Arg Arg Ala Ala Ala Ala Ser Ala Ala Glu Ala Gly He Ala 235 240 245 ACG ACT GGG ACT GAA GAC TCA GAC GAT GCC CTG CTG AAG ATG ACC ATC 939 Thr Thr Gly Thr Glu Asp Ser Asp Asp Ala Leu Leu Lys Met Thr He 250 255 260 265 AGC CAG CAA GAG TTT GGC CGC ACT GGG CTT CCT GAC CTA AGC AGT ATG 987 Ser Gin Gin Glu Phe Gly Arg Thr Gly Leu Pro Asp Leu Ser Ser Met 270 275 280 ACT GAG GAA GAG CAG ATT GCT TAT GCC ATG CAG ATG TCC CTG CAG GGA 1035 Thr Glu Glu Glu Gin He Ala Tyr Ala Met Gin Met Ser Leu Gin Gly 285 290 295 GCA GAG TTT GGC CAG GCG GAA TCA GCA GAC ATT GAT GCC AGC TCA GCT 1083 Ala Glu Phe Gly Gin Ala Glu Ser Ala Asp He Asp Ala Ser Ser Ala 300 305 310 ATG GAC ACA TCC GAG CCA GCC AAG GAG GAG GAT GAT TAC GAC GTG ATG 1131 Met Asp Thr Ser Glu Pro Ala Lys Glu Glu Asp Asp Tyr Asp Val Met 315 320 325 CAG GAC CCC GAG TTC CTT CAG AGT GTC CTA GAG AAC CTC CCA GGT GTG 1179 Gin Asp Pro Glu Phe Leu Gin Ser Val Leu Glu Asn Leu Pro Gly Val 330 335 340 345 GAT CCC AAC AAT GAA GCC ATT CGA AAT GCT ATG GGC TCC CTG GCC TCC 1227 Asp Pro Asn Asn Glu Ala He Arg Asn Ala Met Gly Ser Leu Ala Ser 350 355 360 CAG GCC ACC AAG GAC GGC AAG AAG GAC AAG AAG GAG GAA GAC AAG AAG 1275 Gin Ala Thr Lys Asp Gly Lys Lys Asp Lys Lys Glu Glu Asp Lys Lys 365 370 375 TGAGACTGGA GGGAAAGGGT AGCTGAGTCT GCTTAGGGAC TGCATGGGGG AATTC 1330 (2) INFORMATION FOR SEQ ID NO:2: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 377 amino acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (11) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : Met Val Leu Glu Ser Thr Met Val Cys Val Asp Asn Ser Glu Tyr Met 1 5 10 15 Arg Asn Gly Asp Phe Leu Pro Thr Arg Leu Gin Ala Gin Gin Asp Ala 20 25 30 Val Asn He Val Cys His Ser Lys Thr Arg Ser Asn Pro Glu Asn Asn 35 40 45 Val Gly Leu He Thr Leu Ala Asn Asp Cys Glu Val Leu Thr Thr Leu 50 55 60 Thr Pro Asp Thr Gly Arg He Leu Ser Lys Leu His Thr Val Gin Pro 65 70 75 80 Lys Gly Lys He Thr Phe Cys Thr Gly He Arg Val Ala His Leu Ala 85 90 95 Leu Lys His Arg Gin Gly Lys Asn His Lys Met Arg He He Ala Phe 100 105 110 Val Gly Ser Pro Val Glu Asp Asn Glu Lys Asp Leu Val Lys Leu Ala 115 120 125 Lys Arg Leu Lys Lys Glu Lys Val Asn Val Asp He He Asn Phe Gly 130 135 140 Glu Glu Glu Val Asn Thr Glu Lys Leu Thr Ala Phe Val Asn Thr Leu 145 150 155 160 Asn Gly Lys Asp Gly Thr Gly Ser H s Leu Val Thr Val Pro Pro Gly 165 170 175 Pro Ser Leu Ala Asp Ala Leu He Ser Ser Pro He Leu Ala Gly Glu 180 185 190 Gly Gly Ala Met Leu Gly Leu Gly Ala Ser Asp Phe Glu Phe Gly Val 195 200 205 Asp Pro Ser Ala Asp Pro Glu Leu Ala Leu Ala Leu Arg Val Ser Met 210 215 220 Glu Glu Gin Arg Gin Arg Gin Glu Glu Glu Ala Arg Arg Ala Ala Ala 225 230 235 240 Ala Ser Ala Ala Glu Ala Gly He Ala Thr Thr Gly Thr Glu Asp Ser 245 250 255 Asp Asp Ala Leu Leu Lys Met Thr He Ser Gin Gin Glu Phe Glv Arg 260 265 270 Thr Gly Leu Pro Asp Leu Ser Ser Met Thr Glu Glu Glu Gin He Ala 275 280 285 Tyr Ala Met Gin Met Ser Leu Gin Gly Ala Glu Phe Gly Gin Ala Glu 290 295 300 Ser Ala Asp He Asp Ala Ser Ser Ala Met Asp Thr Ser Glu Pro Ala 305 310 315 320 Lys Glu Glu Asp Asp Tyr Asp Val Met Gin Asp Pro Glu Phe Leu Gin 325 330 335 Ser Val Leu Glu Asn Leu Pro Gly Val Asp Pro Asn Asn Glu Ala lie- 340 345 350 Arg Asn Ala Met Gly Ser Leu Ala Ser Gin Ala Thr Lys Asp Gly Lys 355 360 365 Lys Asp Lys Lys Glu Glu Asp Lys Lys 370 375 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3841 base pairs (B) TYPE: nucleic acid (C) STRANDEDNEΞS : single (D) TOPOLOGY: linear (IX) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..3121 (lx) FEATURE: (A) NAME/KEY: mi s c feature (B) LOCATIO : 1..3F 1 (D) OTHER INFORMATION: /note= "GT24" (XI) SEQUENCE DESCRIPTION: SEQ ID NO : 3 : T TCA CAG CTC CCG GCC CGA GGC ACA CAA GCC CGA GST ACG GGC CAG 46 Ser Gin Leu Pro Ala Arg Gly Thr Gin Ala Arg Xaa Thr Gly Gin 1 5 10 15 AGC TTC AGC CAG GGC ACG ACC AGC CGC GCC GGC CAC CTG GCG GGG CCC 94 Ser Phe Ser Gin Gly Thr Thr Ser Arg Ala Gly His Leu Ala Gly Pro 20 25 30 GAG CCC GCG CCG CCG CCG CCG CCG CCR CCG CGG GAG CCG TTC GCG CCC 142 Glu Pro Ala Pro Pro Pro Pro Pro Xaa Pro Arg Glu Pro Phe Ala Pro 35 40 45 AGC CTG GGC AGC GCC TTC CAC CTG CCC GAC GCG CCG CCC GCC GCC GCC 190 Ser Leu Gly Ser Ala Phe His Leu Pro Asp Ala Pro Pro Ala Ala Ala 50 55 60 GCC GCC GCG CTC TAC TAC TCC AKC TCC ACG CTG CCC GCG CCG CCG CGC 238 Ala Ala Ala Leu Tyr Tyr Ser Xaa Ser Thr Leu Pro Ala Pro Pro Arg 65 70 75 GGG GGC TCC CCG CTG GCC GCG CCC CAG GGC GGT TCG CCC ACC AAG CTG 286 Gly Gly Ser Pro Leu Ala Ala Pro Gin Gly Gl; Ser Pro Thr Lys Leu 80 85 95 CAG CGC GGC GGC TCG GCC CCC GAG GGC GCC ACC TAC GCC GCG CCG CGC 334 Gin Arg Gly Gly Ser Ala Pro Glu Gly Ala Thr Tyr Ala Ala Pro Arg 100 105 110 GGC TCC TCG CCC AAG CAG TCG CCC AGC CGC CTG GCC AAG TCC TAC AGC 382 Gly Ser Ser Pro Lys Gin Ser Pro Ser Arg Leu Ala Lys Ser Tyr Ser 115 120 125 ACC AGC TCG CCC ATC AAC ATC GTC GTG TCC TCG GCC GGC CTG TCC CCG 430 Thr Ser Ser Pro He Asn He Val Val Ser Ser Ala G Gllyy Leu Ser Pro 130 135 140 ATC CGC GTG ACC TCG CCC CCC ACC GTG CAG TCC ACC ATC TCC TCC TCG 478 He Arg Val Thr Ser Pro Pro Thr Val Gin Ser Thr He Ser Ser Ser 145 150 155 CCC ATC CAC CAG CTG AGC TCC ACC ATC GGC ACG TAC GCC ACC CTG TCG 526 Pro He His Gin Leu Ser Ser Thr He Gly Thr Tyr Ala Thr Leu Ser 160 165 170 175 CCC ACC AAG CGC CTG GTC CAC GCG TCC GAG CAG TAC AGC AAG CAC TCG 574 Pro Thr Lys Arg Leu Val His Ala Ser Glu Gin Tyr Ser Lys His Ser 180 185 190 CAG GAG CTG TAT GCC ACG GCC ACC CTC CAG AGG CCG GGC AGC CTG GCA 622 Gin Glu Leu Tyr Ala Thr Ala Thr Leu Gin Arg Pro Gly Ser Leu Ala 195 200 205 GCT GGT TCC CGA GCC TCA TAC AGC AGC CAG CAT GGG CAC CTG GGC CCA 670 Ala Gly Ser Arg Ala Ser Tyr Ser Ser Gin His Gly His Leu Gly Pro 210 215 220 GAG TTG CGG GCC CTG CAG TCC CCA GAA CAC CAC ATA GAT CCC ATC TAT 718 Glu Leu Arg Ala Leu Gin Ser Pro Glu His His He Asp Pro He Tyr 225 230 235 GAA GAC CGC GTC TAT CAG AAG CCC CCT ATG AGG AGT CTC AGC CAG AGC 766 Glu Asp Arg Val Tyr Gin Lys Pro Pro Met Arg Ser Leu Ser Gin Ser 240 245 250 255 CAG GGG GAC CCT CTG CCG CCA GCA CAC ACC GGC ACC TAC CGC ACG AGC 814 Gin Gly Asp Pro Leu Pro Pro Ala His Thr Gly Thr Tyr Arg Thr Ser 260 265 270 ACA GCC CCA TCT TCC CCT GGT GTC GAC TCC GTC CCC TTG CAG CGC ACA 862 Thr Ala Pro Ser Ser Pro Gly Val Asp Ser Val Pro Leu Gin Arg Thr 275 280 285 GGC AGC CAG CAC GGC CCA CAG AAT GCC GCC GCG GCC ACC TTC CAG AGG 910 Gly Ser Gin His Gly Pro Gin Asn Ala Ala Ala Ala Thr Phe Gin Arg 290 295 300 GCC AGC TAT GCC GCC GGC CCA GCC TCC AAT TAC GCG GAC CCC TAC CGA 958 Ala Ser Tyr Ala Ala Gly Pro Ala Ser Asn Tyr Ala Asp Pro Tyr Arg 305 310 315 CAG CTG CAG TAT TGT CCC TCT GTT GAG TCT CCA TAC AGC AAA TCC GGC 1006 Gin Leu Gin Tyr Cys Pro Ser Val Glu Ser Pro Tyr Ser Lys Ser Gly 320 325 330 335 CCT GCT CTC CCG CCT GAA GGC ACC TTG GCC AGG TCC CCG TCC ATT GAT 1054 Pro Ala Leu Pro Pro Glu Gly Thr Leu Ala Arg Ser Pro Ser He Asp 340 345 350 AGC ATT CAG AAA GAT CCC AGA GAA TTT GGA TGG AGA GAC CCG GAA CTG 1102 Ser He Gin Lys Asp Pro Arg Glu Phe Gly Trp Arg Asp Pro Glu Leu 355 360 365 CCG GAA GTG ATT CAG ATG TTG CAG CAC CAG TTT CCC TCG GTC CAG TCT 1150 Pro Glu Val He Gin Met Leu Gin His Gin Phe Pro Ser Val Gin Ser 370 375 380 AAC GCG GCA GCC TAC TTG CAA CAC CTC TGT TTT GGA GAC AAC AAA ATT 1198 Asn Ala Ala Ala Tyr Leu Gin His Leu Cys Phe Gly Asp Asn Lys He 385 390 395 AAA GCC GAG ATA AGG AGA CAA GGA GGC ATC CAG CTC CTG GTG GAC CTG 1246 Lys Ala Glu He Arg Arg Gin Gly Gly He Gin Leu Leu Val Asp Leu 400 405 410 415 TTG GAT CAT CGG ATG ACC GAA GTC CAC CGT AGT GCC TGT GGA GCT CTG 1294 Leu Asp His Arg Met Thr Glu Val His Arg Ser Ala Cys Gly Ala Leu 420 425 430 AGA AAC CTG GTG TAT GGG AAG GCC AAC GAT GAT AAC AAA ATT GCC CTG 1342 Arg Asn Leu Val Tyr Gly Lys Ala Asn Asp Asp Asn Lys He Ala Leu 435 440 445 AAA AAC TGT GGT GGC ATC CCA GCA CTG GTG AGG TTA CTC CGC AAG ACG 1390 Lys Asn Cys Gly Gly He Pro Ala Leu Val Arg Leu Leu Arg Lys Thr 450 455 460 ACT GAC CTG GAG ATC CGG GAG CTG GTC ACA GGA GTC CTT TGG AAC CTC 1438 Thr Asp Leu Glu He Arg Glu Leu Val Thr Gly Val Leu Trp Asn Leu 465 470 475 TCC TCA TGC GAT GCA CTC AAA ATG CCA ATC ATC CAG GAT GCC CTA GCA 1486 Ser Ser Cys Asp Ala Leu Lys Met Pro He He Gin Asp Ala Leu Ala 480 485 490 495 GTA CTG ACC AAC GCG GTG ATT ATC CCC CAC TCA GGC TGG GAA AAT TCG 1534 Val Leu Thr Asn Ala Val He He Pro His Ser Gly Trp Glu Asn Ser 500 505 510 CCT CTT CAG GAT GAT CGG AAA ATA CAG CTG CAT TCA TCA CAG GTG CTG 1582 Pro Leu Gin Asp Asp Arg Lys He Gin Leu His Ser Ser Gin Val Leu 515 520 525 CGT AAC GCC ACC GGG TGC CTA AGG AAT GTT AGT TCG GCC GGA GAG GAG 1630 Arg Asn Ala Thr Gly Cys Leu Arg Asn Val Ser Ser Ala Gly Glu Glu 530 535 540 GCC CGC AGA AGG ATG AGA GAG TGT GAT GGG CTT ACG GAT GCC TTG CTG 1678 Ala Arg Arg Arg Met Arg Glu Cys Asp Gly Leu Thr Asp Ala Leu Leu 545 550 555 TAC GTG ATC CAG TCT GCG CTG GGG AGC AGT GAG ATC GAT AGC AAG ACC 1726 Tyr Val He Gin Ser Ala Leu Gly Ser Ser Glu He Asp Ser Lys Thr 560 565 570 575 GTT GAA AAC TGT GTG TGC ATT TTA AGG AAC CTC TCG TAC CGG CTG GCG 1774 Val Glu Asn Cys Val Cys He Leu Arg Asn Leu Ser Tyr Arg Leu Ala 580 585 590 GCA GAA ACG TCT CAG GGA CAG CAC ATG GGC ACG GAC GAG CTG GAC GGG 1822 Ala Glu Thr Ser Gin Gly Gin His Met Gly Thr Asp Glu Leu Asp Gly 595 600 605 CTA CTC TGT GGC GAG GCC AAT GGC AAG GAT GCT GAG AGC TCT GGG TGC 1870 Leu Leu Cys Gly Glu Ala Asn Gly Lys Asp Ala Glu Ser Ser Gly Cys 610 615 620 TGG GGC AAG AAG AAG AAG AAA AAG AAA TCC CAA GAT CAG TGG GAT GGA 1918 Trp Gly Lys Lys Lys Lys Lys Lys Lys Ser Gin Asp Gin Trp Asp Gly 625 630 635 GTA GGA CCT CTT CCA GAC TGT GCT GAA CCA CCA AAA GGG ATC CAG ATG 1966 Val Gly Pro Leu Pro Asp Cys Ala Glu Pro Pro Lys Gly He Gin Met 640 645 650 655 CTG TGG CAC CCA TCA ATA GTC AAA CCC TAC CTC ACA CTG CTC TCT GAG 2014 Leu Trp His Pro ser He Val Lys Pro Tyr Leu Thr Leu Leu Ser Glu 660 665 670 TGC TCA AAT CCA GAC ACG CTG GAA GGG GCG GCA GGC GCC CTG CAG AAC 2062 Cys Ser Asn Pro Asp Thr Leu Glu Gly Ala Ala Gly Ala Leu Gin Asn 675 680 685 TTG GCT GCA GGG AGC TGG AAG TGG TCA GTA TAT ATC CGA GCC GCT GTC 2110 Leu Ala Ala Gly Ser Trp Lys Trp Ser Val Tyr He Arg Ala Ala Val 690 695 700 CGA AAA GAG AAA GGC CTG CCC ATC CTC GTG GAG CTG CTC CGA ATA GAC 2158 Arg Lys Glu Lys Gly Leu Pro He Leu Val Glu Leu Leu Arg He Asp 705 710 715 AAT GAC CGT GTG GTG TGC GCG GTG GCC ACT GCG CTG CGG AAC ATG GCC 2206 Asn Asp Arg Val Val Cys Ala Val Ala Thr Ala Leu Arg Asn Met Ala 720 725 730 735 TTG GAC GTC AGA AAT AAG GAG CTC ATC GGC AAA TAC GCC ATG CGA GAC 2254 Leu Asp Val Arg Asn Lys Glu Leu He Gly Lys Tyr Ala Met Arg Asp 740 745 750 CTA GTC CAC AGG CTT CCA GGA GGG AAC AAC AGC AAC AAC ACT GCA AGC 302 Leu Val His Arg Leu Pro Gly Gly Asn Asn Ser Asn Asn Thr Ala Ser 755 760 765 AAG GCC ATG TCG GAT GAC ACA GTG ACA GCT GTC TGC TGC ACA CTG CAC 2350 Lys Ala Met Ser Asp Asp Thr Val Thr Ala Val Cys Cys Thr Leu His 770 775 780 GAA GTG ATT ACC AAG AAC ATG GAG AAC GCC AAG GCC TTA CGG GAT GCC 2398 Glu Val He Thr Lys Asn Met Glu Asn Ala Lys Ala Leu Arg Asp Ala 785 790 795 GGT GGC ATC GAG AAG TTG GTC GGC ATC TCC AAA AGC AAA GGA GAT AAA 2446 Glv Gly He Glu Lys Leu Val Gly He Ser Lys Ser Lys Gly Asp Lys 800 805 810 815 CAC TCT CCA AAA GTG GTC AAG GCT GCA TCT CAG GTC CTC AAC AGC ATG 2494 His Ser Pro Lys Val Val Lys Ala Ala Ser Gin Val Leu Asn Ser Met 820 825 830 TGG CAG TAC CGA GAT CTG AGG AGT CTC TAC AAA AAG GAT GGA TGG TCA 2542 Trp Gin Tyr Arg Asp Leu Arg Ser Leu Tyr Lys Lys Asp Gly Trp Ser 835 840 845 CAA TAC CAC TTT GTA GCC TCG TCT TCA ACC ATC GAG AGG GAC CGG CAA 2590 Gin Tyr His Phe Val Ala Ser Ser Ser Thr He Glu Arg Asp Arg Gin 850 855 860 AGG CCC TAC TCC TCC TCC CGC ACG CCC TCC ATC TCC CCT GTG CGC GTG 2638 Arg Pro Tyr Ser Ser Ser Arg Thr Pro Ser He Ser Pro Val Arg Val 865 870 875 TCT CCC AAC AAC CGC TCA GCA AGT GCC CCA GCT TCA CCT CGG GAA ATG 2686 Ser Pro Asn Asn Arg Ser Ala Ser Ala Pro Ala Ser Pro Arg Glu Met 880 885 890 895 ATC AGC CTC AAA GAA AGG AAA ACA GAC TAC GAG TGC ACC GGC AGC AAC 2734 He Ser Leu Lys Glu Arg Lys Thr Asp Tyr Glu Cys Thr Gly Ser Asn 900 905 910 GCC ACC TAC CAC GGA GGT AAA GGC GAA CAC ACT TCC AGG AAA GAT GCC 2782 Ala Thr Tyr His Gly Gly Lys Gly Glu His Thr Ser Arg Lys Asp Ala 915 920 925 ATG ACA GCT CAA AAC ACT GGA ATT TCA ACT TTG TAT AGG AAT TCT TAT 2830 Met Thr Ala Gin Asn Thr Gly He Ser Thr Leu Tyr Arg Asn Ser Tyr 930 935 940 GGT GCG CCC GCT GAA GAC ATC AAA CAC AAC CAG GTT TCA GCA CAG CCA 2878 Gly Ala Pro Ala Glu Asp He Lys His Asn Gin Val Ser Ala Gin Pro 945 950 955 GTC CCA CAG GAG CCC AGC AGA AAA GAT TAC GAG ACC TAC CAG CCA TTT 2926 Val Pro Gin Glu Pro Ser Arg Lys Asp Tyr Glu Thr Tyr Gin Pro Phe 960 965 970 975 CAG AAT TCC ACA AGA AAT TAC GAT GAG TCC TTC TTC GAG GAC CAG GTC 2974 Gin Asn Ser Thr Arg Asn Tyr Asp Glu Ser Phe Phe Glu Asp Gin Val 980 985 990 CAC CAT CGC CCT CCC GCC AGC GAG TAC ACC ATG CAC CTG GGT CTC AAG 3022 His His Arg Pro Pro Ala Ser Glu Tyr Thr Met His Leu Gly Leu Lys 995 1000 1005 TCC ACC GGC AAC TAC GTT GAC TTC TAC TCA GCT GCC CGT CCC TAC AGT 3070 Ser Thr Gly Asn Tyr Val Asp PPhhee TTyyrr SSeerr AAllaa AAllaa AArrgg IPro Tyr Ser lOlC 1"0"1"5' 1020 GAA CTG AAC TAT GAA ACG AGC CAC TAC CCG GCC TCC CCC GAC TCC TGG 3118 Glu Leu Asn Tyr Glu Thr Ser His Tyr Pro Ala Ser Pro Asp Ser Trp 1025 1030 1035 GTG TGAGGAGCAG GGCACAGGCG CTCCGGGAAA CAGTGCATGT GCATGCATAC 3171 Val 1040 CACAAGACAT TTCTTTCTGT TTTGGTTTTT TTCTCCTGCA AATTTAGTTT GTTAAAGCCT 3231 GTTCCATAGG AAGGCTGTGA TAACCAGTAA GGGAAATATT AAGAGCTATT TTAGAAAGCT 3291 AAATGAATCG CAAGTTAACT TGGAAATCAG TAGAAAGCTA AAGTGATCCT AAATATGACA 3351 GTGGGCAGCA CCTTTCCTAG CGTGTTNTGT TAGGAGTAAC GAGAAGTGCT TTATACTGAA 3411 CGTGGGTTGN TTGGTAGGGT GGAGNCGAGG CATTCGGGCC GGTGGGGCGT AAGGGTTATC 3471 GTTAAGCACA AGACACAGAA TAGTTTACAC ACTGTGTGGG GGACGGCTTC TCACGCTTTG 3531 TTTACTCTCT TCATCCGTTG TGACTCTAGG CTTCAGGTTG CATTGGGGTT CCTCTGTACA 3591 GCAAGATGTT TCTTGCCTTT TGTTAATGCA TTGTTGTAAA GTATTTGATG TACATTACAG 3651 ATTAAAGAAG NAAAGCGCGT TGTGTATATT ACACCAATNC CGCCGTGTTT CCTCATCTAT 3711 GGTTCTAAAT ATTGCTTCAA TTTCNAACTT TTGAAAGATG TATGGATTTC CAGTTTTTCT 3771 TTACTTTCTC CCAGTATGTT TTAACCNMMN AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 3831 AAAACTCGAG 3841 (2) INFORMATION FOR SEQ ID NO:4 : (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1040 amino acids (B) TYPE: ammo acid (D) TOPOLOGY: linear (ll) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4 : Ser Gin Leu Pro Ala Arg Gly Thr Gin Ala Arg Xaa Thr Gly Gin Ser 1 5 10 15 Phe Ser Gin Gly Thr Thr Ser Arg Ala Gly His Leu Ala Gly Pro Glu 20 25 30 Pro Ala Pro Pro Pro Pro Pro Xaa Pro Arg Glu Pro Phe Ala Pro Ser 35 40 45 Leu Gly Ser Ala Phe His Leu Pro Asp Ala Pro Pro Ala Ala Ala Ala 50 55 60 Ala Ala Leu Tyr Tyr Ser Xaa Ser Thr Leu Pro Ala Pro Pro Arg Gly 65 70 75 80 Gly Ser Pro Leu Ala Ala Pro Gin Gly Gly Ser Pro Thr Lys Leu Gin 85 90 95 Arg Gly Gly Ser Ala Pro Glu Gly Ala Thr Tyr Ala Ala Pro Arg Gly 100 105 110 Ser Ser Pro Lys Gin Ser Pro Ser Arg Leu Ala Lys Ser Tyr Ser Thr 115 120 125 Ser Ser Pro lie Asn He Val Val Ser Ser Ala Gly Leu Ser Pro He 130 135 140 Arg Val Thr Ser Pro Pro Thr Val Gin Ser Thr He Ser Ser Ser Pro 145 150 155 160 He His Gin Leu Ser Ser Thr He Gly Thr Tyr Ala Thr Leu Ser Pro 165 170 175 Thr Lys Arg Leu Val His Ala Ser Glu Gin Tyr Ser Lys His Ser Gin 180 185 190 Glu Leu Tyr Ala Thr Ala Thr Leu Gin Arg Pro Gly Ser Leu Ala Ala 195 200 205 Gly Ser Arg Ala Ser Tyr Ser Ser Gin His Gly His Leu Gly Pro Glu 210 215 220 Leu Arg Ala Leu Gin Ser Pro Glu His His He Asp Pro He Tyr Glu 225 230 235 240 Asp Arg Val Tyr Gin Lys Pro Pro Met Arg Ser Leu Ser Gin Ser Gin 245 250 255 Gly Asp Pro Leu Pro Pro Ala His Thr Gly Thr Tyr Arg Thr Ser Thr 260 265 270 Ala Pro Ser Ser Pro Gly Val Asp Ser Val Pro Leu Gin Arg Thr Gly 275 280 285 Ser Gin His Gly Pro Gin Asn Ala Ala Ala Ala Thr Phe Gin Arg Ala 290 295 300 Ser Tyr Ala Ala Gly Pro Ala Ser Asn Tyr Ala Asp Pro Tyr Arg Gin 305 310 315 320 Leu Gin Tyr Cys Pro Ser Val Glu Ser Pro Tyr Ser Lys Ser Gly Pro 325 330 335 Ala Leu Pro Pro Glu Gly Thr Leu Ala Arg Ser Pro Ser He Asp Ser 340 345 350 He Gin Lys Asp Pro Arg Glu Phe Gly Trp Arg Asp Pro Glu Leu Pro 355 360 365 Glu Val He Gin Met Leu Gin His Gin Phe Pro Ser Val Gin Ser Asn 370 375 380 Ala Ala Ala Tyr Leu Gin His Leu Cys Phe Gly Asp Asn Lys He Lys 385 390 395 400 Ala Glu He Arg Arg Gin Gly Gly He Gin Leu Leu Val Asp Leu Leu 405 410 415 Asp His Arg Met Thr Glu Val His Arg Ser Ala Cys Gly Ala Leu Arg 420 425 430 Asn Leu Val Tyr Gly Lys Ala Asn Asp Asp Asn Lys He Ala Leu Lys 435 440 445 Asn Cys Gly Gly He Pro Ala Leu Val Arg Leu Leu Arg Lys Thr Thr 450 455 460 Asp Leu Glu He Arg Glu Leu Val Thr Gly Val Leu Trp Asn Leu Ser 465 470 475 480 Ser Cys Asp Ala Leu Lys Met Pro He He Gin Asp Ala Leu Ala Val 485 490 495 Leu Thr Asn Ala Val He He Pro His Ser Gly Trp Glu Asn Ser Pro 500 505 510 Leu Gin Asp Asp Arg Lys He Gin Leu His Ser Ser Gin Val Leu Arg 515 520 525 Asn Ala Thr Gly Cys Leu Arg Asn Val Ser Ser Ala Gly Glu Glu Ala 530 535 540 Arg Arg Arg Met Arg Glu Cys Asp Gly Leu Thr Asp Ala Leu Leu Tyr 545 550 555 560 Val He Gin Ser Ala Leu Gly Ser Ser Glu He Asp Ser Lys Thr Val 565 570 575 Glu Asn Cys Val Cys He Leu Arg Asn Leu Ser Tyr Arg Leu Ala Ala 580 585 590 Glu Thr Ser Gin Gly Gin His Met Gly Thr Asp Glu Leu Asp Gly Leu 595 600 605 Leu Cys Gly Glu Ala Asn Gly Lys Asp Ala Glu Ser Ser Gly Cys Trp 610 615 620 Gly Lys Lys Lys Lys Lys Lys Lys Ser Gin Asp Gin Trp Asp Gly Val 625 630 635 640 Gly Pro Leu Pro Asp Cys Ala Glu Pro Pro Lys Gly He Gin Met Leu 645 650 655 Trp His Pro Ser He Val Lys Pro Tyr Leu Thr Leu Leu Ser Glu Cys 660 665 670 Ser Asn Pro Asp Thr Leu Glu Gly Ala Ala Gly Ala Leu Gin Asn Leu 675 680 685 Ala Ala Gly Ser Trp Lys Trp Ser Val Tyr He Arg Ala Ala Val Arg 690 695 700 Lys Glu Lys Gly Leu Pro He Leu val Glu Leu Leu Arg He Asp Asn 705 710 715 720 Asp Arg al Val Cys Ala Val Ala Thr Ala Leu Arg Asn Met Ala Leu 725 730 735 Asp Val Arg Asn Lys Glu Leu He Gly Lys Tyr Ala Met Arg Asp Leu 740 745 750 Val His Arg Leu Pro Gly Gly Asn Asn Ser Asn Asn Thr Ala Ser Lys 755 760 765 Ala Met Ser Asp Asp Thr Val Thr Ala Val Cys Cys Thr Leu His Glu 770 775 780 Val He Thr Lys Asn Met Glu Asn Ala Lys Ala Leu Arg Asp Ala Gly 785 790 795 800 Gly He Glu Lys Leu Val Gly He Ser Lys Ser Lys Gly Asp Lys His 805 810 815 Ser Pro Lys Val Val Lys Ala Ala Ser Gin Val Leu Asn Ser Met Trp 820 825 830 Gin Tyr Arc Asp Leu Arg Ser Leu Tyr Lys Lys Asp Gly Trp Ser Gin 83f 840 845 Tyr His Phe Val Ala Ser Ser Ser Thr He Glu Arg Asp Arg Gin Arg 850 955 860 Pro Tyr Ser Ser Ser Arg Thr Pro Ser He Ser Pro Val Arg Val Ser 865 870 875 880 Pro Asn Asn Arg Ser Ala Ser Ala Pro Ala Ser Pro Arg Glu Met He 885 890 895 Ser Leu Lys Glu Arg Lys Thr Asp Tyr Glu Cys Thr Gly Ser Asn Ala 900 905 910 Thr Tyr His Gly Gly Lys Gly Glu His Thr Ser Arg Lys Asp Ala Met 915 920 925 Thr Ala Gin Asn Thr Gly He Ser Thr Leu Tyr Arg Asn Ser Tyr Glv 930 935 940 Ala Pro Ala Glu Asp He Lys His Asn Gin Val Ser Ala Gin Pro Val 945 950 955 960 Pro Gin Glu Pro Ser Arg Lys Asp Tyr Glu Thr Tyr Gin Pro Phe Gin 965 970 975 Asn Ser Thr Arg Asn Tyr Asp Glu Ser Phe Phe Glu Asp Gin Val His 980 985 990 His Arg Pro Pro Ala Ser Glu Tyr Thr Met His Leu Gly Leu Lys Ser 995 1000 1005 Thr Gly Asn Tyr Val Asp Phe Tyr Ser Ala Ala Arg Pro Tyr Ser Glu 1010 1015 1020 Leu Asn Tyr Glu Thr Ser His Tyr Pro Ala Ser Pro Asp Ser Trp Val 1025 1030 1035 1040 (2) INFORMATION FOR SEQ ID N0:5: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3907 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 142..3777 (D) OTHER INFORMATION: /note= "p0071" (XI) SEQUENCE DESCRIPTION: SEQ ID NO : 5 : CTACTGTTGT TTTTGAGGGG CGGGCAGCCG CGCCGCCGCG GCACTTTTTT AATTTTTTCG 60 GGTGCCGCAG CAGCGACCCC TCGGCGCCGA TGTCCCTGAT CCCTGGAGCG ACGACGGCCG 120 CTGCCTAAGC TGGGAAGAGG A ATG CCA GCT CCT GAG CAG GCC TCA TTG GTG 171 Met Pro Ala Pro Glu Gin Ala Ser Leu Val 1 5 10 GAG GAG GGG CAA CCA CAG ACC CGC CAG GAA GCT GCC TCC ACT GGC CCA 219 Glu Glu Gly Gin Pro Gin Thr Arg Gin Glu Ala Ala Ser Thr Gly Pro 15 20 25 GGC ATG GAA CCC GAG ACC ACA GCC ACC ACT ATT CTA GCA TCC GTG AAG 267 Gly Met Glu Pro Glu Thr Thr Ala Thr Thr He Leu Ala Ser Val Lys 30 35 40 GAG CAG GAG CTT CAG TTT CAG CGA CTC ACC CGA GAA CTG GAA GTG GAA 315 Glu Gin Glu Leu Gin Phe Gin Arg Leu Thr Arg Glu Leu Glu Val Glu 45 50 55 AGG CAG ATT GTT GCC AGT CAG CTA GAA AGA TGT AGG CTT GGA GCA GAA 363 Arg Gin He Val Ala Ser Gin Leu Glu Arg Cys Arg Leu Gly Ala Glu 60 65 70 TCA CCA AGC ATC GCC AGC ACC AGC TCA ACT GAG AAG TCA TTT CCT TGG 411 Ser Pro Ser He Ala Ser Thr Ser Ser Thr Glu Lys Ser Phe Pro Trp 75 80 85 90 AGA TCA ACA GAC GTG CCA AAT ACT GGT GTA AGC AAA CCT AGA GTT TCT 459 Arg Ser Thr Asp Val Pro Asn Thr Gly Val Ser Lys Pro Arg Val Ser 95 100 105 GAC GCT GTC CAG CCC AAC AAC TAT CTC ATC AGG ACA GAG CCA GAA CAA 507 Asp Ala Val Gin Pro Asn Asn Tyr Leu He Arg Thr Glu Pro Glu Gin 110 115 120 GGA ACC CTC TAT TCA CCA GAA CAG ACA TCT CTC CAT GAA AGT GAG GGA 555 Gly Thr Leu Tyr Ser Pro Glu Gin Thr Ser Leu His Glu Ser Glu Gly 125 130 135 TCA TTG GGT AAC TCA AGA AGT TCA ACA CAA ATG AAT TCT TAT TCC GAC 603 Ser Leu Gly Asn Ser Arg Ser Ser Thr Gin Met Asn Ser Tyr Ser Asp 140 145 150 AGT GGA TAC CAG GAA GCA GGG AGT TTC CAC AAC AGC CAG AAC GTG AGC 651 Ser Gly Tyr Gin Glu Ala Gly Ser Phe His Asn Ser Gin Asn Val Ser 155 160 165 170 AAG GCA GAC AAC AGA CAG CAG CAT TCA TTC ATA GGA TCA ACT AAC AAC 699 Lys Ala Asp Asn Arg Gin Gin His Ser Phe He Gly Ser Thr Asn Asn 175 180 185 CAT GTG GTG AGG AAT TCA AGA GCT GAA GGA CAA ACA CTG GTT CAG CCA 747 His Val Val Arg A"sn Ser Arg Ala Glu Gly Gin Thr Leu Val Gin Pro 1 90 1 95 200 TCA GTA GCC AAT CGG GCC ATG AGA AGA GTT AGT TCA GTT CCA TCT AGA 795 Ser Val Ala Asn Arg Ala Met Arg Arg Val Ser Ser Val Pro Ser Arg 205 210 215 GCA CAG TCT CCT TCT TAT GTT ATC AGC ACA GGC GTG TCT CCT TCA AGG 843 Ala Gin Ser Pro Ser Tyr Val He Ser Thr Gly Val Ser Pro Ser Arg 220 225 230 GGG TCT CTG AGA ACT TCT CTG GGT AGT GGA TTT GGC TCT CCG TCA GTG 891 Gly Ser Leu Arg Thr Ser Leu Gly Ser Gly Phe Gly Ser Pro Ser Val 235 240 245 250 ACC GAC CCC CGA CCT CTG AAC CCC AGT GCA TAT TCC TCC ACC ACA TTA 939 Thr Asp Pro Arg Pro Leu Asn Pro Ser Ala Tyr Ser Ser Thr Thr Leu 255 260 265 CCT GCT GCA CGG GCA GCC TCT CCG TAC TCA CAG AGA CCC GCC TCC CCA 987 Pro Ala Ala Arg Ala Ala Ser Pro Tyr Ser Gin Arg Pro Ala Ser Pro 270 275 280 ACA GCT ATA CGG CGG ATT GGG TCA GTC ACC TCC CGG CAG ACC TCC AAT 1035 Thr Ala He Arg Arg He Gly Ser Val Thr Ser Arg Gin Thr Ser Asn 285 290 295 CCC AAC GGA CCA ACC CCT CAA TAC CAA ACC ACC GCC AGA GTG GGG TCC 1083 Pro Asn Gly Pro Thr Pro Gin Tyr Gin Thr Thr Ala Arg Val Gly Ser 300 305 310 CCA CTG ACC CTG ACG GAT GCA CAG ACT CGA GTA GCT TCC CCA TCC CAA 1131 Pro Leu Thr Leu Thr Asp Ala Gin Thr Arg Val Ala Ser Pro Ser Gin 315 320 325 330 GGC CAG GTG GGG TCG TCG TCC CCC AAA CGC TCA GGG ATG ACC GCC GTA 1179 Gly Gin Val Gly Ser Ser Ser Pro Lys Arg Ser Gly Met Thr Ala Val 335 340 345 CCA CAG CAT CTG GGA CCT TCA CTG CAA AGG ACT GTT CAT GAC ATG GAG 1227 Pro Gin His Leu Gly Pro Ser Leu Gin Arg Thr Val His Asp Met Glu 350 355 360 CAA TTC GGA CAG CAG CAG TAT GAC ATT TAT GAG AGG ATG GTT CCA CCC 1275 Gin Phe Gly Gin Gin Gin Tyr Asp He Tyr Glu Arg Met Val Pro Pro 365 370 375 AGG CCA GAC AGC CTG ACA GGC TTA CGG AGT TCC TAT GCT AGT CAG CAT 1323 Arg Pro Asp Ser Leu Thr Gly Leu Arg Ser Ser Tyr Ala Ser Gin His 380 385 390 AGT CAG CTT GGG CAA GAC CTT CGT TCT GCC GTG TCT CCC GAC TTG CAC 1371 Ser Gin Leu Gly Gin Asp Leu Arg Ser Ala val Ser Pro Asp Leu His 395 400 405 410 ATT ACT CCT ATA TAT GAG GGG AGG ACC TAT TAC AGC CCA GTG TAC CGC 1419 He Thr Pro He Tyr Glu Gly Arg Thr Tyr Tyr Ser Pro Val Tyr Arg 415 420 425 AGC CCA AAC CAT GGA ACT GTG GAG CTC CAA GGA TCG CAG ACG GCG TTG 1467 Ser Pro Asn His Gly Thr Val Glu Leu Gin Gly Ser Gin Thr Ala Leu 430 435 440 TAT CGC ACA GGT GTA TCA GGT ATT GGA AAT CTA CAA AGG ACA TCC AGC 1515 Tyr Arg Thr Gly Val Ser Gly He Gly Asn Leu Gin Arg Thr Ser Ser 445 450 455 CAA CGA AGT ACC CTT ACA TAC CAA AGA AAT AAT TAT GCT CTG AAC ACA 1563 Gin Arg Ser Thr Leu Thr Tyr Gin Arg Asn Asn Tyr Ala Leu Asn Thr 460 465 470 ACA GCT ACC TAC GCG GAG CCC TAC AGG CCT ATA CAA TAC CGA GTG CAA 1611 Thr Ala Thr Tyr Ala Glu Pro Tyr Arg Pro He Gin Tyr Arg Val Gin 475 480 485 490 GAG TGC AAT TAT AAC AGG CTT CAG CAT GCA GTG CCG GCT GAT GAT GGC 1659 Glu Cys Asn Tyr Asn Arg Leu Gin His Ala Val Pro Ala Asp Asp Gly 495 500 505 ACC ACA AGA TCC CCA TCA ATA GAC AGC ATT CAG AAG GAC CCC AGG GAG 1707 Thr Thr Arg Ser Pro Ser He Asp Ser He Gin Lys Asp Pro Arg Glu 510 515 520 TTT GCC TGG CGT GAT CCT GAG TTG CCT GAG GTC ATT CAC ATG CTT GAG 1755 Phe Ala Trp Arg Asp Pro Glu Leu Pro Glu val He His Met Leu Glu 525 530 535 CAC CAG TTC CCA TCT GTT CAG GCA AAT GCA GCG GCC TAC CTG CAG CAC 1803 His Gin Phe Pro Ser Val Gin Ala Asn Ala Ala Ala Tyr Leu Gin His 540 545 550 CTG TGC TTT GGT GAC AAC AAA GTG AAG ATG GAG GTG TGT AGG TTA GGG 1851 Leu Cys Phe Gly Asp Asn Lys Val Lys Met Glu Val Cys Arg Leu Gly 555 560 565 570 GGA ATC AAG CAT CTG GTT GAC CTT CTG GAC CAC AGA GTT TTG GAA GTT 1899 Gly He Lys His Leu Val Asp Leu Leu Asp His Arg Val Leu Glu Val 575 5B0 585 CAG AAG AAT GCT TGT GGT GCC CTT CGA AAC CTC GTT TTT GGC AAG TCT 1947 Gin Lys Asn Ala Cys Gly Ala Leu Arg Asn Leu Val Phe Gly Lys Ser 590 595 600 ACA GAT GAA AAT AAA ATA GCA ATG AAG AAT GTT GGT GGG ATA CCT GCC 1995 Thr Asp Glu Asn Lys He Ala Met Lys Asn Val Gly Gly He Pro Ala 605 610 615 TTG TTG CGA CTG TTG AGA AAA TCT ATT GAT GCA GAA GTA AGG GAG CTT 2043 Leu Leu Arg Leu Leu Arg Lys Ser He Asp Ala Glu Val Arg Glu Leu 620 625 630 GTT ACA GGA GTT CTT TGG AAT TTA TCC TCA TGT GAT GCT GTA AAA ATG 2091 Val Thr Gly Val Leu Trp Asn Leu Ser Ser Cys Asp Ala Val Lys Met 635 640 645 650 ACA ATC ATT CGA GAT GCT CTC TCA ACC TTA ACA AAC ACT GTG ATT GTT 2139 Thr He He Arg Asp Ala Leu Ser Thr Leu Thr Asn Thr Val He Val 655 660 665 CCA CAT TCT GGA TGG AAT AAC TCT TCT TTT GAT GAT GAT CAT AAA ATT 2187 Pro His Ser Gly Trp Asn Asn Ser Ser Phe Asp Asp Asp His Lys He 670 675 680 AAA TTT CAG ACT TCA CTA GTT CTG CGT AAC ACG ACA GGT TGC CTA AGG 2235 Lys Phe Gin Thr Ser Leu Val Leu Arg Asn Thr Thr Gly Cys Leu Arg 685 690 695 AAC CTC ACG TCC GCG GGG GAA GAA GCT CGG AAG CAA ATG CGG TCC TGC 2283 Asn Leu Thr Ser Ala Gly Glu Glu Ala Arg Lys Gin Met Arg Ser Cys 700 705 710 GAG GGG CTG GTA GAC TCA CTG TTG TAT GTG ATC CAC ACG TGT GTG AAC 2331 Glu Gly Leu Val Asp Ser Leu Leu Tyr Val He His Thr Cys Val Asn 715 720 725 730 ACA TCC GAT TAC GAC AGC AAG ACG GTG GAG AAC TGC GTG TGC ACC CTG 2379 Thr Ser Asp Tyr Asp Ser Lys Thr Val Glu Asn Cys Val Cys Thr Leu 735 740 745 AGG AAC CTG TCC TAT CGG CTG GAG CTG GAG GTG CCC CAG GCC CGG TTA 2427 Arg Asn Leu Ser Tyr Arg Leu Glu Leu Glu Val Pro Gin Ala Arg Leu 750 755 760 CTG GGA CTG AAC GAA TTG GAT GAC TTA CTA GGA AAA GAG TCT CCC AGC 2475 Leu Gly Leu Asn Glu Leu Asp Asp Leu Leu Gly Lys Glu Ser Pro Ser 765 770 775 AAA GAC TCT GAG CCA AGT TGC TGG GGG AAG AAG AAG AAA AAG AAA AAG 2523 Lys Asp Ser Glu Pro Ser Cys Trp Gly Lys Lys Lys Lys Lys Lys Lys 780 785 790 AGG ACT CCG CAA GAA GAT CAA TGG GAT GGA GTT GGT CCT ATC CCA GGA 2571 Arg Thr Pro Gin Glu Asp Gin Trp Asp Gly Val Gly Pro He Pro Gly 795 800 805 810 CTG TCG AAG TCC CCC AAA GGG GTT GAG ATG CTG TGG CAC CCA TCG GTG 2619 Leu Ser Lys Ser Pro Lys Gly Val Glu Met Leu Trp His Pro Ser Val 815 820 825 GTA AAA CCA TAT CTG ACT CTT CTA GCA GAA AGT TCC AAC CCA GCC ACC 2667 Val Lys Pro Tyr Leu Thr Leu Leu Ala Glu Ser Ser Asn Pro Ala Thr 830 835 840 TTG GAA GGC TCT GCA GGG TCT CTC CAG AAC CTC TCT GCT AGC AAC TGG 2715 Leu Glu Gly Ser Ala Gly ser Leu Gin Asn Leu Ser Ala Ser Asn Trp 845 850 855 AAG TTT GCA GCA TAT ATC CGG GGC GGC CGT CCG AAA AGA AAA GGG CTC 2763 Lys Phe Ala Ala Tyr He Arg Gly Gly Arg Pro Lys Arg Lys Gly Leu 860 865 870 CCC ATC CTT GTG GAG CTT CTG AGA ATG GAT AAC GAT AGA GTT GTT TCT 2811 Pro He Leu Val Glu Leu Leu Arg Met Asp Asn Asp Arg Val Val Ser 875 880 885 890 TCC GGT GCA ACA GCC TTG AGG AAT ATG GCA CTA GAT GTT CGC AAC AAG 2859 Ser Gly Ala Thr Ala Leu Arg Asn Met Ala Leu Asp Val Arg Asn Lys 895 900 905 GAG CTC ATA GGC AAA TAC GCC ATG CGA GAC CTG GTC AAC CGG CTC CCC 2907 Glu Leu He Gly Lys Tyr Ala Met Arg Asp Leu Val Asn Arg Leu Pro 910 915 920 GGC GGC AAT GGC CCC AGT GTC TTG TCT GAT GAG ACC ATG GCA GCC ATC 2955 Gly Gly Asn Gly Pro Ser Val Leu Ser Asp Glu Thr Met Ala Ala He 925 930 935 TGC TGT GCT CTG CAC GAG GTC ACC AGC AAA AAC ATG GAG AAC GCA AAA 3003 Cys Cys Ala Leu His Glu Val Thr Ser Lys Asn Met Glu Asn Ala Lys 940 945 950 GCC CTG GCC GAC TCA GGA GGC ATA GAG AAG CTG GTG AAC ATA ACC AAA 3051 Ala Leu Ala Asp Ser Gly Gly He Glu Lys Leu Val Asn He Thr Lys 955 960 965 970 GGC AGG GGC GAC AGA TCA TCT CTG AAA GTG GTG AAG GCA GCA GCC CAG 3099 Gly Arg Gly Asp Arg Ser Ser Leu Lys Val Val Lys Ala Ala Ala Gin 975 980 985 GTC TTG AAT ACA TTA TGG CAA TAT CGG GAC CTC CGG AGC ATT TAT AAA 3147 Val Leu Asn Thr Leu Trp Gin Tyr Arg Asp Leu Arg Ser lie Tyr Lys 990 995 1000 AAG GAT GGG TGG AAT CAG AAC CAT TTT ATT ACA CCT GTG TCG ACA TTG 3195 Lys Asp Gly Trp Asn Gin Asn His Phe He Thr Pro Val Ser Thr Leu 1005 1010 1015 GAG CGA GAC CGA TTC AAA TCA CAT CCT TCC TTG TCT ACC ACC AAC CAA 3243 Glu Arg Asp Arg Phe Lys Ser His Pro Ser Leu Ser Thr Thr Asn Gin 1020 1025 1030 CAG ATG TCA CCC ATC ATT CAG TCA GTC GGC AGC ACC TCT TCC TCA CCA 3291 Gin Met Ser Pro He He Gin Ser Val Gly Ser Thr Ser Ser Ser Pro 1035 1040 1045 1050 GCA CTG TTA GGA ATC AGA GAC CCT CGC TCT GAA TAC GAT AGG ACC CAG 3339 Ala Leu Leu Gly He Arg Asp Pro Arg Ser Glu Tyr Asp Arg Thr Gin 1055 1060 1065 CCA CCT ATG CAG TAT TAC AAT AGC CAA GGG GAT GCC ACA CAT AAA GGC 3387 Pro Pro Met Gin Tyr Tyr Asn Ser Gin Gly Asp Ala Thr His Lys Gly 1070 1075 1080 CTG TAC CCT GGC TCC AGC AAA CCT TCA CCA ATT TAC ATC AGT TCC TAT 3435 Leu Tyr Pro Gly Ser Ser Lys Pro Ser Pro He Tyr He Ser Ser Tyr 1085 1090 1095 TCC TCA CCA GCA AGA GAA CAA AAT AGA CGG CTA CAG CAT CAA CAG CTG 3483 Ser Ser Pro Ala Arg Glu Gin Asn Arg Arg Leu Gin His Gin Gin Leu 1100 1105 1110 TAT TAT AGT CAA GAT GAC TCC AAC AGA AAG AAC TTT GAT GCA TAC AGA 3531 Tyr Tyr Ser Gin Asp Asp Ser Asn Arg Lys Asn Phe Asp Ala Tyr Arg 1115 1120 1125 1130 TTG TAT TTG CAG TCT CCT CAT AGC TAT GAA GAT CCT TAT TTT GAT GAC 3579 Leu Tyr Leu Gin Ser Pro His Ser Tyr Glu Asp Pro Tyr Phe Asp Asp 1135 1140 1145 CGA GTT CAC TTT CCA GCT TCT ACT GAT TAC TCA ACA CAG TAT GGA CTG 3627 Arg Val His Phe Pro Ala Ser Thr Asp Tyr Ser Thr Gin Tyr Gly Leu 1150 1155 1160 AAA TCG ACC ACA AAT TAT GTA GAC TTT TAT TCC ACT AAA CGA CCT TCT 3675 Lys Ser Thr Thr Asn Tyr Val Asp Phe Tyr Ser Thr Lys Arg Pro Ser 1165 1170 1175 TAT AGA GCA GAA CAG TAC CCA GGG TCC CCA GAC TCA TGG GTG TAC GAT 3723 Tyr Arg Ala Glu Gin Tyr Pro Gly Ser Pro Asp Ser Trp Val Tyr Asp 1180 1185 1190 CAA GAT GCC CAA CAG AGG AAC TCT TTC TTT CTA ACC TTG TTC AGA TTG 3771 Gin Asp Ala Gin Gin Arg Asn Ser Phe Phe Leu Thr Leu Phe Arg Leu 1195 1200 1205 1210 AGG TGA AAAGTCCATC TTGCTGATTT CATGATTGAA ATGTGAAAGT GAAGTGGAAG 3827 Arg * GAATGAATGA AGTGTGTTTT TTTTTCCTTT TTGAGGAATT ATCAGGGGAA TTCGATATCA 3887 AGCTTATCGA TACCGTCGAC 3907 (2) INFORMATION FOR SEQ ID NO:6: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1212 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Pro Ala Pro Glu Gin Ala Ser Leu Val Glu Glu Gly Gin Pro Gin 1 5 10 15 Thr Arg Gin Glu Ala Ala Ser Thr Gly Pro Gly Met Glu Pro Glu Thr 20 25 30 Thr Ala Thr Thr He Leu Ala Ser Val Lys Glu Gin Glu Leu Gin Phe 35 40 45 Gin Arg Leu Thr Arg Glu Leu Glu Val Glu Arg Gin He Val Ala Ser 50 55 60 Gln Leu Glu Arg Cys Arg Leu Gly Ala Glu Ser Pro Ser He Ala Ser 65 70 75 80 Thr Ser Ser Thr Glu Lys Ser Phe Pro Trp Arg Ser Thr Asp Val Pro 85 90 95 Asn Thr Gly Val Ser Lys Pro Arg Val Ser Asp Ala Val Gin Pro Asn 100 105 110 Asn Tyr Leu He Arg Thr Glu Pro Glu Gin Gly Thr Leu Tyr Ser Pro 115 120 125 Glu Gin Thr Ser Leu His Glu Ser Glu Gly Ser Leu Gly Asn Ser Arg 130 135 140 Ser Ser Thr Gin Met Asn Ser Tyr Ser Asp Ser Gly Tyr Gin Glu Ala 145 150 155 160 Gly Ser Phe His Asn Ser Gin Asn Val Ser Lys Ala Asp Asn Arg Gin 165 170 175 Gin His Ser Phe He Gly Ser Thr Asn Asn His Val Val Arg Asn Ser 180 185 190 Arg Ala Glu Gly Gin Thr Leu Val Gin Pro Ser Val Ala Asn Arg Ala 195 200 205 Met Arg Arg Val Ser Ser Val Pro Ser Arg Ala Gin Ser Pro Ser Tyr 210 215 220 Val He Ser Thr Gly Val Ser Pro Ser Arg Gly Ser Leu Arg Thr Ser 225 230 235 240 Leu Gly Ser Gly Phe Gly Ser Pro Ser Val Thr Asp Pro Arg Pro Leu 245 250 255 Asn Pro Ser Ala Tyr Ser Ser Thr Thr Leu Pro Ala Ala Arg Ala Ala 260 265 270 Ser Pro Tyr Ser Gin Arg Pro Ala Ser Pro Thr Ala He Arg Arg He 275 280 285 Gly Ser val Thr Ser Arg Gin Thr Ser Asn Pro Asn Gly Pro Thr Pro 290 295 300 Gin Tyr Gin Thr Thr Ala Arg Val Gly Ser Pro Leu Thr Leu Thr Asp 305 310 315 320 Ala Gin Thr Arg Val Ala Ser Pro Ser Gin Gly Gin Val Gly Ser Ser 325 330 335 Ser Pro Lys Arg Ser Gly Met Thr Ala Val Pro Gin His Leu Gly Pro 340 345 350 Ser Leu Gin Arg Thr Val His Asp Met Glu Gin Phe Gly Gin Gin Gin 355 360 365 Tyr Asp He Tyr Glu Arg Met Val Pro Pro Arg Pro Asp Ser Leu Thr 370 375 380 Gly Leu Arg Ser Ser Tyr Ala Ser Gin His Ser Gin Leu Gly Gin Asp 385 390 395 400 Leu Arg Ser Ala Val Ser Pro Asp Leu His He Thr Pro He Tyr Glu 405 410 415 Gly Arg Thr Tyr Tyr Ser Pro Val Tyr Arg Ser Pro Asn His Gly Thr 420 425 430 Val Glu Leu Gin Gly Ser Gin Thr Ala Leu Tyr Arg Thr Gly Val Ser 435 440 445 Gly He Gly Asn Leu Gin Arg Thr Ser Ser Gin Arg Ser Thr Leu Thr 450 455 460 Tyr Gin Arg Asn Asn Tyr Ala Leu Asn Thr Thr Ala Thr Tyr Ala Glu 465 470 475 480 Pro Tyr Arg Pro He Gin Tyr Arg Val Gin Glu Cys Asn Tyr Asn Arg 485 490 495 Leu Gin His Ala Val Pro Ala Asp Asp Gly Thr Thr Arg Ser Pro Ser 500 505 510 He Asp Ser He Gin Lys Asp Pro Arg Glu Phe Ala Trp Arg Asp Pro 515 520 525 Glu Leu Pro Glu Val He His Met Leu Glu His Gin Phe Pro Ser Val 530 535 540 Gin Ala Asn Ala Ala Ala Tyr Leu Gin His Leu Cys Phe Gly Asp Asn 545 550 555 560 Lys Val Lys Met Glu Val Cys Arg Leu Gly Gly He Lys His Leu Val 5 65 57 0 57 5 A s p L e u L e u As p H i s A r g Va l L e u G l u Va l G i n L y s A s n Al a C y s G l y 58 0 58 5 5 90 Ala Leu Arg Asn Leu Val Phe Gly Lys Ser Thr Asp Glu Asn Lys He 595 600 605 Ala Met Lys Asn Val Gly Gly He Pro Ala Leu Leu Arg Leu Leu Arg 610 615 620 Lys Ser He Asp Ala Glu Val Arg Glu Leu Val Thr Gly Val Leu Trp 625 630 635 640 Asn Leu Ser Ser Cys Asp Ala Val Lys Met Thr He He Arg Asp Ala 645 650 655 Leu Ser Thr Leu Thr Asn Thr Val He Val Pro His Ser Gly Trp Asn 660 665 670 Asn Ser Ser Phe Asp Asp Asp His Lys He Lys Phe Gin Thr Ser Leu 675 680 685 Val Leu Arg Asn Thr Thr Gly Cys Leu Arg Asn Leu Thr Ser Ala Gly 690 695 700 Glu Glu Ala Arg Lys Gin Met Arg Ser Cys Glu Gly Leu Val Asp Ser 705 710 715 720 Leu Leu Tyr Val He His Thr Cys Val Asn Thr Ser Asp Tyr Asp Ser 725 730 735 Lys Thr Val Glu Asn Cys Val Cys Thr Leu Arg Asn Leu Ser Tyr Arg 740 745 750 Leu Glu Leu Glu Val Pro Gin Ala Arg Leu Leu Gly Leu Asn Glu Leu 755 760 765 Asp Asp Leu Leu Gly Lys Glu Ser Pro Ser Lys Asp ser Glu Pro Ser 770 775 780 Cys Trp Gly Lys Lys Lys Lys Lys Lys Lys Arg Thr Pro Gin Glu Asi 785 790 795 80( Gin Trp Asp Gly Lys Gly Val Glu Met Leu Trp His Pro Ser Val Val Lys Pro Tyr Leu Thr 820 825 830 Leu Leu Ala Glu Ser Ser Asn Pro Ala Thr Leu Glu Gly Ser Ala Gly 835 840 845 Ser Leu Gin Asn Leu Ser Ala Ser Asn Trp Lys Phe Ala Ala Tyr He 850 855 860 Arg Gly Gly Arg Pro Lys Arg Lys Gly Leu Pro He Leu Val Glu Leu 865 S70 875 Leu Arg Met Asp Asn Asp Arg Val Val Ser Ser Gly Ala Thr Ala Leu 885 890 Θ95 Arg Asn Met Ala Leu Asp Val Arg Asn Lys Glu Leu He Gly Lys Tyr 900 905 910 Ala Met Art Asp Leu Val Asn Arg Leu Pro Gly Gly Asn Gly Pro Ser 9li 920 925 Val Leu Ser Asp Glu Thr Met Ala Ala He Cys Cys Ala Leu His Glu 930 935 940 Val Thr Ser Lys Asn Met Glu Asn Ala Lys Ala Leu Ala Asp Ser Gly 945 950 955 960 Gly He Glu Lys Leu Val Asn He Thr Lys Gly Arg Gly Asp Arg Ser 965 Vo 975 Ser Leu Lys Val Val Lys Ala Ala Ala Gin Val Leu Asn Thr Leu Trp 980 985 990 Gin Tyr Arg Asp Leu Arg Ser He Tyr Lys Lys Asp Gly Trp Asn Gin 995 1000 1005 Asn His Phe He Thr Pro Val Ser Thr Leu Glu Arg Asp Arg Phe Lys 1010 1015 1020 Ser His Pro Ser Leu Ser Thr Thr Asn Gin Gin Met Ser Pro He He 1025 1030 1035 1040 Gin Ser Val Gly Ser Thr Ser Ser Ser Pro Ala Leu Leu Gly He Arg 1045 1050 1055 Asp Pro Arg Ser Glu Tyr Asp Arg Thr Gin Pro Pro Met Gin Tyr Tyr 1060 1065 1070 Asn Ser Gin Gly Asp Ala Thr His Lys Gly Leu Tyr Pro Gly Ser Ser 1075 1080 1085 Lys Pro Ser Pro He Tyr He Ser Ser Tyr Ser Ser Pro Ala Arσ Glu 1090 1095 1100 Gin Asn Arg Arg Leu Gin His Gin Gin Leu Tyr Tyr Ser Gin Asp Asp 1105 1110 1115 1120 Ser Asn Arg Lys Asn Phe Asp Ala Tyr Arg Leu Tyr Leu Gin Ser Pro 1125 1130 1135 His Ser Tyr Glu Asp Pro Tyr Phe Asp Asp Arg Val His Phe Pro Ala 1140 1145 1150 Ser Thr Asp Tyr Ser Thr Gin Tyr Gly Leu Lys Ser Thr Thr Asn Tvr 1155 1160 H65 Val Asp Phe Tyr Ser Thr Lys Arg Pro Ser Tyr Arg Ala Glu Gin Tvr 1170 1175 1180 Pro Gly Ser Pro Asp Ser Trp Val Tyr Asp Gin Asp Ala Gin Gin Arg 1185 1190 1195 1200 Asn Ser Phe Phe Leu Thr Leu Phe Arg Leu Arg * 1205 1210 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 970 base pairs (B) TYPE: nucleic acid (C) ΞTRANDEDNESS : single (D) TOPOLOGY: linear (IX) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION: 1..970 (D) OTHER INFORMATION: /note- "Y2H9" (XI) SEQUENCE DESCRIPTION: SEQ ID NO : : GAATTCCCAC AGATACCACT GCTGCTCCCG CCCTTTCGCT CCTCGGCCGC GCAATGGGCA 60 CCCGCGACGA CGAGTACGAC TACCTCTTTA AAGTTGTCCT TATTGGAGAT TCTGGTGTTG 120 GAAAGAGTAA TCTCCTGTCT CGATTTACTC GAAATGAGTT TAATCTGGAA AGCAAGAGCA 180 CCATTGGAGT AGAGTTTGCA ACAAGAAGCA TCCAGGTTGA TGGAAAAACA ATAAAGGCAC 240 AGATATGGGA CACAGCAGGG CAAGAGCGAT ATCGAGCTAT AACATCAGCA TATTATCGTG 300 GAGCTGTAGG TGCCTTATTG GTTTATGACA TTGCTAAACA TCTCACATAT GAAAATGTAG 360 AGCGATGGCT GAAAGAACTG AGAGATCATG CTGATAGTAA CATTGTTATC ATGCTTGTGG 420 GCAATAAGAG TGATCTACGT CATCTCAGGG CAGTTCCTAC AGATGAAGCA AGAGCTTTTG 480 CAGAAAAGAA TGGTTTGTCA TTCATTGAAA CTTCGGCCCT AGACTCTACA AATGTAGAAG 540 CTGCTTTTCA GACAATTTTA ACAGAGATTT ACCGCATTGT TTCTCAGAAG CAAATGTCAG 600 ACAGACGCGA AAATGACATG TCTCCAAGCA ACAATGTGGT TCCTATTCAT GTTCCACCAA 660 CCACTGAAAA CAAGCCAAAG GTGCAGTGCT GTCAGAACAT CTAAGGCATT TCTCTTCTCC 720 CCTAGAAGGC TGTGTATAGT CCATTTCCCA GGTCTΞASAT TTAAATATAW TTGTAATTCT 780 TGTGTCAC-TT TTGTGTTTTA TTACTTCATA CTTATGAATT TTTCCATGTC CTAAGTCTTT 840 TGATTTTGMT TTATAAAATC ATCCACTTGT NCCGAATGNC TGCAGCTTTT TTTCATGCTA 900 TGGCTTCACT AGCCTTAGTT TNATAAACTG AATGTTTGGA TTCCTCCCCC CAAAAAAAAA 960 AAAACTCGAG 970 (2) INFORMATION FOR SEQ ID NO:8: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 264 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (lx) FEATURE: (A) NAME/KEY: misc feature ( B) LOCATION : 1..2^4 (D) OTHER INFORMATION: /note- 'Y2H23b' (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: GAATTCGCGG CCGNGTCGAC CCCCCACCCC CGATGCCACC ACCCCCANTG GGNTCTCCCN 60 NCCCAGTCAT CAGTTCTTCC ATGGNGTNCC CTGGTCTGCC CCCTCCAGCT CCCCCAGGCN 120 TTCTCCGGGT CTGNCAGCAG CCNCCAGATT AACTCAACAG TGTCACTCCC TGGGGGTGGG 180 TCTGGNCCCC CTGANGATGT GAAGCCACCA GTCTNAGNGG TCCGGGGTCT GTACTGTCCA 240 CCCCCTCCAG GTGGACCTGG CGCT 264 (2) INFORMATION FOR SEQ ID NO:9: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 340 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (IX) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION : 1..3 ~ 0 (D) OTHER INFORMATION: /note- "Y2H27" (XI) SEQUENCE DESCRIPTION: SEQ ID NO: 9- GAATTCGCGG CCGCGTCGAC CGCGGTCGCG TCGACCTGTT GCCCAGGCCC TAGAGGTCAT 60 TCCTCGTACC CTGATCCAGA ACTGTGGGGC CAGCACCATC CGTCTACTTA CCTCCCTTCG 120 GGCCAAGCAC ACCCAGGAGA ACTGTGAGAC CTGGGGTGTA AATGGTGAGA CGGGTACTTT 180 GGTGGACATG AAGGAACTGG GCATATGGGA GCCATTGGCT GTGAAGCTGC AGACTTATAA 240 GACAGCAGTG GAGACGGCAG TTCTGCTACT GCGAATTGAT GACATCGTTT CAGGCCACAA 300 AAAGAAAGGC GATGACCAGA GCCGGCAAGG CGGNGCTCCT 340 (2) INFORMATION FOR SEQ ID NO:10: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 404 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION : 1..4ϋ4 (D) OTHER INFORMATION: /note- "Y2H35" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: GAATTCGCGG TCGCGTCGAC GGTTAGTCCC ACTGGNCGCA TCGAGGGNTT CACCAACGTC 60 ATGGAGCTGT ATGGCANGAT CGCCGAGGTC TTCCNCCTGC CAACTGCCGA GGTGATGTTC 120 TGCACCCTGA NCACCCACAA AGTGGACATN GACAAGCTCC TGGGGGGCCA GATCGGGCTG 180 GAGGACTTCA TCTTCGCCCA CGTGAAGGGG YAGCGCAAGG AGGTGGAGGT GTTCAWGTCG 240 GAGGATGYAC TCGGKCTCAC CATCACGGAC AACGGGGCTG GCTACGCTTC CATCAAGCGC 300 ATCAAGGAGG GCAGCGTGAT CGACCACATC CACCTCATCA GCGTGGGCGA CATGATCGAG 360 GCCATTAACG GGCAGAGCTT CCTGGGCTGC CGGCATTACG AGGT 404 (2) INFORMATION FOR SEQ ID NO:ll: (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 350 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION: 1..350 (D) OTHER INFORMATION: /note- "Y2H171" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: ll: GAATTCGCGG CCGCGTCGAC AAAAAAAGTA AAAGGAACTC GGCAAATCTT ACCCCGCCTG 60 TTTACCAAAA ACATCACCTC TAGCATCACC AGTATTAGAG GCACCGCCTG CCCAGTGACA 120 CATGTTTAAC GGCCGCGGTA CCCTAACCGT GCAAAGGTAG CATAATCACT TGTTCCTTAA 180 GTAGGGACCT GTATGAATGG CTCCACGAGG GTTCAGCTGT CTCTTACTTT TAACCARTGA 240 AATTGACCTG CCCGTGAAGA GGCGGGCATG ACACAGCAAG ACGAGAAGAC CCTATGGAGC 300 TTTAATTTAT TAATGCAAAC AGTACCTAAC AAACCCACAG GGTCCTAAAC 350 (2) INFORMATION FOR SEQ ID NO:12: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 350 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: misc feature (B) LOCATION: 1..350 (D) OTHER INFORMATION: /note- "Y2H41" (X ) SEQUENCE DESCRIPTION: SEQ ID NO:12: GAATTCGCGG NCGCGTCGAC AGATAATGAA AAAACCAGAG GTTCCCTTCT TTGGTCCCCT 60 NNNNGATGGT GCTATTGTGA ATGGAAAGGT TCTACCCATT ATGGTTAGAG CAACAGCTAT 120 AAATGCAAGC CGTGCTCTGA AATCTCTGAT TCCATTGTAT CAAAACTTCT ATGAGGAGAG 180 AGCACGATAC CTGCAAACAA TTGTCCAGCA CCACTTAGAA CCAACAACAT TTGAAGATTT 240 TGNAGCACAG GTTTTTTCTC CAGCTCCCTA CCACCATTTA CCATCTGATG CCGTTGGCTC 300 CTACCCAGAG ATTCTACCCA GTGAAAACTC CCACAGCAAC GCAGGTAGGA 350

Claims: CLAIMS What is claimed is: 1. An isolated nucleic acid comprising a nucleotide sequence encoding at least a presenilin-interacting domain of a presenilin-interacting protein selected from the group consisting of a mammalian S5a (approximately residues 70-377 of SEQ ID NO: 2), GT24 (approximately residues 346-862 of SEQ ID NO: 4), p0071 (approximately residues 509- 1022 of SEQ ID NO: 6), Rab 11 (SEQ ID NO: 7), retinoid X receptor-β (SEQ ED NO: 8), cytoplasmic chaperonin (SEQ ID NO: 9), Y2H35 (SEQ ID NO: 10), Y2H171 (SEQ ED NO: 11), and a Y2H41 (SEQ ED NO: 12) presenilin-interacting domain. 2. An isolated nucleic acid comprising a nucleotide sequence of at least 10 consecutive nucleotides selected from the group consisting of SEQ ED NO: 1, SEQ ED NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ED NO: 8, SEQ ED NO: 9, SEQ ED NO: 10, SEQ ED NO: 11, SEQ ED NO: 12, GenBank Accession Numbers F08730, T18858, X81889, X56740, X53143, M84820, X63522, M81766, U17104, X74801, R12984, D55326, and T64843, and a sequence complementary to any of these sequences. 3. An isolated nucleic acid as in claim 2 comprising a nucleotide sequence of at least 15 consecutive nucleotides selected from said group. 4. An isolated nucleic acid as in claim 2 comprising a nucleotide sequence of at least 20 consecutive nucleotides selected from said group. 5. An isolated nucleic acid comprising a nucleotide sequence encoding an antigenic determinant of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rabl 1, retinoid X receptor-β, cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein. 6. A method for identifying allelic variants or heterospecific homologues of a human presenilin-interacting protein gene comprising choosing a nucleic acid probe or primer capable of hybridizing to a human presenilin-interacting protein gene sequence under stringent hybridization conditions; mixing said probe or primer with a sample of nucleic acids which may contain a nucleic acid corresponding to said variant or homologue; detecting hybridization of said probe or primer to said nucleic acid corresponding to said variant or homologue. 7. A method as in claim 6 wherein said sample comprises a sample of nucleic acids selected from the group consisting of human genomic DNA, human mRNA, and human cDNA. 8. A method as in claim 6 wherein said sample comprises a sample of nucleic acids selected from the group consisting of mammalian genomic DNA, mammalian mRNA, and mammalian cDNA. 9. A method as in claim 6 wherein said sample comprises a sample of nucleic acids selected from the group consisting of invertebrate genomic DNA, invertebrate mRNA, and invertebrate cDNA. 10. A method as in claim 6 further comprising the step of isolating said nucleic acid corresponding to said variant or homologue. 11. A method as in claim 6 wherein said nucleic acid is identified by hybridization. 12. A method as in claim 6 wherein said nucleic acid is identified by PCR amplification. 13. A method for identifying allelic variants or heterospecific homologues of a human presenilin-interacting protein gene comprising choosing an antibody capable of selectively binding to a human presenilin-interacting protein; mixing said antibody with a sample of proteins which may contain a protein corresponding to said variant or homologue; detecting binding of said antibody to said protein corresponding to said variant or homologue. 14. A method as in claim 13 wherein said sample comprises a sample of proteins selected from the group consisting of human proteins, human fusion proteins, and proteolytic fragments thereof. 15. A method as in claim 13 wherein said sample comprises a sample of proteins selected from the group consisting of mammalian proteins, mammalian fusion proteins, and proteolytic fragments thereof. 16. A method as in claim 13 wherein said sample comprises a sample of proteins selected from the group consisting of invertebrate proteins, invertebrate fusion proteins, and proteolytic fragments thereof. 17. A method as in claim 13 further comprising the step of substantially purifying said protein corresponding to said variant or homologue. 18. An isolated nucleic acid comprising an allelic variant or a heterospecific homologue of a human presenilin-interacting protein gene. 19. An isolated nucleic acid encoding an allelic variant or heterospecific homologue of a human presenilin-interacting protein. 20. An isolated nucleic acid comprising a recombinant vector including a nucleotide sequence of any one of claims 1-19. 21. An isolated nucleic acid as in claim 20 wherein said vector is an expression vector and said presenilin-interacting protein nucleotide sequence is operably joined to a regulatory region. 22. An isolated nucleic acid as in claim 21 wherein said expression vector may express said presenilin-interacting protein sequence in mammalian cells. 23. An isolated nucleic acid as in claim 22 wherein said cells are selected from the group consisting of fibroblast, liver, kidney, spleen, bone marrow and neurological cells. 24. An isolated nucleic acid as in claim 21 wherein said vector is selected from the group consisting of vaccinia virus, adenovirus, retrovirus, neurotropic viruses and Herpes simplex. 25. An isolated nucleic acid as in claim 21 wherein said expression vector encodes at least a presenilin-interacting domain of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071 , Rab 11 , retinoid X receptor-β, cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein. 26. .An isolated nucleic acid as in claim 21 wherein said vector further comprises sequences encoding an exogenous protein operably joined to said presenilin-interacting protein sequence and whereby said vector encodes a presenilin- interacting protein fusion protein. 27. An isolated nucleic acid as in claim 26 wherein said exogenous protein is selected from the group consisting of lacZ, trpE, maltose-binding protein, a poly-His tag, glutathione-S-transferase, a GAL4-DNA binding domain, and a GAL4 activation domain. 28. An isolated nucleic acid comprising a recombinant expression vector including nucleotide sequences corresponding to an endogenous regulatory region of a presenilin-interacting protein gene. 29. An isolated nucleic acid as in claim 28 wherein said endogenous regulatory region is operably joined to a marker gene. 30. A host cell transformed with an expression vector of any one of claims 20- 29, or a descendant thereof. 31. A host cell as in claim 30 wherein said host cell is selected from the group consisting of bacterial cells and yeast cells. 32. A host cell as in claim 30 wherein said host cell is selected from the group consisting of fetal cells, embryonic stem cells, zygotes, gametes, and germ line cells. 33. A host cell as in claim 30 wherein said cell is selected from the group consisting of fibroblast, liver, kidney, spleen, bone marrow and neurological cells. 34. A host cell as in claim 30 wherein said cell is an invertebrate cell. 35. A non-human animal model for Alzheimer's Disease, wherein a genome of said animal, or an ancestor thereof, has been modified by at least one recombinant construct, and wherein said recombinant construct has introduced a modification selected from the group consisting of (1) insertion of nucleotide sequences encoding at least a functional domain of a heterospecific normal presenilin-interacting protein, (2) insertion of nucleotide sequences encoding at least a functional domain of a heterospecific mutant presenilin-interacting protein, (3) insertion of nucleotide sequences encoding at least a functional domain of a conspecific homologue of a heterospecific mutant presenilin-interacting protein, and (4) inactivation of an endogenous presenilin-interacting protein gene. 36. An animal as in claim 35 wherein said modification is insertion of a nucleotide sequence encoding at least a functional domain of a normal human presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rabl 1, retinoid X receptor-β, cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein. 37. An animal as in claim 35 wherein said modification is insertion of a nucleotide sequence encoding at least a functional domain of a mutant human presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rabl 1, retinoid X receptor-β, cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein. 38. An animal as in claim 35 wherein said animal is selected from the group consisting of rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates. 39. An animal as in claim 35 wherein said animal is an invertebrate. 40. A method for producing at least a functional domain of a presenilin- interacting protein comprising culturing a host cell of any of claims 30-34 under suitable conditions to produce said presenilin by expressing said nucleic acid. 41. A substantially pure preparation of a protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rabl 1, retinoid X receptor-β, cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein. 42. A substantially pure preparation of a polypeptide comprising an amino acid sequence of at least 10 consecutive amino acid residues selected from the group consisting SEQ ED NO: 2, SEQ ED NO: 4, SEQ ID NO: 6, and GenBank Accession Numbers F08730, T18858, X81889, X56740, X53143, M84820, X63522, M81766, U17104, X74801, R12984, D55326, and T64843. 43. A substantially pure preparation of a polypeptide as in claim 42 comprising an amino acid sequence of at least 15 consecutive amino acid residues selected from said group. 44. A substantially pure preparation of a polypeptide comprising at least a presenilin-interacting domain of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rabl 1, retinoid X receptor-β, cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein. 45. A substantially pure preparation of a polypeptide comprising an antigenic determinant of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rabl 1, retinoid X receptor-β, cytoplasmic chaperonin, Y2H35, Y2H 171 , and Y2H41 protein. 46. A method of producing antibodies which selectively bind to a presenilin- interacting protein comprising the steps of administering an irnrnunogenically effective amount of a presenilin- interacting protein immunogen to an animal; allowing said animal to produce antibodies to said immunogen; and obtaining said antibodies from said animal or from a cell culture derived therefrom. 47. A substantially pure preparation of an antibody which selectively binds to an antigenic determinant of a presenilin-interacting protein selected from the group consisting of a mammalian S5a, GT24, p0071, Rabl 1, retinoid X receptor-β, cytoplasmic chaperonin, Y2H35, Y2H171, and Y2H41 protein. 48. A substantially pure preparation of an antibody as in claim 47 wherein said antibody selectively binds to an antigenic determinant of a mutant presenilin- interacting protein and fails to bind to a normal presenilin-interacting protein. 49. A cell line producing an antibody of any one of claims 47-48. 50. A method for identifying compounds which can modulate the expression of a presenilin-interacting protein gene comprising contacting a cell with a test candidate wherein said cell includes a regulatory region of a presenilin-interacting protein gene operably joined to a coding region; and detecting a change in expression of said coding region. 51. A method as in claim 50 wherein said change comprises a change in a level of an mRNA transcript encoded by said coding region. 52. A method as in claim 50 wherein said change comprises a change in a level of a protein encoded by said coding region. 53. A method as in claim 50 wherein said change is a result of an activity of a protein encoded by said coding region. 54. A method as in claim 50 wherein said coding region encodes a marker protein selected from the group consisting of β-galactosidase, alkaline phosphatase, green fluorescent protein, and luciferase. 55. A method for identifying compounds which can selectively bind to a presenilin-interacting protein comprising the steps of providing a preparation including at least one presenilin-interacting protein component; contacting said preparation with a sample including at least one candidate compound; and detecting binding of said presenilin-interacting protein component to said candidate compound. 56. The method in 55 wherein said binding to said presenilin-interacting component is detected by an assay selected from the group consisting of: affinity chromatography, co-immunoprecipitation, a Biomolecular Lnteraction Assay, and a yeast two-hybrid system. 57. A method of identifying compounds which can modulate activity of a presenilin-interacting protein comprising the steps of providing a cell expressing a normal or mutant presenilin-interacting protein gene; contacting said cell with at least one candidate compound; and detecting a change in a marker of said activity. 58. A method as in claim 57 wherein measurement of said marker indicates a difference between cells bearing an expressed mutant presenilin-interacting protein gene and otherwise identical cells free of an expressed mutant presenilin-interacting protein gene. 59. A method as in claim 57 wherein said change comprises a change in a non¬ specific marker of cell physiology selected from the group consisting of pH; intracellular Ca " ^, Na\ or K + ; cyclic AMP levels; GTP/GDP ratios; phosphatidylinositol activity; and protein phosphorylation. 60. A method as in claim 57 wherein said change comprises a change in expression of said presenilin-interacting protein. 61. A method as in claim 57 wherein said change comprises a change in intracellular concentration or flux of an ion selected from the group consisting of Ca 2+ , Na + and K\ 62. A method as in claim 57 wherein said change comprises a change in occurrence or rate of apoptosis or cell death. 63. A method as in claim 57 wherein said change comprises a change in production of Aβ peptides. 64. A method as in claim 57 wherein said change comprises a change in phosphorylation of at least one microtubule associated protein. 65. A method as in claim 57 wherein said cell is a cell cultured in vitro. 66. A method as in claim 65 wherein said cell is a transformed host cell of any one of claims 30-34. 67. A method as in claim 65 wherein said cell is explanted from a host bearing at least one mutant presenilin-interacting protein gene. 68. A method as in claim 65 wherein said cell is explanted from a transgenic animal of any one of claims 35-39. 69. A method as in claim 57 wherein said cell is a cell in a live animal. 70. A method as in claim 69 wherein said cell is a cell of a transgenic animal of any one of claims 35-39. 71. A method as in claim 57 wherein said cell is in a human subject in a clinical trial. 72. A diagnostic method for determining if a subject bears a mutant presenilin- interacting protein gene comprising the steps of providing a biological sample of said subject; detecting in said sample a mutant presenilin-interacting protein nucleic acid, a mutant presenilin-interacting protein, or a mutant presenilin-interacting protein activity. 73. A method as in claim 72, wherein a mutant presenilin-interacting protein nucleic acid is detected by an assay selected from the group consisting of direct nucleotide sequencing, probe specific hybridization, restriction enzyme digest and mapping, PCR mapping, ligase-mediated PCR detection, RNase protection, electrophoretic mobility shift detection, and chemical mismatch cleavage. 74. A method as in claim 72, wherein a mutant presenilin-interacting protein is detected by an assay selected from the group consisting of an immunoassay, a protease assay, and an electrophoretic mobility assay. 75. A pharmaceutical preparation comprising a substantially pure presenilin- interacting protein and a pharmaceutically acceptable carrier. 76. A pharmaceutical preparation comprising an expression vector operably encoding a presenilin-interacting protein, wherein said expression vector may express said presenilin-interacting protein in a human subject, and a pharmaceutically acceptable carrier. 77. A pharmaceutical preparation comprising an expression vector operably encoding a presenilin-interacting protein antisense sequence, wherein said expression vector may express said presenilin-interacting protein antisense sequence in a human subject, and a pharmaceutically acceptable carrier. 78. A pharmaceutical preparation comprising a substantially pure antibody, wherein said antibody selectively binds to a mutant presenilin-interacting protein, and a pharmaceutically acceptable carrier. 79. A pharmaceutical preparation as in claim 78 wherein said preparation is essentially free of an antibody which selectively binds a normal presenilin-interacting protein. 80. A pharmaceutical preparation comprising a substantially pure preparation of an antigenic determinant of a mutant presenilin-interacting protein. 81. A pharmaceutical preparation as in claim 80 wherein said preparation is essentially free of an antigenic determinant of a normal presenilin-interacting protein. 82. A method of treatment for a patient bearing a mutant presenilin-interacting protein gene comprising the step of administering to said patient a therapeutically effective amount ofthe pharmaceutical preparation of any one of claims 75-81. 83. A method as in claim 82, wherein said pharmaceutical preparation is targeted to a cell type is selected from the group consisting of heart, brain, lung, liver, skeletal muscle, kidney, pancreas and neurological cells.

Inventors: FRASER PAUL E, ROMMENS JOHANNA M, ST GEORGE-HYSLOP PETER H, FRASER, PAUL, E., ROMMENS, JOHANNA, M., ST. GEORGE-HYSLOP, PETER, H.
Applicants: FRASER PAUL E, HSC RES DEV LP, ROMMENS JOHANNA M, ST GEORGE HYSLOP PETER H, UNIV TORONTO, FRASER, PAUL, E., HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP, ROMMENS, JOHANNA, M., ST. GEORGE-HYSLOP, PETER, H., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Application year: 1997
Main classification: C12N15
IPC codes: A01K67, A61K31, A61K38, A61K39, A61K48, A61P25, C07K14, C07K16, C12N5, C12N15, C12P21, C12Q1, C12R1